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Abstract
Oral squamous cell carcinoma (OSCC) and oral epithelial dysplasia 
(OED) are known to be associated with high tobacco and/or alcohol 
consumption. A viral aetiology for OSCC and OED has been proposed, in 
particular human papillomavirus (HPV).
The overall aim of the present work was to determine the geographical 
prevalence and viral interactions of HPV, CMV, EBV and HHV-8 in oral 
squamous cell carcinoma (OSCC) and potentially malignant oral mucosal 
diseases (oral epithelial dysplasia (OED), oral lichen planus (OLP) and 
proliferative verrucous leukoplakia (PVL)), as well as a range of salivary 
gland tumours and samples from HIV infected individuals.
Extraction of DNA from archival paraffin-embedded lesional tissues of 
histopathologically proven OSCC, OED, OLP, PVL, and normal oral mucosa 
of HIV-infected individuals, various salivary gland tumours and normal oral 
mucosa was performed. Viral DNA of HPV, human herpesvirus (HHV-8), 
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) was detected by 
nested polymerase chain reaction (PCR), and the genotype of HPV was 
determined using reverse line blotting hybridisation (RLB).
The proportion of HPV-DNA detected in OSCC was higher when 
compared to all other examined mucosal and salivary gland lesions. There 
were trends of an increased prevalence of HPV within OED, PVL and OLP 
when compared to normal-control oral mucosa. The proportion of HHV-8 was 
not increased in any oral mucosal lesion except in HIV-individuals when 
compared to normal-control, which was expected. With respect to EBV, the
proportion of EBV in PVL samples was increased when compared to normal- 
control. The CMV-DNA was detected in a low percentage of both PVL and 
OED samples when compared to the normal-control. There was no evidence 
of any interactions between any herpes viruses with HPV in OSCC.
It is concluded that HPV infection may be associated with OSCC and OED.
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Chapter 1 Introduction, Human papillomavirus
1.1 OVERVIEW OF HUMAN PAPILLOMAVIRUS
1.1.1 General features
Human papillomaviruses (HPVs) are small DNA tumour viruses of 
approximately 55 nm in diameter (Figure 1.1), and up to 200 different types 
and many more sequences that are less well characterized have been 
identified (Brenna and Syrjanen, 2003). These viruses are classified, 
according to their tissue tropism, into dermatotropic and mucosotropic groups 
(Van Ranst et al., 1992). Moreover, human papillomaviruses have the ability 
to cause both genital and extra-genital infections. The skin is the most 
common site of extra-genital HPV infection but other extra-genital sites 
including the mouth, nose, oesophagus, larynx, trachea, and conjunctiva 
have been also involved (Karcioglu and Issa, 1997; Buchwald et al., 1997; 
McKaig et al., 1998). Lesions caused by some types of HPV are benign, 
while malignant lesions are associated with other HPV types, thus, HPV can 
be classified also by their oncogenic potentials as low-risk and high-risk types 
(zur Hausen, 1991).
Figure 1.1 Idealised electron-microscopic depiction of HPV  
Adapted from: http://www.hhmi.org/news/popups/hpv_pop1 .html
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1.1.2 Virology
Human papillomavirus comprises a group of non-enveloped viruses of 
the papovaviridae family, with icosahedral capsids that replicate their 
genomes within the nuclei of infected host cells. The double stranded, 
circular DNA genomes of all HPVs are approximately 8 kb in size. The viral 
genomes carry an average of nine major open reading frames (ORFs) (Table 
1.1) (Molijn et al., 2005), and these are generated from polycistronic mRNAs 
transcribed from a single DNA strand. The early region makes up 
approximately 45% of the viral genome, the late region 40%, and a non­
coding region containing viral regulatory elements make up the remaining 5% 
(Sanclemente and Gill, 2002; Hafkamp e ta l , 2004).
The early genes serve to regulate the transcription of DNA, while the 
late genes encode for proteins involved in viral spread, such as capsids 
proteins. A non-coding region of about 1 kb in size, known as the upstream 
regulatory region (URR) or the long control region (LCR), separates the early 
and the late region gene clusters. The early genes include E1, E2, E4, E5, 
E6 and E7, while the late genes are L1 and L2. Since the sum of the sizes of 
all genes exceeds the coding capacity of the genome, a certain amount of 
overlap of genes is expected and has indeed been found (Figure 1.2). Two 
late genes encode structural proteins of the virions: the L1 protein is the 
major capsid protein and L2 protein is the minor capsid protein. The URR 
contains the origin of DNA replication, promoters and other transcription 
regulatory elements. E1 and E2 proteins are two important regulatory 
proteins for HPV; their functions are essential for viral DNA replication and
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thus permissive HPV infection. E6 and E7 proteins are important for host 
DNA synthesis (Severson etal., 2001).
It has been demonstrated that a virus with less than 90% homology in 
the L1 and E6 genes and URR to known types is defined as a new type, one 
with 90% - 98% homology is categorized as a subtype, and one with >98%  
homology defined as a variant (Severson et al., 2001; Chen etal., 2005a).
Table 1.1 Summary of the functions of human papillomavirus (HPV) open reading frames
Gene Function
E1 DNA helicase activity, DNA-dependent ATP-binding, ATPase activity. Role in replication and 
replication repression
E2 Regulate of viral transcription and replication, control of early region viral gene expression, 
necessary for efficient viral DNA replication together with E1
E3 No known function (only present in a minority of papillomavirus)
E4 Expressed as a late gene primarily in differentiating epithelium, role in productive 
infection, associated with the keratin cytoskeleton of cultured epithelial cells, role in viral 
regress
E5 Transforming activity in HPV-16 in vitro. Presumably stimulates benign cell proliferation in 
vivo but might have a role in the initiation of carcinogenesis
E6 Role in transformation process together with E7. Transcriptional activation properties. E6 of 
high-risk HPVs inactivates p53 by inducing its degradation. Together with E7 provides a 
cellular environment for viral DNA replication
E7 Transactivating properties similar to the adenovirus E2 promoter, induces DNA synthesis in 
quiescent cells, role in rodent cell transformation in co-operation with an activated ras 
oncogene. E7 binds to the hypophosphorylated form of the retinoblastoma protein (pRB) 
resulting in its functional inactivation permitting cell progression to S phase of the cell cycle. 
E7 proteins from the low risk HPV types 6 and 11 bind less efficiently than the E7 protein 
from high risk HPVs (types 16 and 18)
L1 A major capsid protein
L2 A minor capsid protein
(Adapted from Sanclemente and Gill, 2002)
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Figure 1.2 Genome organizations of papillomaviruses. Open bars represent open 
reading frame, which are labelled E or L depending on their position in the early or late 
region of the genome. (Adapted from Baron etal., 1996)
1.1.3 HPV life cycle and biology
The papillomavirus life cycle requires the availability of epidermal or 
mucosal epithelial cells that are able to proliferate, i.e., basal layer cells. In 
these cells, viral gene expression is largely suppressed, although the limited 
expression of specific 'early' viral genes (such as E5, E6, E7) results in 
enhanced proliferation of the infected cells, where the infected cells divide 
(zur Hausen, 2002) (Figure 1.3). Following entry into the suprabasal layers, 
'late' viral gene expression is initiated; the circular viral genome is then 
replicated and structural proteins form.
The viruses may have two modes of replication, either by stable 
replication in low copy number in episomal form in the proliferating basal cells 
or by replication taking place in terminally differentiated layers productively 
with the infected cell dividing repeatedly to form a wart (Garland, 2002). Upon
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cell division, a daughter cell will remain as a part of the basal layer, while the 
other daughter cell will migrate outwards to start differentiation. At this stage, 
HPV-DNA segregates with the two daughter cells and replicates to sustain 
the maintenance of 50-100 copies of the genome per cell. In the upper 
layers of the epidermis or mucosa, complete viral particles are assembled 
and released (Severson et al., 2001; zur Hausen, 2002).
Vims, particle release I I I
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andparttcK
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basal la w  cels, 
commonly wa Late ral expansion
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Figure 1.3 Human papillomavirus life cycle. Infection takes place in proliferating tissue, 
through a microlesion of the mucosa or the skin. Some of the infected cells migrate to the 
suprabasal layer, where viral genes are activated. Virions are released at the uppermost 
surface. (Adapted from zur Hausen, 2002)
1.1.4 Epidemiology of human papillomavirus infections
HPV is a very common infection; it can infect individuals without any 
clinical manifestation. Thus, only small fraction of infected patients will 
progress to invasive cancer. HPV has been classified to high risk, 
intermediate and low risk types (Table 1.2) (Baseman and Koutsky, 2005; 
Chen et al., 2005a).
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Table 1.2 Showing classifications of HPVs according to their risk
Risk classification HPV types
High-risk 16,18,31,33,35,39,45,51,52
56,58,59,68,73,82
Probable high-risk 26,53,66
Low-risk 6,11,40,42,43,44, 54,61,70,72,81 ,C06108
Undetermined risk 34,57.83
(Adapted from Baseman and Koutsky, 2005; Chen et al., 2005)
It has been estimated that the population prevalence of HPV infection 
among women worldwide ranges from 2% to 44%. This wide variation 
explained by some authors due to the different sensitivity of the detection 
methods, and the age range of the samples (Baseman and Koutsky, 2005). 
In one study the results show that >50% of sexually active women have been 
infected by one or more genital HPV types (Bosch and de Sanjose, 2003). 
While in another study done in the US, the prevalence of high-risk HPV 
infection among women, with mean age of 25 years, was 27% (Kulasingam 
and Myers, 2003). A recent study in Scotland, women attending a routine 
cervical cancer screening (mean age: 36.6 years), showed that the 
prevalence of PCR-detected HPV-DNA was approximately 20.5% for all 
HPVs and 15.7% for high-risk HPVs (Cuschieri et al., 2004). Although HPV 
type 16 is the most common type among cervical cancer cases, it is also the 
most common type found in cytologically normal women (Schiffman, 1992a; 
Woodman etal., 2001; Munoz etal., 2003).
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Data from multiple international studies show that the median age of 
oncogenic HPV prevalence among all women is 15%, while the median 
oncogenic HPV prevalence among women age 30 and older is 9% (Bosch 
and de Sanjose, 2003). It appears that the prevalence of HPV infection is 
highest among young women, decreasing with increasing age (Schiffman, 
1992b). Other studies have shown a peak prevalence of HPV infection in 
women below 25 years of age, with a decrease among women aged between 
35-54 years and a second peak of prevalence was reported to be after the 
age of 55 years (Herrero et al., 2000).
Other studies suggested that the incidence of HPV infection with 
oncogenic types is higher than that of the non-oncogenic HPV (Ho et al., 
1998; Giuliano et al., 2002; Richardson et al., 2003). The cumulative 
incidence of high-risk HPV infection among women aged 15-19 years in 
England was found to be 44% over a 3-year period of time, which increased 
to 60% after 5 years (Woodman et al., 2001). Studies conducted in the US 
showed similar results among women within the same age group (Ho et al., 
1998; Winer et al., 2003; Baseman and Koutsky, 2005).
1.2 Genotypes of Human papillomavirus
To date, up to 200 types have been identified (Garland, 2002; Munger 
et al., 2004). HPV is classified according to genetic similarity with identified 
types, or grouped according to their tissue tropism (dermatotropic or 
mucosotropic), and as outlined earlier, by their potential to induce malignant 
transformation (Brentjens et al., 2002). HPV types that are found 
preferentially in cervical and other anogenital cancers have been designated
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as 'high-risk' types. Conversely, those found primarily in genital warts and 
non-malignant lesions are considered as 'low-risk' (Ostwald et al., 2003) 
(Table 1.3).
Genotypically, papillomaviruses may also be divided into supergoups 
A-E, each with various subgroups (Chan et al., 1995). The differences and 
similarities among HPV types are graphically represented as phylogenic 
trees as in Figure 1.4. Genital and mucosal HPVs belong to supergroup A, 
although typical genital viruses are also found in oral or laryngeal mucosa. 
Supergroup B contains most of the HPVs associated with epidermodysplasia 
verruciformis (EV), while supergroup E contains other human and animal 
HPV types. The differentiation of supergroups A and B was supported by 
their differences in natural history based on morphology, high bootstrap 
scores of phylogenetic trees and biological differences in gene regulation, 
e.g., similar cis-responsive elements being shared by types of the same 
supergroup (Tan et al., 1994). Supergroups A6, A7, and A9 include viruses 
frequently demonstrated in genital high-grade dysplasia and carcinomas, 
leading to the concept of low and high-risk HPV infections (zur Hausen, 
1987). Intragenomic variability has also been observed in different HPV 
types. Approximately 2% of sequence variability takes place in the coding 
region, while 5% occurs in the non-coding region (Campione-Piccardo et al., 
1991).
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Figure 1.4 A phylogenetic tree of 92 HPV types based on weighted parsimony evaluation 
of the 291 bp L1 segment, showing supergroups A, B, C, D and E. (Adapted from Chan et 
al., 1995)
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Table 1.3 Summary of some of the different HPV genotypes and the disease associated
Clinical manifestation HPV type
Cutaneous lesions
skin warts
Plantar warts 1.2,4
Common warts 2,4,26,27,29,49,57
Flat warts 3,10,28,41,49
Butchers warts 7
Epidermodysplasia verruciformis (EV) 3„5,8,9,10,12,14,15,17,1 
9-25,36,47,50
Squamous cell carcinomas (actinic keratosis) 16
Squamous cell carcinomas (keratoacanthoma) 37
Squamous cell carcinomas (immunocompromised) 48,60
Mucosal lesions
Anogenital warts
Condyloma acuminatum 6,11,16,18,30,42,43,44,5
5,70
Anogenital carcinoma
High risk 16,18
Intermediate risk 31,33,35,39,45,51,52,56,
58,59,68,73
Low risk 6,11,26,40,42,43,44,53,5
4,55,62,66
Aerodigestive lesions
Recurrent respiratory papillomatosis 6,11
Nasal papillomas, dysplasias, carcinomas 57
Laryngeal condylomata 6,11
Oral lesions
Focal epithelial hyperplasia (Heck's disease) 13,32
Vermillion warts 2
Squamous papilloma 6,7,11,16,32
Condyloma acuminatum 6,11
Verruca vulgaris 6,11
Oral hyperplasia 58
Oral leukoplakia 16,18,33
Oral lichen planus 6,11,16,18,31
Proliferative verrucous leukoplakia 18
Oral epithelial dysplasia 16
Oral squamous cell carcinoma 16,18,33,45
Conjunctival papilloma 6,11,16
Tonsillar carcinoma 16
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1.2.1 Serological evidences and serotyping
The concept of serotype has been useful in characterizing human viral 
pathogens, and in designing a protective vaccine against them. Difficulties in 
propagating HPV virions in cultured cells have obstructed efforts to identify 
and characterize viral immunologic variants (Kirnbauer et al., 1992; Volpers 
etal., 1994; Giroglou etal., 2001).
There are many reasons for HPV serological assay to be laborious. 
First, there are over 200 different types, many of which are not malignancy 
associated and not sexually transmitted, so serological cross-reactions are 
hard to predict based on DNA homology. Second, most of HPV-infections are 
rapidly cleared spontaneously. Thus, many people testing negative for HPV- 
DNA may have had a previous infection. Third, in cutaneous HPVs, 
seroconversion can appear many months after infections. Also for genital 
HPVs, seroconversion can be delayed many months after the detection of 
viral DNA. Finally, testing for HPV genome of samples taken from the uterine 
cervix will not detect infections at other sites in the body (Dillner, 1999).
The relation between papillomavirus genotypes and serotypes 
remains an important issue for vaccine development, e.g., antibody- 
mediated neutralization of infectious virions appears to be genotype- 
restricted, i.e., certain types have demonstrated relatively unique capsid 
antigenic features, while others have demonstrated an ability to participate in 
cross-neutralization. It may be that certain genotypes denote unique 
serotypes, while others fall within serogroups consisting of two or more
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related variants (Christensen etal., 1994; White etal., 1998; Giroglou etal.,
2001).
Of note, serum immunologic markers in HPV have not routinely been 
used in identifying the virus in acute or chronic diseases. The antibodies to 
HPV remain detectable for many years following infection, hence, serology is 
not suitable for distinguishing present and past infections (Molijn et al., 2005). 
In addition, viral subtyping of HPV by serology is problematic as the capsid 
proteins of different HPV subtypes are antigenically quite similar (Garland,
2002).
Several studies which have investigated the presence of antibodies 
against L1, L2, E2, E4, E6 and E7 of high-risk group genotypes (mostly HPV 
16 and 18) in cervical cancer patients, indicate that a humoral immune 
response to the virus does occur in such individuals (Zumbach et al., 2000; 
Rosales etal., 2001; Bosch et al., 2002; Chang etal., 2005). The frequency 
of seropositivity is higher in patients with HPV-associated genital lesions 
compared with appropriate control subjects. It has been postulated that the 
presence of the IgG antibody to the HPV-16 L1 capsid protein is an indication 
of persistent infection, and the presence of an antibody against HPV-16 E6 
and E7 predicts HPV-associated malignancy (Chen et al., 2005a). Also, it 
has been suggested that serum antibodies against HPV-16 L1, E6 and E7 
are associated with increased risk for HNSCC and that they correlate with the 
presence of HPV-16 DNA in oral tumour specimens (Schwartz et al., 1998; 
Zumbach etal., 2000; Mork etal., 2001).
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1.3 Immune response to HPV
Human papillomaviruses are atypical viruses, as they cause no 
systemic infection. They are non-lytic (there is therefore no viraemia) and 
lesions with a productive viral infection do not have an associated 
inflammatory response or any significant histological evidence of immune 
activity. However, it is evident that the immune system is important in 
controlling HPV infections, both the specific immune response (humoral 
immune response) and the adaptive immune response (cellular immune 
response) being involved in the process (Sanclemente and Gill, 2002).
1.3.1 Humoral immune response
The human antibody response to HPV capsid antigen is type-specific, 
reacts mainly against conformational epitopes, and develops more than 8 
months after productive infection occurs. Systemic anti HPV-IgG levels 
usually correlate with persistent HPV infection, while IgA against HPV-16 
may exert some protective role against HPV infection (Carter et al., 1996; 
Hagensee, 2000). It has been suggested that HPV-L1 antibody levels may 
fade away over time, but no changes in HPV-16 antibody levels have been 
detected in women followed up for 4 years (Hagensee, 2000). In addition, the 
increased rate of seroconversion among women with prevalent HPV-16 
infection may be related to the fact that a higher percentage of prevalent 
versus incident HPV-16 infections are likely to be persistent (Carter et al., 
2000). However, once an infection has occurred, antibodies are not usually 
able to eliminate the virus, particularly if the virus is capable of entering a
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latent state in which its DNA is integrated into host chromosomal DNA 
(Sanclemente and Gill, 2002).
1.3.2 Cellular immune response
It has been postulated that escape from immune-surveillance 
mechanisms is an important step in the progression of HPV tumourogenesis 
(zur Hausen, 2002). Activated Th1 responses seem to be important in 
controlling HPV via the production of cytokines, including interferon (IFN) and 
interleukin (IL-2). Interferon-a acts directly to eliminate virus by inducing an 
antiviral state in cells, while IL-2 acts indirectly by assisting the activation of 
cytotoxic T-cell lymphocytes (CTL). Both IFN-y and IL-2 (activate natural 
killer cells (NK)) are important in the first few days of infection until a specific 
CTL response develops. In most viral infections, a CTL response develops 
within 3-4 days. As CTLs destroy infected cells, they also eliminate potential 
sources of new infection (Sanclemente and Gill, 2002).
1.4 Diagnostic aids and detection methods
Human papillomavirus is a particular difficult virus to study from an 
epidemiologic point of view. The low incidence of clinical manifestations, the 
inability to grow HPV in tissue culture and the exclusive species specificity of 
HPV, each limits the success rates in studying the virus among infected 
people with HPV.
There are many methods by which HPV can be detected, each having 
strengths and weaknesses.
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1. 4.1 Direct Visual Inspection
The first step in diagnosis is the clinical assessment (sometimes 
termed as the visual test, or direct visual inspection (DVI)), where 
manifestations of HPV become visible. However, in only a minority of 
persons infected with the virus have early clinical signs of disease (Garland, 
2002; Zanotti and Belinson, 2002).
In the cervix, early HPV lesions may appear white after staining with 
acetic acid (vinegar). Likewise, vital staining with Lugol’s iodine may aid 
identification of HPV-associated diseases. The advantage of such methods is 
that they entail no need for laboratory processing of lesional material and the 
result is immediate. However, it does necessitate careful clinical evaluation 
by an experienced clinician (ACCP, 2004).
1. 4.2 Papanicolaou smear test
The Papanicolaou smear test is one of the most effective indicators of 
common and potentially serious clinical manifestations of HPV infection in 
women. It detects abnormal cells in a sample taken from the cervix. It 
involves performing a speculum examination to expose the cervix and 
collecting cervical cells using a wooden or plastic spatula or brush. These 
cells are then smeared and fixed on a glass microscope slide. These slides 
are transported to a laboratory where they are usually processed, and 
examined under the microscope. Histopathological examination of the smear 
then takes place. Cytological changes such as koilocytes, nuclear atypia, 
delayed maturation, hyperkeratosis, and parakeratosis are all highly 
associated with HPV infection and identify neoplastic cervical precursor
15
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lesions with a high degree of accuracy. The success of the "Pap” smear in 
cervical cancer screening programmes has served as a model for population- 
based screening, early detection, and treatment (Garland, 2002; Zanotti and 
Belinson, 2002). The disadvantage of such procedures is the multistage 
process which can take several weeks before the results are available 
(ACCP, 2004).
Abnormalities found by the "Pap” smear are usually further evaluated 
by colposcopy, which involves high-powered illuminated magnification of the 
cervix using a colposcope (a binocular magnifying instrument). This enables 
the operator to determine the extent of any lesion, to taking biopsies and to 
provide treatment with cryotherapy or loop electrosurgical excision procedure 
(LEEP). Colposcopy is non-invasive and performed as an outpatient 
procedure. It does not require anaesthesia, but it is an expensive procedure, 
requiring appropriately trained clinician (ACCP, 2004).
Direct punch biopsies taken from colposcopic abnormalities are fixed 
in formalin and processed in H&E sections for light microscopy. On 
histological examination, the lesions are graded using the UN nomenclature 
and categorized as cervical intraepithelial neoplasms (CIN). The other 
morphological evidence for HPV infection (koilocytosis, dyskeratosis, 
multinucleation) also recorded (Branca etal., 2004).
1. 4.3 Serum immunologic markers
As mentioned in Section 1.3, the detection of antibodies to HPV is not 
always diagnostically helpful. However, enzyme-linked immunosorbent 
assays (ELISA) tests for serum antibody against HPV proteins have been
16
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developed which correlate well with the presence of HPV-DNA in the cervical 
samples (Kirnbauer et al., 1994), and it has been suggested that the 
antibodies detected by ELISA are highly HPV-type-specific (Zumbach et al., 
2000). Of note, in the absence of HPV positive samples, it is impossible to 
pinpoint the anatomic site of the infection. Furthermore, antibody presence is 
not necessarily indicative of active infection, latent integration or oncoprotein 
production. It has been claimed that HPV seropositivity may be an indication 
of possible risk of oral cancer (Ha and Califano, 2004).
1.5 Molecular detection methods for HPV
A variety of molecular methods has been developed for the detection 
of HPV-DNA. All vary in their sensitivity, specificity and complexity. (Figure 
1.5). It is worth to mention that HPVs can not be adequately cultured in vitro 
since it needs proliferating tissues, and serological assays only have limited 
accuracy since they can not distinguish between currently existing and 
passed-off infection.
1. 5.1 In situ hybridization (ISH)
In situ hybridization (ISH) permits the site of HPV-DNA within a cellular 
tissue to be identified. It involves the use of type-specific radioactively or 
enzymatically labelled DNA probes complementary to a particular HPV 
sequence. In situ and filter in situ hybridization (FISH) do not require DNA 
isolation from tissue but rather probe directly for the presence of viral 
sequence in tissues and smears (McKaig etal., 1998). The sensitivity of this 
assay is of the order of 20-50 copies per cell (Syrjanen et al., 1988).
17
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However, it has been demonstrated that ISH depends upon the 
consistency of the complementary sequence present in the samples, and as 
the presence of the HPV-DNA in the oral cavity is known to be inconsistent. It 
has been demonstrated that the sensitivity of this assay to detect HPV in oral 
samples may not be high (Ha and Califano, 2004). Aside from the 
disadvantages of its low sensitivity and assay time, in situ hybridization 
affords the lowest specificity for the detection of HPV sequences in clinical 
samples (Hubbard, 2003).
1. 5.2 Dot blot hybridization (DB)
Both Dot blot hybridization and Southern blot hybridization methods 
require the isolation and purification of cellular DNA from a specimen. Dot 
blot hybridization is a rapid technique that can be used to screen multiple 
specimens and requires small quantities of DNA. It does not require digestion 
of the DNA sample with restriction enzymes or gel electrophoresis before 
hybridization. Instead, extracted DNA is denatured, bound to membrane and 
hybridized with specific HPV-DNA probes. It is sensitive to about one copy of 
cellular DNA per genome, but not as specific as Southern blotting and cannot 
distinguish between episomal or integrated HPV genomes (McKaig et al., 
1998).
1.5.3 Southern blot (SB)
Southern blot has long been one of the principal methods for the 
detection of HPV-DNA. It offers the ability to distinguish between episomal 
and integrated DNA, and it can detect up to 0.1 copies per cell (Syrjanen, 
1990). Southern blot may have less sensitivity than PCR (Schiffman, 1992b;
18
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Frazer et al., 1993; McKaig et al., 1998), and requires the use of radioactive 
probes, it is labour intensive and is thus expensive (Zanotti and Belinson,
2002).
1. 5.4 Hybrid capture-2 (HC2)
Hybrid capture-2 (HC2) is based upon hybridization in solution of long 
synthetic RNA probes complementary to the genomic sequence of 13 high- 
risk and 5 low-risk HPV types. This method has the advantages of high 
sensitivity, ease of performance in clinical sittings, and suitability for 
automation for genotyping. It does not require special facilities to avoid cross 
contamination, and does not require the use of radioactivity, in addition, it is 
commercially available. Cross reactivity of HC2 high-risk probes to HPV 
types that have a significant risk for cervical cancer may be considered as an 
advantage in identifying persons with high-risk HPV infection, but cross­
reaction with low-risk types may cause false positive results that can lessen 
the specificity of the assay. Recently, HC2 has been approved by Food and 
Drug Administration (FDA) for in vitro diagnostic use (Konya et al., 2000; 
Vernon et al., 2000; Zanotti and Belinson, 2002; Iftner and Villa, 2003).
1.5.5 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) is a valuable tool because it allows 
in vitro multiplication of unique regions of DNA so they can be detected within 
a large background. The sensitivity and specificity of PCR-based assays are 
varied, depending mainly upon the primer sets used, the size of the PCR 
product, reaction conditions, the performance of the DNA polymerase used in 
the reaction, the spectrum of HPV-DNA amplified and ability to detect
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multiple types (Iftner and Villa, 2003). This technology can be used for viral 
detection, viral load quantitation, DNA sequencing, and mutation analysis 
and can also be performed in multiplex, whereby multiple target DNA 
sequences can be analyzed simultaneously (Hubbard, 2003). The commonly 
used PCR assays have a sensitivity of 1 to 10 virions per sample (Garland,
2002). Due to this high sensitivity, care must be taken to ensure the amplified 
target does not contaminate negative specimens and lead to false positives 
(Hubbard, 2003). In general, the efficiency of the PCR assay decreases with 
increasing amplicon size. Consequently, the efficiency of PCR primers 
generating a small product is considerably higher than primers yielding larger 
amplicons (Park etal., 2004; Molijn etal., 2005).
The use of consensus or general primer-mediated approach allows 
the detection of a broad spectrum of HPV genotypes in one assay. The first 
generation consensus PCR is designed to detect mucosotropic HPVs, and 
uses primers (MY 09/11 and GP+ 5/6) which anneal to highly conserved 
region L1 open reading frame (Remmerbach et al., 2004). In this particular 
assay, the primers or the PCR conditions are adapted to accommodate 
detection of as many different HPV types as possible (Qu et al., 1997; 
Garland, 2002; Castle etal., 2002).
The use of consensus primers vs. specific primers would theoretically 
result in higher detection rates, as many different types of HPV can be 
identified. However, an advantage of using primers for E6 and E7 is that they 
allow the detection of the high-risk types of HPV (Harnish et al., 1999; Chow 
etal., 2000; Sasagawa etal., 2000; Venturoli etal., 2002). A modification of 
MY 9/11 to the PGMY 09/11 primer system has been developed which has
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addressed some of the limitations of these traditional degenerate primer sets. 
The PGMY primer set has a significantly increased ability to detect multiple 
infections as it amplifies certain HPV types that are inefficiently detected by 
using the MY 09/11 set and thus detects approximately 10% more HPV 
positives samples (Gravitt etal., 2000; Garland, 2002; Coutlee etal., 2002). 
Another modification is the use of short PCR fragment primers (SPF), which 
enables the generation of a smaller amplicon, which has the advantage of 
more efficiently detecting HPV-DNA in formalin-fixed paraffin-embedded 
materials and archival Pap smear than other sets of previously mentioned 
primers (Garland, 2002; Perrons etal., 2002).
Viral load quantitation using PCR technologies has become a 
methodological challenge since it has been suggested that high viral copy 
numbers correlate with increased risk of development of HPV-associated 
cervical lesions (Ha et al., 2002; Kreimer et al., 2005). Real-time PCR or 
Real Quantitation PCR (rt-PCR or RQ-PCR) represents perhaps the best 
approach to target nucleic acid quantitation. This technique allows 
continuous monitoring of PCR products, since dual-labelled fluorigenic 
probes emit fluorescence as the PCR reaction proceeds. Reactions are 
performed in well plates without the need to analyze the PCR products on 
gel, making it a useful tool for simultaneous testing of a large number of 
samples. This method has the advantage of being reproducible, rapid and 
applicable in clinical settings. Additionally, reactions can be run in multiplex 
with the use of different fluorochromes, such that, the starting concentrations 
of several target DNAs can be analyzed at once (Ha et al., 2002; Hubbard, 
2003). However, like any PCR based methodology, this technique is subject
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to variations according to the primer sequence, target DNA and method of 
storage of the study tissues. Moreover, it requires expensive equipment and 
reagents. Nevertheless, its use in epidemiological studies seems to be 
warranted by the information provided. Unfortunately, the true clinical 
relevance of viral load measurement may be overshadowed by sampling 
error in the collection of tissue specimens, e.g., difficulty in controlling the 
lesion size and proportion of infected cells to normal cells (Strauss et al., 
2000; Gravitt etal., 2003; Iftner and Villa, 2003; Pretet et al., 2004).
Major limitations to this method include the fact that the amount of 
cancer cells in a biopsy specimen may affect viral quantitation, and a 
considerable variability may exist in viral load measurements within a single 
tumour. Additionally, the viral load results may be either due to a 
measurement of a few cells with greater number of HPV-DNA copies, or 
many cells with few copies (Klussmann et al., 2001; Kreimer et al., 2005). 
Recently, however, a variation of rt-PCR that uses self probing amplicons 
known as Scorpions has been developed for detection, typing and 
quantification of more than 40 different HPV types in clinical samples (Hart et 
al., 2001; Gravitt etal., 2003; Iftner and Villa, 2003).
1.6 Genotyping
Once PCR using consensus primers has been performed, detection of 
individual genotypes can be maintained by several methods including 
restriction fragment length polymorphism (RFLP), reverse line blot 
hybridization (RLB) and direct DNA sequencing. An alternative approach is to 
use type specific PCR that are used to identify individual HPV type based on
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E6 or E7 polymorphism (Clavel et al., 1998; Kado et al., 2001; Hubbard,
2003).
Restriction fragment length polymorphism methods (RFLP) are used 
to identify HPV genotype-specific restriction patterns derived from post-PCR 
consensus primers. The restriction enzymes used for most analysis are 
typically BamHI, Ddel, Haelll, Hinfl, and Pstl. Human papillomavirus RFLP 
data are sometimes difficult to interpret, especially when mixed infections are 
encountered, and since RFLP are not in practice, positively identified by 
specific hybridization (e.g., Southern blot), identification of false bands can 
lead to major uncertainty in assigning genotypes (Astori et al., 1999; Grce et 
al., 2000; Kay et al., 2002; Hubbard, 2003).
For individual HPV typing, a non-radioactive reverse line blot 
hybridization system has been developed. This allows a rapid typing of 
consensus PCR products in a single hybridization step and requires only a 
limited amount of PCR product (Coutlee et al., 1999; Jordens et al., 2000; 
Laconi et al., 2001; Koskinen et al., 2003; Molijn et al., 2005) (more details 
in chapter 2, section 2.3.8).
The gold standard for recognition of all HPV types in a clinical sample 
is DNA sequencing, either by direct sequencing of the fragment or after 
cloning into plasmids, this method is however, expensive and thus has 
limitations for use as a diagnostic tool (Feoli-Fonseca et al., 2001; Garland, 
2002; Hubbard, 2003). Moreover, direct sequencing is not appropriate in 
instances of multiple HPV genotypes in clinical samples. Sequences that 
represent a minority genotype in the total PCR product may remain 
undetected and thus may underestimate the prevalence of infections with
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multiple HPV genotypes. Comparing DNA direct sequencing with 
hybridization, the former detects multiple types in only 2% of samples, while 
reverse hybridization will identify multiple types in 25% of samples (Molijn et 
al., 2005).
Sensitivity
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Figure 1.5 Relative sensitivities of different nucleic acid analysis methods.
(Adapted from Hubbard, 2003)
1.7 Clinical associations
There are three types of HPV infections: latent, subclinical and clinical. 
In latent infection, HPV-DNA is present in host tissue and can be detected by 
molecular biological techniques, but causes no cytological abnormalities or 
clinical signs. In subclinical infection, there are histopathologically detectable 
cellular changes but no clinically detectable signs of disease. Finally, clinical 
HPV infection gives rise to both microscopically and macroscopically 
detectable disease (Severson et al., 2001).
A variety of benign papillomavirus lesions of the skin and squamous 
mucosa are caused by human papillomavirus. These include common and 
plantar warts, flat warts, anal and genital condylomata acuminatum, cervical 
flat warts, macular pityriasis-like lesions in patients with epidermodysplasia 
verruciformis, oral papillomas and juvenile laryngeal papillomas. Laryngeal
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papillomas are of concern as they occur in young children, tend to cause 
acute respiratory obstruction and often recur (Severson et al., 2001; 
Syrjanen, 2003).
1.7.1 Genital lesions associated with HPV
Although papillomavirus infections may be subclinical, the most 
common clinical changes in both males and females are anogenital warts 
(Sanclemente and Gill, 2002). HPV infections usually occur throughout the 
lower female genital tract, and multiple sites are often involved, including the 
cervix, vagina and in the vulvar region. Lesions termed cervical intraepithelial 
neoplasia (CIN) are strongly associated with HPV infection, reflect mild to 
moderate cervical dysplasia, and are typified by large round cells termed 
'koilocytes'. In men, anal condylomas and penile warts occurring separately 
or together have HPV aetiology. The male counterparts of CIN are penile 
intraepithelial neoplasia (PIN). The lesions generally occur at a much lower 
rate than CIN, but are highly associated with high risk HPV infection and can 
undergo malignant progression to penile carcinoma (Munger, 2002). It has 
been postulated that HPV plays a major role in the pathogenesis of anal and 
peri-anal cancer (Beckmann et al., 1989; Palefsky et al., 1991; Palefsky et 
al., 1998).
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1.7.2 Cervical cancer
1.7.2.1 Epidemiology of cervical cancer
Worldwide, approximately 500,000 cases of invasive cervical cancer 
are diagnosed each year. It is considered the second most common cancer 
in women worldwide following breast cancer, and it is also considered as the 
principal cancer of women in most developing countries, where 80% of all 
cases are recorded (Franco et al., 2001; Garland, 2002; Munoz et al.,
2003). However, it is evident that this may be a preventable malignancy as 
the mortality associated with cervical cancer has decreased by over 70% in 
the last 50 years in the United States, principally due to the wide spread use 
of cytology-based screening (Saslow et al., 2002; Jemal etal., 2004) (Table 
1.4).
1.7.2.2 HPV In cervical cancer
Genital HPV infections are generally acquired via sexual intercourse 
(Koutsky et al., 2002). However, HPV can sometimes be detected in the 
cervix of virgins, suggesting other routes of transmission (Xi et al., 2002). If 
women are carefully followed up, about 50% will be infected with genital HPV 
within 2 years of sexual debut (Kjaer et al., 2001; Koutsky et al., 2002). It is 
estimated that the lifetime risk of contracting a genital HPV infection is 80%; 
however, this leads to genital warts in only 5% of infected individuals. While 
abnormal cervical scrapes (i.e. contain abnormal cellular atypia) occurs in 
35% of infected females, cervical intraepithelial neoplasia (CIN) develops in 
25%, and invasive carcinoma in less than 1% of HPV infected women 
(Schiffman, 1992b; Kjaer et al., 2001; Koutsky et al., 2002). It has been 
demonstrated that most HPV infections and low-grade CIN lesion
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spontaneously regress within 8 months following identification (Hinchliffe et 
al., 1995; Wheeler et al., 1996; Moscicki et al., 1998; Ho et al., 1998; 
Koutsky et al., 2002). The odds ratios of HPV in cervical cancer has been 
suggested to range from 72 to 347 according to the HPV oncogen presence. 
(Munoz, 2000; Garland, 2002)
Epidemiological studies have also established that HPV infection is a 
central cause of intracervical carcinoma (ICC) and its precursor lesions 
(Walboomers et al., 1999; Franco et al., 2001; Bosch and de Sanjose,
2003). In particular, HPV types 16, 18 and 45 have been found to be the 
principal viruses associated with cervical malignancy. Recent studies have 
confirmed earlier reports that an increased HPV-16 viral load detected in a 
cervical smear is associated with the presence or development of CIN/3 
cervical cancer (Bekkers etal., 2004; Rousseau etal., 2004).
HPV is thought to enter the cervical mucosa via microabrasions to the 
epithelium. In benign lesions (warts) and low-grade dysplasias, the virus 
exists in an episomal form in basal cells and more differentiated cells. It 
replicates only in the nuclei of infected cells and is not transmitted from one 
cell to another; rather, release of virus from infected cells is the result of 
degeneration of desquamating cells. At the cytological and histological level, 
the cytopathic effect of HPV is the development of 'koilocytes', a mature 
squamous cell with a large perinuclear halo and enlarged hyperchromatic 
nucleus. Precursor lesions reflect the spectrum of epithelial atypia induced by 
HPV infection, ranging from permissive viral growth and benign epithelial 
proliferation (low-grade dysplasia) to disordered cell growth, genetic 
instability and deregulated viral gene expression (high-grade dysplasia). The
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target for infection by oncogenic HPV types is usually the basal cells of 
squamocolumnar junction of the transformation zone of the cervix (the part of 
the ectocervix where the epithelium undergoes transformation from columnar 
to squamous during a woman’s lifetime), and this is where the neoplasia 
usually originates (Garland, 2002).
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Table 1.4 Cervical Cancer Incidence World Wide
ncidence (Ferlay et al., 
2001)
Region
No of cases, 1985 
(Parkin et al., 1985)
No of cases, 1990 
(Parkin et al., 1999 )
No of cases, 2000 
(Ferlay et al., 2001)
CR ASRW 15-44 45-54 55-64 65+
World 437 300 371 200 470 606 15.7 16.1 9.5 44.9 51.9 41.9
More developed 93 700 83 300 91 451 15.0 11.3 11.9 22.4 23.8 26.3
Less developed 343 600 287 900 379 153 15.8 18.7 9.0 53.6 65.0 53.8
Africa 51 500 52 500 67 078 17.1 27.3 11.0 71.5 100.5 95.4
Eastern 21 800 21 500 30 206 24.4 44.3 16.1 114.8 174.4 153.9
Middle 6600 5700 6947 14.4 25.1 8.5 54.0 73.3 137.4
Northern 6200 5200 10479 12.2 16.8 6.2 49.0 68.5 45.9
Southern 6600 6500 5541 23.2 30.3 15.5 67.8 98.5 118.2
Western 10 300 13 600 13 903 12.5 20.3 9.5 57.4 70.6 60.3
America 68 000 74 800 92 136 22.0 21 15.1 55.2 57.8 55.0
Caribbean 3000 5000 6670 34.8 35.8 17.7 82.7 102.1 155.6
Central 13 700 17 700 21596 31.7 40.3 22.5 111.7 109.9 136.1
South 35 300 36 900 49 025 28.1 30.9 16.8 85.5 90.2 101.4
United States and Canada 16 OOO 15 200 14 845 9.5 7.9 9.0 15.4 16.8 14.2
Europe 67 OOO 58 200 64928 17.2 13 14.1 26.3 26.5 28.1
Eastern 40 100 27 500 35482 21.9 16.8 17.8 34.5 34.9 36.6
Northern 6300 7600 6049 12.6 9.8 12.0 17.6 16.7 20.2
Southern 8600 9900 10 116 13.7 10.2 10.5 20.8 23.7 20.9
Western 11 900 13 200 13 282 14.2 10.4 11.3 20.5 19.6 25.1
Asia 249 OOO 183 400 245 670 13.6 14.9 7.2 44.0 52.8 39.6
Asia excluding China 170 800 158 700 212297 18.0 21.1 10.3 63.0 75.0 53.5
Eastern 94 200 42 500 51 266 7.1 6.4 2.6 18.4 18.9 25.4
China 78 200 24 700 33 373 5.4 5.2 1.7 17.2 16.1 19.1
Japan 9400 8500 11681 18.1 11.1 8.8 21.2 25.6 42.2
Other 6600 9300 6212 16.2 15.3 10.3 33.6 41.9 55.0
South easten 42 500 30 900 39 648 15.3 18.3 9.1 59.0 58.2 45.9
Southcentral 109 500 107 OOO 151 297 20.9 26.5 11.9 79.2 100.8 65.6
Western 2800 3000 3458 3.8 4.8 2.6 13.1 15.3 14.1
Oceania 1800 2100 2156 14.2 12.6 12.3 27.4 28.2 29.0
Pacific islandsf 500 800 1078 29.1 40.3 23.1 91.2 107.1 167.8
Australia /  N.Zealand 1300 1300 1077 9.4 7.7 8.6 15.5 14.8 16.6
CR= crude rates per 100 OOO; ASRW= age-standardized rates per 100 000. World standard population. All rates correspond to the most recent compilation of cancer incidence. 
T Melanesia, Micronesia and Polynesia 
Adapted from Bosch and deSanjose., 2003
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1.8 Routes of transmission of HPV
Human papillomavirus is mainly transmitted by direct contact with the 
source. Thus, the incidence of the skin HPV infection is known to increase 
when schoolchildren first make body contact with one another. 
Epidemiological studies of cervical cancer have clearly documented that 
HPVs are transmitted by sexual contact (IARC, 1995; Bosch et al., 2002; 
Waller et al., 2005). Recent studies have shown that 50%-80% of male 
partners of women with either CIN or genital warts or who were attending a 
gynaecology referral clinic have lesions with clinical or morphological 
features consistent with HPV infection. The transmission of anogenital HPV- 
16 infections have been consistently associated with sexual contact and the 
prevalence of cervical HPV infections increases between the ages of 15 and 
40 years; especially among persons with multiple sexual contacts (Severson 
etal., 2001).
The relationship between the sexual behaviour of patients, regarding 
age of sexual debut, number of partners, the practicing of oral sex and any 
history of genital warts has been extensively studied. It has been reported 
that, high risk HPVs were detected more often in patients with more sexual 
partners than the controls. Also, a higher risk of infection is found among 
those reporting oral-anal contact (Smith et al., 2000; Gillison and Lowy, 
2004; Scully, 2005). Furthermore, one study has shown that husbands of 
uterine cervical cancer patients have a higher risk of developing both tonsillar 
cancer and cancer of the tongue (Hemminki et al., 2000; Hafkamp et al.,
2004). Of note, it has been demonstrated that people with a history of oral 
sex show a four-fold higher chance of HPV infection than those without
30
Chapter 1____________________________________________________Introduction. Human papillomavirus
(Ritchie et al., 2003; Hafkamp et al., 2004). Although, in a recent article it 
has been suggested tha oral sex had no association to oral HPV infection, 
indeed, they have proposed that a persistent oral HPV infection of the 
spouse may increase the risk 10-folds of persistent oral HPV infection in the 
other spouse (Rintala et al., 2006). It has also been suggested that the oral 
cavity may play a role as a reservoir for HPV infection. The vertical 
transmission of mucosotropic HPV from mother to baby during natural 
childbirth has also been observed (Daling et al., 1986; McKaig et al., 1998; 
Severson etal., 2001).
1.9 Mechanism of HPV pathogenesis
As discussed in Section 1.1.3, HPV must infect mitotically active cells 
to enable it to proliferate. The receptors for entry of the virus into these cells 
are currently unknown. However, heparan sulphate has been proposed as 
mediator of initial attachment of virions to cells (Joyce et al., 1999; Giroglou 
et al., 2001; Longworth and Laimins, 2004). Three possible paths of entry 
have been suggested; from the site of mucosal injury; via metaplastic 
epithelium and from the squamo-columnar cell junction (Szentirmay et al.,
2005). Cells in the basal layer consist of stem cells and transient-amplifying 
cells that are continuously dividing, which provide a reservoir of cells for the 
suprabasal region. Infection of these cells by HPV leads to the activation of a 
cascade of viral gene expression that results in the production of 
approximately 20 to 100 extrachromosomal copies of viral DNA per cell. This 
average copy number is stably maintained in undifferentiated basal cells 
throughout the course of the infection (Longworth and Laimins, 2004).
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1.9.1 Integration of HPV-DNA
The progression from pre-invasive to invasive cancer may be related 
to the physical state of HPV-DNA (episomal, integrated or mixed). Many 
researchers have demonstrated that the integration of HPV-DNA into the 
host cell genome occurs early in cancer development, and it is an important 
step in malignant transformation. However, integration appears to occur more 
frequently in HPV-18 associated cervical cancer than in HPV-16 associated 
cervical cancer (Munger, 2002; Sanclemente and Gill, 2002; Ha etal., 2002; 
zur Hausen, 2002). Integration usually disrupts or deletes either E1 or the E2 
open reading frames, which result in loss of expression of the corresponding 
gene product and also to upregulation of the viral oncoproteins E6 and E7 
(Motoyama etal., 2004; Szentirmay etal., 2005).
HPV genes that cause cancer are of two distinct types: oncogenes 
(e.g. E6 and E7), and tumour-suppressor genes (e.g. p53 and pRb). The two 
types have opposite effects in carcinogenesis. Oncogenes facilitate 
malignant transformation, whereas tumour-suppressor genes block tumour 
development by regulating genes involved in cell growth. The E6 and E7 
proteins of high risk HPVs are essential for initiation and maintenance of the 
transformed state (Munger, 2002; Longworth and Laimins, 2004).
1.9.2 The E6 protein
The E6 proteins are of both high and low-risk types, and are 
approximately 150 amino acids in size. They can interact with the cellular 
wild-type p53 tumour suppressor protein, inducing p53 degradation (a well- 
characterized tumour suppressor that regulates the expression of proteins
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involved in cell cycle control, including the cyclin kinase inhibitor). Normally, 
p53 prevents cells with damaged DNA from progressing through the cell 
cycle by arresting them at the transition from Gi to the S phase, thus allowing 
time for DNA repair. In case of excessive damage to the DNA, the cell will 
undergo p53 and BAK-mediated apoptosis. Therefore, inactivation of p53 by 
E6 leads to deregulation of the cell cycle and promotes accumulation of 
mutations as well as chromosomal instability. E6 oncoproteins activates host 
cell telomerase (a ribonucleotide complex that synthesizes telomere repeat 
sequences), which is critical for cell immortalization during cell growth 
(Hafkamp etal., 2004). .
1. 9.3 The E7 protein
It has been demonstrated that the major function of E7 protein is the 
interaction with the cellular pRb protein (important as a regulator of the cell 
division). The binding of E7 protein to Rb results in pRb degradation 
(normally prevents cells from entering the cell cycle by inactivating E2F). It is 
known that E7 from the oncogenic HPV type 16 and 18 binds with pRb more 
strongly than does E7 from the benign HPV types. E7 appears to block the 
function of cyclin-dependant kinase inhibitor p2 i WAF/CIP1 and to induce 
centriole amplification. These actions of E7 protein also contribute to 
tumourogenesis by stimulating cell cycle progression and the development of 
genetic instability and aneuploidy (Hagensee, 2000; Hafkamp etal., 2004).
Loss of Rb function can also lead to activation of p53, which normally 
suppresses cell growth and induces or potentiates apoptosis. In many 
cancers, a combination of mutation and gene deletion leads to loss of p53
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activity. However, in cervical cancer, the p53 gene is intact and the p53 
protein is expressed in the transformed cells, but its activity is lost by binding 
to the HPV-E6 oncoprotein. The loss of p53 mediated apoptosis is thought to 
be an important part in tumour progression (Garland, 2002) (Figure 1.6).
It has been suggested that the differences between the ability of the 
low and high-risk HPV types to induce immortalization and transformation 
may depend on their abilities to interact with the cell cycle components, 
resulting in the loss of multiple cell cycle checkpoints that are essential in 
maintaining host genome fidelity, thus leading to potential accumulation of 
genetic abnormalities (Brenna and Syrjanen, 2003).
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Figure 1.6 In premalignant lesions, the HPV genome is present as circular DNA in the 
nucleus of infected cells, harbouring the ORFs. During cancer development, the viral DNA 
becomes integrated into the host, cell genomic DNA, thereby frequently losing (parts of E2, 
E4, E5 and L2 genes). In most cases, the integrated viral DNA contains the intact E6 and E7 
genes of which the expression is upregulated. (Adapted From Hafkamp et al., 2004)
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1.9.4 Co-factors in HPV carcinogenesis
As discussed previously, epidemiological studies have indicated that 
only a small percentage of infected women with oncogenic HPV types will 
progress to high-grade squamous intraepithelial lesions (HSIL) or cervical 
malignancy. Thus, it has been suggested that other factors acting in 
conjunction with HPV influence the transition from cervical HPV infection to 
malignancy (Castellsague and Munoz, 2003). A high percentage of infected 
women usually clear the infection by the immunological mechanisms (zur 
Hausen, 2002).
Many sexual behaviour parameters have been examined to determine 
their relationship with HPV infection. A wide variety of co-factors (that do not 
themselves cause cervical cancer, but may possibly influence its 
development) have been identified, which includes high parity, long term use 
of oral contraceptives, cervical trauma and co-infection with other microbes 
(e.g. C.trachomatis, HSV-2 and HIV). Of note, and similar to oral squamous 
cell carcinoma, tobacco smoking (Trimble et al., 2005) and poor diets has 
been suggested to positively influence the development of HPV related 
cervical malignancy. Finally, host co-factors, including endogenous 
hormones, genetic factors such as human leukocytes antigen (HLA) and 
other host factors related to the host’s immune response, may influence the 
risk of progression from HPV infection to malignancy (Castellsague and 
Munoz, 2003) (Figure 1.7).
Defective immunosurveillance certainly plays a role in the likelihood of 
females developing cervical malignancy. Women with HIV infection or AIDS
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are known to be at an increased risk for HPV infection and cervical 
malignancy (Branca etal., 2000; Branca etal., 2004). HPV infection and CIN 
in HIV infected women can rapidly progress to high-grade CIN and cancer 
(Amit et al., 2001; Hawes et al., 2003).
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Figure 1.7 Factors and co-factors in cervical malignancy. 
(Adapted from Castellsague et al., 2002)
1.10 Therapies
Generally, therapy of HPV infections can be divided into antitumour 
(i.e., anti-wart) and antiviral interventions. For the dysplastic and neoplastic 
lesions, surgery is the standard of care with adjunctive chemotherapy and/or 
radiotherapy for some malignancies. Treatment of benign lesions, especially 
non-anogenital warts, usually remains antitumour in most cases, 
chemotherapeutic, cytodestructive, surgery, etc. Such non-antiviral
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interventions are also used in the majority of cases of condyloma 
acuminatum. Therapies that are neither antiviral nor immunomodulator 
remain the standard of care for most cases of non-anogenital warts and for a 
number of genital warts. Surgical excision offers the advantage of rapid 
removal of the warts but is associated with high recurrence rates as well as 
the potential for bleeding, scarring, and bacterial infection (Stone et al., 
1990). Electrosurgery may reduce the amount of bleeding but not the 
problem of recurrences. Treating warts with CO2 laser can achieve excellent 
results, but recurrences rates can be as high as with other surgical 
treatments. Disadvantage of CO2 laser is its high cost and the possibility of 
the presence of HPV-DNA in the laser plume (Ferenczy etal., 1995).
Cryotherapy is a destructive treatment for warts that is bloodless but 
can be painful, and often requires a series of treatments over several weeks 
(Abdullah etal., 1993). A number of chemotherapeutic/cytodestructive agents 
are available with different qualities. The logical approach to a viral infection 
such as HPV is to use an antiviral drug. This criterion is met by the interferon 
(IFN) a, p, y as well as by Imiquimod and Cidofovir. Immunotherapies are 
promising because they are thought to enhance the effectiveness of local 
therapy while decreasing the recurrence rates (Severson etal., 2001).
Interferon is a protein that interferes with viral replication; they have 
been identified as the body’s first line of defence against most major viral 
diseases. Interferons are divided into Type 1 (a and p) Type 2 (y). Type 1 
shares the same membrane receptors, and is predominantly antiproliferative, 
while Type 2 has a distinct receptor, and act mostly as immunomodulators 
promoting cell-mediated immunity. Interferon a (IFN a) is a multigene product
37
Chapter 1 Introduction. Human papillomavirus
formed by B-lymphocytes, null lymphocytes and macrophages in response to 
viral particles or nucleic acids. Interferon p (IFN p) is a single gene product 
formed by fibroblasts, epithelial cells and macrophages in response to viral 
particles to nucleic acids. In addition, Interferon y (IFN y) is a single gene 
product formed by T-lymphocytes in response to foreign antigens (Rockley 
and Tyring, 1995; Severson etal., 2001).
Interferon alpha (IFN a) was the first antiviral agent approved by the 
United States Food and Drug Administration (FDA) for the treatment of 
condyloma acuminatum. Despite its efficacy and safety, IFN a never became 
widely used for genital warts because of its route of administration, side 
effects and cost. Imiquimod is an immune response modifier with antiviral 
activity that has been recently FDA approved for genital wart therapy. It is 
topically self-applied, safe, effective and appears to be associated to 
determine objectively the cost effectiveness of various therapies for 
condyloma acuminatum in the absence of head-to-head trials. Many studies 
showed 5% solution of Imiquimod was more effective than control (clearance 
rates 52% compared with placebo). Further studies showed that Imiquimod 
has induced tumour wart regression which was associated with local 
interferon and tumour necrosis factor a production (Tyring et al., 1998; 
Hagensee, 2000).
1.11 Vaccines
There are three approaches to HPV vaccine development. The first 
approach is to block HPV-induced neoplasia by preventing the virus from 
establishing infection in the epithelium, mainly through the induction of
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neutralizing antibody via viral capsid protein. A prophylactic vaccine should 
stimulate the complete neutralization of free virus upon exposure before 
infection can occur. However, this may be of less benefit to those individuals 
who already have established infection and dysplasia. The second approach 
of vaccine development addresses the needs of these patients by attempting 
to induce a cellular immune response, which may be able to prevent and 
induce the regression of neoplastic lesions. This strategy is known as 
antigen-specific immunotherapy. Finally, the third approach seeks to combine 
prophylaxis and therapy in one vaccine, in an attempt to provide total 
coverage for people who are newly exposed to high risk virus and for people 
with current infections and dysplasia (Devaraj etal., 2003).
It has been demonstrated that a prophylactic or therapeutic vaccine 
may prevent HPV-associated HNSCC in the future. Since, a prophylactic 
vaccine composed of HPV-16 viral capsid proteins has shown promise for 
the prevention of persistent cervical infections (Koutsky etal., 2002; Gillison,
2004).
In-vitro, production of HPV empty capsids has led to the development 
of vaccines against various types of HPV. Prophylactic vaccines against HPV 
will probably target the empty capsid as an antigen but will need to be 
multivalent to be effective. Although, therapeutic vaccines target is less well- 
defined, modified empty capsids may also be a vaccine candidate. HPV-16 
E6 and E7 conjugated with L2 protein and assembled with L1 into empty 
capsids have the potential advantage of combining a prophylactic and a 
therapeutic vaccine (Hagensee, 2000).
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1.12 Epidemiology of head and neck squamous cell carcinoma (HNSCC)
Head and neck squamous cell carcinoma (HNSCC) comprises a 
related group of cancers including neoplasms originating from the oral cavity, 
pharynx, larynx and oesophagus. Worldwide, HNSCC represent 6.5% of the 
annual cancer cases with an estimated number of new cases per annum of 
38.3/100,000 in the US (Forastiere et al., 2001). In recent decades, the 
incidence of HNSCC has increased in Western Europe and the US (Hafkamp 
et al., 2004). Tobacco smoking, extensive alcohol drinking and betel quid 
chewing are well known risk factors in the aetiology of HNSCC. These factors 
are independent and it has been suggested that their effects are synergistic 
when combined (Lewin etal., 1998; Forastiere etal., 2001).
Some studies observed the effect of alcohol upon the development of 
HNSCC among smokers and non-smokers (Talamini et al., 1990). Other 
studies have demonstrated the relation of HNSCC with the amount of both 
tobacco and alcohol consumption. An increased risk of HNSCC has been 
observed with both quantity of tobacco consumption, and the duration of 
habit. In addition, a decreased risk has been observed following long-term 
cessation of tobacco smoking. Similarly, a dose-relationship has been 
observed with increased alcohol consumption (Brennan and Boffetta, 2004).
1.12.1 The role of genetic factors in HNSCC
It has been demonstrated that in cervical oncogenesis, 
aneuploidization precedes integration of high-risk HPV genomes. 
Deregulated viral oncogene expression appears to result first in 
chromosomal instability and aneuploidization, this being followed by
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integration of high-risk HPV genomes into cellular chromosomes (Cooper et 
al., 2003; Melsheimer etal., 2004).
Braakhuis and colleagues (2004) have recently demonstrated that 
HNSCCs with HPV type 16 DNA expressing E6 and E7 had significantly 
lower rates of loss of heterozygosity (LOH) at chromosomal regions 3p, 9p 
and 17p than tumours that contained inactive HPV-DNA (i.e. no expression 
of E6 and E7), they also observed a negative association between active 
HPV-DNA and mutations in TP53 (the gene encoding the p53 tumour 
suppressor). All of these genetic regions are known to contain tumour 
suppressor genes that are commonly deleted in HNSCC. It is assumed that 
LOH at these regions plays a role in HNSCC tumourogenesis. Hence, 
HNSCC associated with HPV would seem to involve oncogenic mechanisms 
different to that of non-HPV related tumours (typically caused by tobacco 
and/or alcohol).
Head and neck squamous cell carcinoma is occasionally featured in 
several inherited cancer syndromes, in particular, Fanconi’s anaemia, a rare 
autosomal recessive disorder of DNA repair, characterized by congenital 
bony formations, progressive bone marrow failure and predisposition to 
leukemia and carcinomas (e.g. aplastic aneamia). Recently, it has been 
observed that patients with Fanconi’s anaemia have a 500 to 700 fold higher 
incidence of HNSCC than the general population (Syrjanen, 2005). It is 
considered to be an excellent model for studying HPV and its role in 
carcinogenesis (Lowy and Gillison, 2003; Szentirmay et al., 2005), 
particularly as HPV is often detectable in OSCC of patients with Fanconi’s 
anaemia. The virus may be of aetiological importance for the development of
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OSCC in these patients. However, a p53 polymorphism may also be of 
aetiological relevance (Kutler etal., 2003; Gillison and Lowy, 2004).
1.13 Epidemiology of oral squamous cell carcinoma (OSCC)
According to world statistics, approximately 267,000 new oral cancer 
cases were diagnosed and about 128,000 patients died from this cancer in 
the year 2000, the high risk areas and countries include the Bas-Rhino region 
in France, the Vasi region in Hungary, the Hong Kong in China, India, Brazil 
and the Philippines (Ferlay J et al., 2001). Cancer of the oral cavity is the 
sixth most prevalent cancer worldwide and is the third most common cancer 
in the developing countries and the eighth in developed countries. Of note, 
90% of these oral cancers are squamous cell carcinoma (SCCs) (Syrjanen,
2005). The overall incidence and mortality associated with OSCC continues 
to rise. Even though a higher number of new cases of cancer occur in 
developed countries (1,3329000 vs. 787,000) a higher incidence of OSCC 
occur in developing countries (8.4 / 100,000 in men and 2.3 /  100,000 in 
women) than developed countries (5.8 / 100,000 in men and 3.3 /100,000 in 
women) (Greenlee et al., 2000; Carvalho et al., 2004). Trends in 5-year 
survival have not changed since 1974, the overall survival being 53 % for the 
period between 1989 and 1995. Moreover, a recent analysis show that while 
survival is improving for all cancers, the greatest decline in mortality is 
associated with OSCC (Carvalho etal., 2004).
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1.14 Human papillomavirus in head and neck squamous cell carcinoma
Epidemiologic and molecular pathology studies provide substantial 
evidence that HNSCC is usually linked with tobacco and/or alcohol, or betel 
use, but there are group of individuals who develop HNSCC in the absence 
of exposure to these risk factors. The possibility of the involvement of 
microbial agents has been proposed. Syrjanen and colleagues, first 
described the involvement of HPV in the pathogenesis of HNSCC in 1983, 
when morphologic features consistent with HPV infection were identified 
within OSCC tumour cells. A study by the IARC (Herrero et al., 2003) have 
demonstrated that HPV-positive HNSCC are more common in patients who 
do not smoke or chew tobacco, but persistent HPV infection and tobacco 
consumption combined are associated with an increased risk of HNSCC. In a 
recent systematic review, the overall prevalence of HPV in HNSCC was 
25.9% only (Kreimer et al., 2005), while the OR of HPV in HNSCC has been 
reported to range between (3.7-5.4) (Syrjanen, 2005).
It has been observed that HPV positive HNSCC show a statistical 
association among individuals with a history of multiple sexual partners, 
practicing oral sex and with a previous history of genital warts which suggest 
sexual transmission (Schwartz et al., 1998; Herrero et al., 2003). Due to the 
similarities of the mucosal lining in the head and neck region and that of the 
cervix, it is expected that only a small percentage of HNSCC patients with 
HPV infection will develop virus-associated malignancies as in cervical 
cancer, which indicates that other co-factors are involved in the progression 
from an infected cell to a transformed cell with invasive potential (Hafkamp et 
al., 2004).
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Human papillomavirus type 16 has been identified in approximately 
90% of HPV positive HNSCC and is usually present in episomal, integrated 
and mixed forms (Herrero etal., 2003; Gillison and Lowy, 2004; Chen etal., 
2005a). The presence of high-risk type in healthy oral mucosa suggests a 
dormant infection that might contribute to the development of oral cancer 
later (Sugerman and Shillitoe, 1997) or that not all HPV-16 lead to OC . A 
novel HPV-16 related virus has been proposed by Maitland e ta l (1989), they 
have claimed that this subtype is associated with HNSCC causing changes in 
the promoter-enhancer region that make them specifically active in oral 
keratinocytes (Scully, 2002).
The increased distinction between HPV-HNSCC and HPV-negative 
HNSCC supports the hypothesis of the two pathways in the pathogenesis of 
HNSCC (Figure 1.8), one driven by alcohol and tobacco, and the other by 
HPV. The molecular abnormalities found in HPV-HNSCC reflect the 
oncogenic function of viral E6 and E7. The molecular signature of HPV- 
HNSCC includes HPV-DNA, HPV-E6 and E7 expression, TP53, lack of 
promoter methylation of 14-3-3a, lack of RASSF1A, decreased cyclin D 
kinase (CDK), decreased pRb and upregulation of p16. By contrast, HPV- 
negative HNSCC is characterised by tobacco-induced p53 mutation, 
decreased expression of 14-3-3a and RASSF1A, increased CDK, normal or 
increased levels of pRb staining and decreased p16 due to deletion or 
mutation (Gillison, 2004) (Table 1.5).
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Table 1.5 Clinical and molecular differences in HNSCC +positive HPV DNA and HNSCC -  
negative HPV DNA. (Adapted from Hafkamp etal., 2004)
HPV-positive HPV-negative
Clinical characteristics
Location Oropharynx All sites
Differentiation grade Poor Well
Basaloid appearance Yes No
Size at diagnosis Smaller Larger
Disease stage 
Patient’s age
More advanced Less advanced
Younger Older
Patient’s tobacco intake Less More
Patient’s alcohol intake Less More
Overall/disease-free survival Longer Shorter
Molecular characteristics
HPV DNA Yes No
E6/E7 expression Yes No
p53 mutations No Yes
pRb downregulation Yes No
p l6 overexpression Yes No
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The p53 pRb Pathways
Growth promoting
RASSF1A . I  COK4-6
— ICycfcD'Ny/''
col cycle
DNA Damage - *  p53 - *  -p21
DNA
01 -»
HPV Positive HNSCC
RASSF1A ~ I 0' * * ’ 0 '  ------' v '
CydnD *
w t p53
>6E6 p53<Ub)n «Poptosis
(Protsolysts) DNArspsfr
Tobacco
Alcohol
HPV Negative HNSCC
RASSF1A 4—| CydnD ♦ - 'y ' '
ppRb p16 4-
Figure 1.8 Different mechanisms in HPV-HNSCC and HPV-negative HNSCC. (A) The p53 
and pRb pathways commonly altered in human cancers. (B) Molecular alterations in HPV- 
HNSCC reflect the activity of viral oncoproteins E6 and E7. HPV 16 E6 and E7 facilitate the 
proteolysis of p53 and pRb, respectively, and thereby disrupt control of cell cycle progression 
and DNA damage repair (C) Molecular alterations in HPV-negative HNSCC. It is 
characterized by tobacco-induced p53 mutations.
(Adapted from Gillison, 2004)
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1.14.1 Humanpapilloma virus and tonsillar carcinoma
Epidemiological and molecular studies have suggested an aetiological 
role for HPV in tonsillar carcinomas, the detection rate being as high as 51% 
(Syrjanen, 2004). It has been observed that the palatine tonsils are the most 
likely tonsillar tissue to be infected with HPV among other tonsils. It has been 
suggested that the tonsillar tissue may be susceptible to infection by HPV 
that is present in oral and pharyngeal fluids. The HPV particles can easily 
access the basal cell layer due to the thining of the epithelium in some areas 
caused by the deep invagination of the tonsillar epithelial mucosa. In addition 
the local presence of the cytokines produced by lymph nodes tissues may 
positively influence HPV transcription and cellular transformation (Klussmann 
et al., 2001; Syrjanen, 2004).
Recent studies demonstrated that patients with HPV-associated 
anogenital cancer had a 4.3 fold higher risk of tonsillar cancer than other 
patients with no HPV infection in the genital area (Frisch and Biggar, 1999; 
Syrjanen, 2004), which may suggest the involvement of oral sex habit as a 
route of transmission of the virus. High-risk type 16 was the most frequent 
type identified among tonsillar carcinoma samples, and the virus being 
mostly present in an episomal form. However, low risk HPV types 6/11 have 
also been detected in HPV-positive tonsillar carcinoma (Klussmann et al., 
2003; Syrjanen, 2004). Some studies have indicated that patients with HPV- 
16 positive tonsillar carcinoma tend to have a better long-term survival rate 
than those with HPV-negative disease, and thus the former seem to 
represent a distinct group of patients with tonsillar carcinoma (Syrjanen, 
2004; Syrjanen, 2005).
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1.14.2 HPV in salivary glands lesions
There is a little data concerning the association of HPV with salivary 
gland malignancies. One study examined the presence of CMV, HHV8, EBV 
and HPV in pleomorphic adenomas, acinic cell carcinoma, lymphomas of the 
parotid gland, squamous cell carcinoma of salivary gland, mucoepidermoid 
carcinomas, adenocarcinomas, adenoid cystic carcinomas, epithelial- 
myoepithelial carcinomas and myoepithelial carcinomas. The results showed 
no evidence of any association of HPV with salivary gland tumours (Atula et 
al., 1998). Another study also failed to detect HPV in pleomorphic adenomas 
(Rommel et al., 1991). Of note, a recent study had investigated the 
clinicopathological features of condyloma and condyloma like-lesion of the 
oral cavity and suggested that oral condyloma acuminatum may involve the 
excretory duct of minor salivary glands (Henley etal., 2004).
1.14.3 HPV in HNSCC in young adults
An increasing interest has been observed for the possible role of HPV 
in OSCC in young adults (von Doersten et al., 1995), which has a 
tremendous social implications in young populations since the disease is 
fatal. Most clinicians believe that young patients with HNSCC make up a 
distinct subset of HNSCC (usually males under 40 years of age and with little 
or no exposure to known risk factors such as heavy tobacco smoking and 
high alcohol intake), and more concern exists for the prognosis and treatment 
for these young patients. The association between tobacco and alcohol 
intake in OC of older patients has been documented. However, many studies 
have demonstrated a lack of involvement with the traditional habits of
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smoking/alcohol consuming in such young group. Although, HPV has been 
proposed as a possible risk factor for the development of HNSCC, the role of 
HPV in young individuals with HNSCC has not been determined (Sisk et al., 
2000).
The relation between HPV positive HNSCC and prognosis/survival 
rate is not consistent. It has been suggested that patients with HPV infected 
HNSCC have a better prognosis compared with those without HPV infection 
(Haraf et al., 1996; Gillison et al., 2000; Smith et al., 2004). Although, other 
previous studies have observed no differences between the two groups of 
patients (Riethdorf etal., 1997; Pintos etal., 1999). In deed, the prognosis of 
HPV positive patients was poorer than those with HPV negative HNSCC 
group (Clayman et al., 1994). Interestingly, in one study when the results 
stratified for genders, HPV infected HNSCC males show a better prognosis 
than HPV negative males, but this was not the case among females (Ritchie 
et al., 2003). Pertaining to recurrence, Gillison in 2002, have observed that 
patients with HPV positive HNSCC showed a 1.4 fold greater risk of 
recurrence when compared with HPV negative patients.
1.15 Other oral lesions associated with HPV
Histologically, it is known that the oral cavity is lined by a mucous 
membrane consists of a stratified squamous epithelium and lamina propria 
made up of dense connective tissue. The squamous epithelium of the 
gingiva, hard palate and the dorsum of the tongue are completely keratinized 
with a superficial horny layer, whereas in the lip, cheek, vestibular fornix, 
alveolar mucosa, floor of the mouth and soft palate, the epithelium is non­
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keratinized. Thus, the histology of oral mucosa resembles that of the uterine 
cervix, other sites of the lower genital tract or skin, depending upon the 
anatomic site. In view of the similarities, both mucosal and cutaneous HPV 
types would be expected to infect the soft tissue of the mouth lining (Lakshmi 
etal., 1993; Syrjanen, 2003). Considering that, in the genital region this virus 
is implicated in the development of cancer in the uterine cervix, it is possible 
that this link would also be present in relation to oral epithelial cancer. 
Therefore, it has become important to know the frequency of this virus in the 
oral cavity and its probable relationship with the presence of malignant 
neoplasm in the region. HPV infection is known to be associated with oral 
mucosal squamous cell papillomas (SCP), condyloma acuminatum (venereal 
warts), verruca vulgaris (oral warts), and focal epithelial hyperplasia (FEH) 
(Syrjanen, 2003).
1.15.1 Squamous cell papilloma (SCP)
Squamous cell papilloma is a relatively common benign tumour of the 
oral epithelium, it appears clinically as small finger-like projections, resulting 
in a lesion with a rough or cauliflower verrucous surface. Few researchers 
have examined the association of HPV and SCP by different diagnostic 
methods and the results varied considerably, mainly HPV-6, followed by 
HPV-11 are the types most commonly detected in oral squamous papilloma 
of the mouth (Greer and Goldman, 1974; Praetorius, 1997; Syrjanen, 2003).
1.15.2 Condyloma acuminatum (venereal warts)
Condyloma acuminatus is regarded as a sexually transmitted disease 
affecting the skin and mucous membranes of the anogenital tract. Oral
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condyloma can be acquired not only by oral sex but also as a result of 
maternal transmission. In the genital tract, the term condyloma and papilloma 
were used separately, lately; both lesions have been called condylomas. This 
rule applied also with the oral lesions, since both condylomas and papilloma 
harbour the same HPV types found in the genital condylomas. Many studies 
showed the relation of HPV and condyloma acuminatum using different 
laboratory techniques, HPV types 2, 6, and 11 showed high presences in the 
samples up to 90%. One study used specific primers detected HPV 6/11, 
16/18, 31/33 and 35 in lesional tissues (Zeuss et a!., 1991; Praetorius, 
1997; Syrjanen, 2003).
1.15.3 Verruca vulgaris (oral wart)
Verruca vulgaris is the most common prevalent HPV lesion of the skin, 
but is also found in oral mucosa. The most common oral sites of these 
lesions are areas in which keratinization of the epithelium resembles that of 
the skin, i.e., lip, hard palate and gingiva. On clinical examination, verruca 
vulgaris is often indistinguishable from SCP and condyloma. To confirm the 
diagnosis, cutaneous HPV types should be identified in oral verruca. Human 
papillomaviruses types 2 and 57 are the mostly associated HPV types, 
although some studies have found HPV 6/11 in verruca vulgaris (Praetorius, 
1997; Syrjanen, 2003).
1.15.4 Focal epithelial hyperplasia (FEH)
Focal epithelial hyperplasia is known as Heck’s disease, manifests as 
multiple, soft, flat or rounded slightly elevated nodules. The lesions are 
asymptomatic, and may persist for several years, but they tend to regress
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spontaneously, although that the lesions occasionally may recur. It was first 
described in Native American Indians, now it is also known to arise in some 
ethnic groups like the Eskimos (Jayasooriya et al., 2004). It appears that 
HPV types 13 and 32 are strongly associated with FEH, these having been 
detected in 75%-100% of examined FEH specimens (Praetorius, 1997; 
Syrjanen, 2003; Jayasooriya etal., 2004).
1.16 HPV in potentially malignant oral mucosa
It is known that the development of head and neck malignancies such 
as oral squamous cell carcinoma (OSCC), follow a multistep genetic 
progression from normal mucosa to invasive disease (Shin et al., 2001). 
Early disease manifests histopathologically as dysplasia, which may have 
some of the genetic changes observed in OSCC. Such disease manifests 
clinically as a localized area of white and/or red patches described as 
leukoplakia or erythroplakia.
1.16.1 HPV in oral epithelial dysplasia
Oral epithelial dysplasia (OED) may be histologically graded as mild, 
moderate and severe, this being usually, but not always, a predictable 
gradient of malignant potential (Jaber etal., 2003; Sudbo et al., 2004). Oral 
epithelial dysplasia (OED) is thought to be principally caused by prolonged 
high tobacco usage and/or alcohol consumption (Jaber et al., 1999). In 
addition OED can arise with lichen planus (Epstein et al., 2003; Dey, 2004) 
and in areas adjacent to OSCC (Chang et al., 1990). Thus, OSCC may be 
preceded by epithelial changes similar to those of CIN. Thus, it would not be
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unexpected for HPV to be detected in OED. In deed, HPV-DNA has been 
detected in 0-85% of lesions with clinical and/or histopathological features of 
likely OED (Gassenmaier and Hornstein, 1988; Bouda et al., 2000; 
Sugiyama et al., 2003; Ha and Califano, 2004). If HPV is of importance in 
the aetiology of oral squamous cell carcinoma, it would be expected to be 
present in oral epithelial dysplasia (Table 1.6).
However, the results of some of the previous studies must be 
considered carefully as they did not clearly detail the presence and/or 
severity of the OED in the examined lesions. In addition, a plethora of 
different methods of detection of HPV has been employed in these studies of 
OED and other potentially malignant diseases of oral mucosa and OSCC. 
Nevertheless, high risk HPV genotypes particularly HPV-16 or 18 were 
typically present in OED (or OED-like) lesions that carried HPV (Ha and 
Califano, 2004). Sugiyama and colleagues in 2003, suggested that the 
increased carriage of HPV in potentially malignant lesions does raise the 
possibility that this virus may act as an initiator of epithelial proliferation or 
play a role in the early stage of oral carcinogenesis.
Other diseases considered potentially malignant have also been found 
to be infected with HPV. These include oral lichen planus (OLP) (15.4% - 
87.5%) (Kashima etal., 1990; Jontell etal., 1990; Wen etal., 1997b; Sand 
et al., 2000; Ostwald et al., 2003; Lazzari et al., 2004), proliferative 
verrucous leukoplakia (PVL) (10% - 89%) (Palefsky et al., 1995; 
Gopalakrishnan et al., 1997; Fettig et al., 2000; Campisi et al., 2004).
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1.16.2 HPV in proliferative verrucous leukoplakia
Proliferative verrucous leukoplakia is known as a very aggressive form 
of oral leukoplakia with high morbidity and mortality rates due to its high 
potential for malignant transformation. Hansen et al first described PVL in 
1985, and it is characterized histopathologically by the presence of multi­
focal hyperkeratotic lesions, which can easily be misinterpreted as a form of 
simple hyperkeratosis. In the recent years, PVL is considered as a lesion with 
an uncharacteristic entity with high risk of malignant transformation. In deed, 
the transformation rate in PVL is reported in up to 86.7% of the cases 
(Hansen etal., 1985; Silverman S Jr and Gorsky, 1997). The clinical course 
of PVL is gradual but progressive, begins as hyperkeratotic plaques that 
slowly progress into exophytic verrucous plaques. Focal areas of 
erythroplakia are common as a late manifestation of the disease. Patients 
affected with PVL are often middle-aged non-smokers/alcohol drinker 
females (Batsakis et al., 1999; Greer et al., 1999). The aetiology of PVL 
remains elusive. Smoking and the presence of Candida are no longer 
thought to have any influence on the occurrence and progression of PVL 
(Vigliante et al., 2003). In the literature, there are few studies investigating 
the association between PVL and HPV, detection rates ranging from 10-25% 
(Palefsky et al., 1995) to only in 89% of the cases (Gopalakrishnan et al., 
1997; Fettig etal., 2000). In PVL, a non-specific and likely aetiological role of 
HPV infection was eagerly suspected due to the clinical and histological 
warty features of PVL-related lesions. The role of HPV remains speculative 
regarding the significance of its presence and possible regulatory influence 
on PVL-occurrence and progression (Silverman S Jr and Gorsky, 1997;
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Vigliante et al., 2003). In fact, Palefsky and co-workers in 1995 reported that 
HPV-16 plays a fundamental role in the pathogenesis of PVL-associated oral 
epithelial lesions, where HPV type 16 is known to be highly associated with 
cervical cancer. However, a recent study has established that the frequency 
of HPV infection of PVL is not any higher than that of non-proliferative 
supposed potentially malignant leukoplakias (Palefsky et al., 1995; Campisi 
etal., 2004).
1.16.3 HPV in oral lichen planus
Oral lichen planus (OLP) is a common chronic inflammatory disorder 
present in about 0.1 - 4% of the population and usually appears in patients 
over 50 years of age (Scully and el-Kom, 1985). Clinically, OLP presented in 
a variety of clinical types (i.e. reticular, popular, plaque-like, atrophic/erosive, 
ulcerative, and bullous), characterized by multiple lace-like lesions, erosions, 
and ulcerations, affecting mostly the buccal mucosa, followed by the tongue 
and gingiva. Histologically, OLP is characterized by epithelial atrophy, basal 
cell destruction, and a dense band-like infiltrate of mononuclear inflammatory 
cells in the superficial corium (Andreasen, 1968; Eisen, 1993). The World 
Health Organization (WHO) categorized OLP as a premalignant condition, 
particularly if there is evidence of dysplasia. However, the malignant 
transformation of OLP remains a controversial matter. Follow-up studies 
showed that the rate of OLP transforming to OC ranges between <1-5.3 
(Mattsson et al., 2002). Many researchers in recent years have suggested 
the viral infection as a possible factor or co-factor in the pathogenesis of 
OLP, of those, were human herpes viruses and HPV (Kashima et al., 1990;
55
Chapter 1 Introduction. Human papillomavirus
Jontell etal., 1990; Gonzalez-Moles etal., 1994; Ghodratnama etal., 1997; 
Sun et al., 1998). The involvement of HPV in the aetiology of OLP has been 
proposed by some authors (Miller and White, 1996), yet the exact 
involvement, and role of such viruses still need further considerations.
Table 1.6 HPV prevalence in oral cavity pre-malignant lesions
Study Mode of Detoclon HPV+* % lotion Typo
Malfandetaf., 1987 SB uiing HPV 16 prabo 16/21 28.6 Dysplasia keratosis hyperplasia lichen planus
Gassenmaler and HomsMn, 1988 tSH 19/103 18.4 Dysplasia
Syrfanen at at., 1908a ISH 6,11,13,16,18,30 6 /22 27.3 Dysplasia CIS
Graaratd, 1990 ISH 6,11,16,1B, 31,33,35 5/190 26 loukopb Ida dysplasia
Shrayor and Greer, 1991 E6 HPV-16 PCR/ISH 7/48 14.6 Dysplasia hyperplasia keratosis
lava atd., 1991 ISH 6/11,16/18,31/33/35 0/20 0 Dysplasia CIS
Holladay and Gsrald, 1993 El PO 13/45 28.9 CIS dysplasfa inflammation hyperplasia
Fouret at d., 1995 E6 consensus PCR 0 / 3 0 Dysplasia
Mao at d., 1996 LI consensus and E6/7 PCR 8/23 34.8 Dysplasia CIS
Ntolsen a td , 1994 ISH/ HPV 16 PCR, SB PCR 20/49 40.8 Dyplasia leukoplakias
Wen atd., 1997 B6 HPV 16/18 PCR 5 / 17 294 Papiloma leukoplakias lichen planus 
leukoplakias lichen planus submucousD'Gosla a td . 1998 LI conwisus IO 27/80 33.8
Bam in atd, 1998
fibrosis melancplakia
Nat tad LI PCR 4 / 12 33.3 Dysplasia
Malzow atd , 1998 Consensus PCR 1 / 5 20 CIS hyperplasia
Bouda atd., 2000 
Sand at d ,  2000
Notlod consensus PCR 
LI conmuus lype-spodfic
29/34
8/29
85.2
27.6
Hyperplasia dysplasia 
Ucfien planus leukoplakias
Ha atd.. 2002 Quanfiafve PCR 1/102 1.0 Dysplasia CIS
ISH= In situ hybridization, PCR«= Polymerase chain reaction, SB=Southem blotting 
(Adapted from Ha and Califano 2004)
1.17 HPV in immunosuppressed and HIV-infected individuals
Some individuals with HIV-related or iatrogenic immunosuppression
seem to be at risk of human papillomavirus-associated anogenital cancers
(Palefsky and Holly, 2003). Many studies have demonstrated that patients
with HIV infection and AIDS are at increased risk of developing specific types
of cancers, particularly Kaposi’s sarcoma, non-Hodgkin’s lymphoma and
cervical or perioral SCC (Biggar et al., 1996; Beral and Newton, 1998;
Frisch et al., 2000). Most cancers in patients with AIDS are related to
oncogenic virus infections, such as EBV, KS and HPV (Melbye et al., 1994;
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teenyi-Agaba, 1995; Goedert etal., 1998; Frisch eta l., 2000; Aoki and 
Tosato, 2004).
The relationship between HIV and cervical cancer is more complicated 
than that of HIV and KS; there have been some suggested limitations to the 
role of the HIV in cervical neoplasia and malignancy. Current data suggest 
that immunosuppression is not associated with the progression of dysplastic 
tissues to cancer. Although, it is strongly associated with the early stages of 
dysplasia, the immune response may play an important role in controlling 
HPV replication and development of early disease such as CIN I. In contrast, 
progression from high-grade lesion to cancer may be affected by cellular 
genetic changes (Frisch et al., 2000; Palefsky and Holly, 2003; Palefsky, 
2003; Aoki and Tosato, 2004). It has been suggested that HPV-persistence 
in HIV-infected women is linked to a reduction in HLA class II molecules and 
to a greater number of immature Langerhan’s cells within the cervix 
(Goncalves et al., 2004; Moodley, 2005). From a molecular point of view, it 
has been suggested that HIV-associated cancers are likely to progress via 
microsatellite instability pathways, while pathways that involve loss of 
hetrozygosity of tumour suppressor genes may cause HIV-negative cancers 
(Clarke and Chetty, 2002; Moodley, 2005). In addition, men infected with 
HIV and having low CD4 counts showed an increased incidence of HPV 
infection, increased HPV viral load, more persistent detection of HPV and are 
more likely to have multiple types of HPV compared with HIV negative men 
(Palefsky etal., 1998; Hagensee, 2000). However, it has been observed that 
organ transplant recipients are at increased risk of HPV lesions in the oral 
mucosa, skin and anogenital areas (Blessing et al., 1990). In
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immunosuppressed patients, oral papillomas and warts usually have an 
atypical morphology, and the HPV types detected are often unusual, e.g. 
HPV type 7, followed by types 13, 18 and 32 (Greenspan et al., 1988). To 
demonstrate how unusual some of theses findings are, type 7 was originally 
isolated from peculiar type of cutaneous wart, frequently present on the 
hands of butchers (Greenspan et al., 1988; de Villiers, 1989; Syrjanen, 
2003).
The effect of HAART on the incidence and prevalence of HPV 
infection, HPV viral load and CIN in HIV-positive women remains extremely 
conflicting. Some data suggest that the widespread of HAART has not lead to 
reduced prevalence of genital HPV infection on HIV-positive women 
(Palefsky, 2003), while in a recent study, it has been suggested that HAART 
can enhance the regression of CIN (Prins et al., 2005). Furthermore, the 
widespread administration of HAART showed a profound impact on the 
incidence of HIV-associated oral opportunistic infections. The incidences of 
oral thrush and oral hairy leukoplakia have significantly decreased 
(Greenspan et al., 2001). Interestingly, in contrast to these infections, an 
increase in incidence of oral papillomas (warts) have been observed since 
the advent of HAART (Leigh, 2000). In fact, a significant association between 
the rise in warts and HAART have been reported (Greenspan et al., 2001; 
King et al., 2002). The role of HAART on the rate of oral HPV is not clear yet, 
but suggestions that have been proposed include that HAART associated 
increase in CD4+ levels does not reflect HPV-specific immune reconstitution, 
also HAART may lead to immune reconstitution related to other pathogens, 
but has no effect on HPV-specific immunity (Palefsky and Holly, 2003)
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1.18 Summary of HPV and oral diseases
In the past two decades, there has been an increasing interest in the 
association of HPV with different oral diseases, due to some degree to its 
likely role in the pathogenesis of malignant tumours in the cervical and ano­
genital areas. The morphological similarities between oral and cervical 
mucosa would suggest that HPV could play a role in oral mucosal 
oncogenesis. Epidemiological and experimental evidence has implicated 
oncogenic HPV in the development of a subset of HNSCC (most commonly 
high-risk types 16 and 18). Nevertheless, the frequency of HPV in oral 
mucosal lesions varies with the geographic locales and the methods of 
assays employed.
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1.19 Human herpesviruses
1.19.1 General features of herpesviruses
Herpesviridae are the family of enveloped, double-stranded DNA. The 
viruses replicate in the nucleus of a wide range of humans and animals. 
There are 80 known herpesviruses, and at least eight of them are known to 
cause infection in humans. These include herpes simplex virus (HSV) 1 and 
2, varcilla zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus 
(EBV), human herpes virus 6(HHV-6), human herpes virus 7(HHV-7), and 
human herpes virus 8 (HHV-8) (Table 1.7). They are transmitted from host to 
host by direct contact, causing a primary infection and then remain latent 
within the nuclei of specific cells. The site of latency differs among the 
herpesviruses. Herpesviruses (1, 2, and VZV) are known to remain latent in 
the sensory nerve ganglia, CMV remains latent in lymphocytes and possibly 
in salivary gland tissues, EBV remains latent in B lymphocytes and salivary 
gland tissues, herpesviruses (6 and 7) remain latent in CD4 lymphocytes and 
HHV-8 remains latent; although the exact site of latency is still not known 
(Stoopler and Greenberg, 2003).
Table 1.7 The Herpesviruses family is divided into 3 subfamilies:
Alphherpesvirinae Simplexvirus
Varicellovirus
Human herpesvirus 1 (HSV 1, 2) 
Human herpesvirus 3 (VZV)
Betaherpesvirinae Cytomegalovirus
Roseolovirus
Human herpesvirus 5 (HCMV) 
Human herpesvirus 6 (HHV 6, 7)
Gammherpesvirinae Lymphocryptovirus
Rhadinovirus
Human herpesvirus 4 (EBV) 
Simian herpesvirus 2 (HHV 8)
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They share four characteristics biological properties:
• Synthesis of viral DNA and assembly of their capsid occur in the nucleus of 
infected cell.
• They encode their own enzymes involved in nucleic acid metabolism, DNA 
synthesis and protein processing.
• Production of their infectious viral particles is usually accompanied by 
destruction of the infected cell.
•  Latent infection occurs which persist for the life of their natural hosts. The 
latent viral genomes usually take form of circular episomes, with only a 
small subset viral genes being expressed.
1.19.2 Human herpesviruses 1 and 2
Human herpesviruses 1 and 2 are the two major types of herpes 
simplex viruses and are the causative agents in most common intraoral 
herpesviruses infections. Diagnosis is based on the antibodies formed 
against each type of virus or by DNA analysis (Greenberg MS, 2003). 
Classically, HSV 1 causes a majority of oral and pharyngeal HSV infections, 
meningoencephalitis and dermatitis above the waist; while HSV 2 is 
implicated in most genital and anal infection (Stoopler, 2005). It has been 
suggested that the sexual practices may be a cause of primary or secondary 
infection of HSV 1 and 2 in both oral and genital areas (Stoopler and 
Greenberg, 2003)
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1.19.2.1 Primary herpes simplex virus infection
It has been demonstrated that the incidence of primary infections with 
HSV 1 increases after 6 months of age due to the loss of anti-HSV antibodies 
acquired from the mother during gestation. The incidence reaches a peak 
between 2-3 years of age, but the infection may occur in the adolescents and 
adults with occasional cases to occur in patients over 60 years of age. While 
it has been postulated that the primary HSV 2 infection does not increase 
until sexual activity begins (Stoopler and Greenberg, 2003). The majority of 
primary HSV 1 and 2 infections are sub-clinical or may cause a pharyngitis 
making it difficult to distinguish it from upper respiratory tract viral infections. 
The symptomatic infections usually preceded or accompanied by generalized 
symptoms including fever, headache, malaise, nausea, and vomiting. 
Lymphoadenopathy may be evident in occasions. In the oral cavity, vesicles 
and ulcers appear on the oral mucosa, and usually after 24 to 28 hours after 
the prodromal symptoms, a generalized acute marginal gingivitis usually 
occur. In healthy children, primary HSV is usually a self-limiting disease with 
fever disappearing in 3-4 days and the oral lesions healing within 7-10 days 
(Stoopler, 2005).
1.19.2.2 Recurrent herpes simplex virus infection
Following the resolution of a primary HSV infection, the virus migrates 
to the trigeminal nerve ganglion, where it is capable to remain in a latent 
state. Reactivation of the virus may follow an exposure to cold, exposure to 
sunlight, stress, trauma or immunosuppression disease. Recurrent herpes 
labialis (RHL) is the most common form of recurrent oral HSV infection
62
Cfapfer I Introduction. Human herpesvirus
appear on the border of the lip and is commonly referred to as cold sore or a 
fever blister (Stoopler, 2005).
1.19.3 Varcilla zoster virus (VZV)
Varicella zoster virus causes both primary (chickenpox) and recurrent 
infection (shingles) and remains latent in neurons present in sensory ganglia 
(Greenberg MS, 2003).
1.19.3.1 Varicella
Chickenpox is a benign disease of children, spreads by direct contact 
with either the skin lesions or nasopharyngeal secretions of an infected 
patient. The incubation period is 10 to 21 days, and the stage is highly 
infectious for 1 week after symptoms start. One of the major complications is 
encephalitis causing high rate of mortality among adults. Other complications 
include pneumonitis and Reye’s syndrome (Stoopler, 2005). Skin lesions of 
chickenpox are characterized by maculopapular lesions that are intensely 
pruritic. These lesions rapidly progress to fluid-filled vesicles on an 
erythematous base. Oral lesions may appear in vesicle/ulcer form, which is 
not significantly an important symptom (Greenberg MS, 2003).
1.19.3.2 Herpes zoster (HZ)
Following the primary infection, VZV becomes latent in dorsal root of 
cranial nerve ganglia. Only in a small range of population, the virus becomes 
reactivated causing HZ. When HZ involves the trigeminal nerve ganglion, the 
first division (ophthalmic or V1) is most commonly involved. Pain is the main
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initial symptom of HZ, also tenderness and parasthesia along the course of 
the affected nerve. Unilateral vesicles appear 3 to 5 days later, when the 
geniculate ganglion of the facial nerve is infected, typical clinical signs and 
symptoms appear include unilateral vesicles of the external ear and oral 
mucosa as well as unilateral facial paralysis (Stoopler, 2005).
1.19.4 Human herpesvirus 6
Human herpesvirus was first discovered in 1986 (Salahuddin et al., 
1986). It is tropic mainly for CD+4 T cells, however, the replication can also 
occur in CD+8 cells, macrophages and epithelial cells. CD46 has been 
recently identified as a cellular receptor for HHV-6 (De Araujo et al., 2002). 
The virus is ubiquitous in the population with greater than 90% seropositivity 
in adults, and has a worldwide distribution. The virus is transmitted via saliva, 
and usually occurs during the first 2 years of life (Stoeckle, 2000). It has been 
postulated that immunocompromised patients, in particular, solid organ 
transplant, are at greater risk of HHV-6 disease (Emery, 2001).
1.19.5 Human herpesvirus 7
Human herpesvirus 7 was first isolated in 1990 (Frenkel et al., 1990) 
from CD+4 cells of healthy adults. It has been found that HHV-6 and HHV-7 
are closely related by DNA analysis. Human herpesvirus 7 has been isolated 
from saliva of approximately 90% of healthy individuals worldwide. No clear 
association between HHV-7 and any specific clinical disorder has been 
reported, although, it has been associated with febrile illness in children, 
exanthema subitum and pityriasis rosea (De Araujo etal., 2002).
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1.20 Human cytomegalovirus
1.20.1 Virology
Human cytomegalovirus (HHV-5) is a j3 human herpesvirus; it is the 
largest known human herpesvirus, with a genome of about 230 kb. The virus 
has double strand linear DNA, enveloped by a proteinaceous matrix (the 
tegument), which is surrounded by a lipid bilayer that contains viral 
glycoproteins (Figure 1.9). Human cytomegalovirus can be transmitted via 
saliva, sexual contact, placental transfer, breastfeeding, blood transfusion, 
solid organ transplantation or haematopoietic stem cell transplantation. It 
has been demonstrated that the acquisition of the virus rises progressively 
from an early age. The overall seroprevalence of CMV in developed 
countries has been found to be between 30 and 70% (Pass, 1985). However, 
homosexual men, individuals in low socioeconomic groups and residents of 
developing countries have seroprevalence rates that can exceed 90% (Sohn 
et al., 1991; Gandhi and Khanna, 2004).
Figure 1.9 Schematic diagram of Cytomegalovirus 
Adapted from: http://www.biografix.de/
'Membrane
Nudeocapsid
Tegument
♦Genome
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It has been suggested that after the primary infection, 
cytomegalovirus will establish a lifelong latency or persistence within the 
human host in which the principal reservoirs are fibroblasts, myeloid and 
endothelial cells (Mocarski, Jr., 2002; Rowshani et al., 2005). However, it is 
not clear which cell types can harbour the virus and support a productive 
(lytic) infection, nor it is clear whether leukocytes behave as specific carriers 
of the virus during a systemic infection or represent a reservoir of replicating 
virus, or a possible site of latency. Although primary infections or reactivation 
of CMV usually remain either subclinical or self-limiting in immunocompetent 
individuals, this virus is a major cause of morbidity and mortality in 
immunocompromised patients, especially in organ transplants recipients, 
patients receiving immunosuppressive therapy and in those with AIDS (Kano 
and Shiohara, 2000).
1.20.2 CMV and malignancies
Cytomegalovirus DNA, RNA and/or proteins, have been detected in 
some tumour tissues, and CMV infection has been implicated in the 
pathogenesis of several human malignancies (Cinatl, Jr. et al., 2004). 
Recently, studies have demonstrated a high occurrence of CMV in prostate 
carcinoma (Samanta et al., 2003), colon cancer (Harkins et al., 2002) and 
malignant glioma (Cobbs et al., 2002). Furthermore, it has been found that 
no virus was detected in the normal adjacent tissues, indicating a selective 
replication in tumour cells (Hoever etal., 2005).
It has been suggested that the multiple oncogenic activities of CMV 
that infleuence cell cycle progression, angiogenesis, cell invasion and
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immune evasion in cells may account for such associations with malignancy 
(Doniger et al., 1999; Castillo and Kowalik, 2002; Samanta et al., 2003). 
CMV has the ability to interfere with many cellular pathways, which influence 
the malignant behaviour of tumour cells, namely apoptosis, adhesion, 
invasion and angiogenesis. It can also dysregulate many multiple cellular 
pathways and signalling mechanisms involved in malignancy, including 
targeting Rb and p53 that result in promoting of cell cycle progression, 
induction of DNA mutations and blocking of apoptotic pathways (Harkins et 
al., 2002; Samanta et al., 2003). This is similar to the activities of 
oncoproteins in small DNA tumour viruses such as human papillomavirus or 
adenoviruses. It has been suggested that persistence in tumour cells is 
essential for CMV to fully express its oncomodulatory effects (Cinatl, Jr. et 
al., 2004; Hoever etal., 2005).
In a recent study of colorectal cancer, investigators observed that the 
preferential replication of CMV is in dysplastic epithelial cells, these cells are 
known to harbour replicative virus in immunocompromised patients, 
suggesting that dysplastic epithelial cells with impaired cell-cycle control 
mechanisms may provide a unique reservoir for CMV persistence with no 
effect on the overall tumour phenotype. Alternatively, long-term persistent 
CMV infection and expression in dysplastic epithelial cells could be important 
in the promotion of oncogenic action directly implicated in malignant 
progression (Harkins etal., 2002).
Although CMV is well known to interfere with many cellular pathways 
which influence the malignant behaviour of tumour cells (Cinatl, Jr. et al., 
2004; Hoever et al., 2005), its relation with oral cancer has not been yet
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defined. A study investigating the involvement of viral and chemical factors 
with oral cancer in a Taiwanese study group demonstrated that CMV was not 
directly involved in the oncogenic process (Yang etal., 2004).
1.20.3 CMV in salivary gland tissue
The presence of CMV-DNA in salivary gland benign and malignant 
tumours has been investigated using ISH and PCR techniques. However, it 
appears that CMV plays no role in the aetiology of salivary glands 
neoplasms. (Laane et al., 2002; Rivera et al., 2003; Yen et al., 2004).
1.20.4 CMV in oral lesions
Cytomegalovirus is commonly found in periodontal abscesses as well 
as in necrotic pulps and periapical lesions (Sabeti and Slots, 2004; 
Santangelo et al., 2004; Saygun et al., 2004), and has been proposed as a 
putative pathogen in these lesions causing pathosis either by inducing 
immunosuppression with a subsequent risk of aggressive bacterial infection 
or by infecting periodontal cells directly. Alternatively, CMV may give rise to 
periapical disease by inducing cytokines and chemokine release from 
inflammatory and non-inflammatory host cells (Mogensen and Paludan, 
2001; Slots J, 2002; Sabeti et al., 2003; Sabeti and Slots, 2004).
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1.21 Epstein-Barr virus
1.21.1 Virology
Epstein-Barr virus (EBV) or human herpesvirus 4 (HHV-4) is a y- 
herpesvirus which preferentially infects B-lymphocytes, epithelial cells, T 
cells, natural killer (NK) cells and smooth muscle cells. It infects the vast 
majority of adults worldwide, establishing both non-productive (latent) and 
productive (lytic) infections (Iwatsuki et al., 2004).
The EBV genome is a linear double-stranded DNA of 172 kbp and 
was the first herpesvirus genome to be completely sequenced (Baer et al., 
1984) (Figure 1.10). It is able to immortalize B cells both in-vitro and in-vivo. 
Primary EBV syndromes include infectious mononucleosis, chronic EBV 
infection and X-linked lymphoproliferative syndrome (fatal infectious 
mononucleosis) (Goldenberg et al., 2001).
Figure 1.10 Schematic diagram of Epstein Barr-virus 
Adapted from
http://www.brown.edu/Courses/Bio 160/Proiects2000/Herpes/EBV/Epstein-Barr.html
1.21.2 EBV and malignancies
Epstien-Barr virus has a variety of mechanisms that promote 
immortalization of epithelial cells (as in nasopharyngeal carcinoma and oral
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cancer), B-lymphocytes (as in Burkitt’s lymphoma and plasmablastic 
lymphoma), T-lymphocytes (as in NK T-cell lymphoma) and Hodgkin’s 
disease. Epstein-Barr virus is a ubiquitous human herpes virus that can 
cause a lifelong persistent infection of B cells in more than 90% of the adult 
population. In addition it is known to be a B-lymphotropic virus and has the 
ability to transform B cells in vitro. (Goldenberg et al., 2001; Pagano et al., 
2004; Parkin, 2006).
Burkitt’s lymphoma (BL) is a high-grade B cell lymphoma that occurs 
in children and young adults worldwide. Approximately 95-100% of African 
BL tumours contain EBV-DNA, whilst only 20-30% of similar tumours in 
persons resident in Europe and the US are EBV-associated. In the Middle 
East, North Africa and South America, 51-91% of BL tumours are associated 
with EBV. These findings suggest that EBV may not itself be sufficient nor 
essential for the genesis of this lymphoma (Goldenberg et al., 2004; Parkin, 
2006).
Plasmablastic lymphoma (PBL) is classified by the WHO as a unique 
NHL type, characterized by plasma cell differentiation and an immunoblastic 
cellular morphology (Vega et al., 2005). It mainly affects HIV-infected 
individuals, although it has occasionally been observed in immunocompetent 
patients (Lin et al., 2004; Folk et al., 2006). Plasmablastic lymphoma has a 
strong affinity for the oral cavity, stomach, lung, cervical lymph nodes, 
anorectal region and paranasal sinuses (Folk et al., 2006). The most 
common oral sites for plasmablastic lymphoma are the gingivae, palate and 
floor of mouth (Delecluse et al., 1997; Porter et al., 1999; Borrero et al., 
2002).
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Delecluse and co-researchers were the first to describe the strong 
association between EBV and plasmablastic lymphoma, detecting EBV in 9 
out of 15 cases of PBL using in situ hybridization (Delecluse et al., 1997). 
Researchers in recent studies have detected EBV-DNA in most of the 
examined PBL lesions, but none of the examined positive cases 
demonstrates EBV-LMP-1 expression. It has thus been suggested that EBV 
may play a role in the pathogenesis of a majority of PBL but not necessarily 
be the major causative agent (Gaidano et al., 2002; Folk et al., 2006).
Recently, EBV has also been implicated in the pathogenesis of NK T- 
cell lymphomas and has been identified within the NK-T tumour cells 
(Heslop, 2005).
As previously mentioned, EBV can infect epithelial cells causing 
malignancies, most commonly nasopharyngeal carcinoma. Nasopharyngeal 
carcinoma (NCP) is a relatively rare disease worldwide, having a unique 
geographic distribution. The highest incidence has been reported in Chinese 
populations although NCP can occur in other ethnicities (for example South 
East Asians and Eskimos).
It has been suggested that EBV could possibly play a role in the 
pathogenesis of oral squamous cell carcinoma as it has the ability to infect 
epithelial cells. However, the association of EBV and head and neck cancer 
remains controversial (Cruz et al., 1997; Cruz et al., 2000; Goldenberg et 
al., 2001; Sand et al., 2002; Tsang et al., 2003; Goldenberg et al., 2004; 
lamaroon et al., 2004). Despite the well-established influence of EBV on 
human B-lymphocytes, the influence of EBV in oral squamous cell 
carcinomas (OSCC) remains unclear. There has been several reports of
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EBV-DNA occurring in both non-malignant and malignant oral squamous 
epithelial tissues (Talacko etal., 1991; Mao and Smith, 1993; D'Costa etal.,
1998).
Recent studies in Japan have suggested a strong correlation between 
EBV and HNSCC in the Okinawa region, where the OSCC incidence rate is
1.5 times higher than in the mainland, thus supporting the hypothesis that 
geographical variations and racial factors may influence the development of 
EBV-associated OSCC (Tsuhako et al., 2000; Higa et al., 2003). In the 
literature, a possible relationship between EBV infection and the degree of 
differentiation of OSCC has been suggested (Kobayashi et al., 1999; 
Shimakage etal., 2002; Sand etal., 2002). However, some studies report no 
evidence of an association between EBV and OSCC (Cruz et al., 2000; 
Tsang et al., 2003; Yang et al., 2004; Goldenberg et al., 2004). One study 
concluded that there was no evidence to support a clonal association 
between EBV with the neoplastic cells of OSCC, and that the presence of 
EBV in oral cancer samples may simply represent increased shedding of the 
virus in the oral cavity caused by malignancy-associated immunosuppression 
(Cruz et al., 1997). However, EBV-derived latent membrane protein 1 (LMP- 
1) gene was detected only in the tumour cells of malignancy located in the 
nasopharynx, implying that EBV may play an insignificant role in the 
tumourogenesis of carcinomas arising from other locations in the head and 
neck region (Shimakage et al., 2002; Tsang et al., 2003). In addition, it has 
been suggested that the low quantities of EBV detected in a small group of 
HNSCC may originally have been from rare lymphoid or epithelial cells close 
to the primary HNSCC (Liu etal., 2002).
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It has been suggested that the presence of EBV in OSCC is not 
necessarily an indicator that the virus plays an oncogenic role. It has been 
suggested that as EBV is prevalent in the general population, it may be 
possible that neoplastic transformation took place in a cell harbouring EBV, 
the virus having no role in the process (Goldenberg et al., 2001; Chan et al., 
2004). Similarly, it has been suggested that, EBV is unlikely considered to be 
a passenger virus as it has a strong capacity to stimulate cell growth and 
may play a role in the initiation stages rather than the maintenance stage of 
tumourogenesis(Griffin, 2000).
In general, it has been demonstrated that EBV-related malignancies 
may arise after years of viral dormancy being accompanied or triggered by 
viral reactivation (Harkins et al., 2002). Epstein-Barr virus encoded latent 
membrane proteins-1 (LMP-1), have been described as the main 
transforming protein of EBV. It functions as a classic oncogene in rodent- 
fibroblast transformation assays and is essential for EBV-induced B cell 
transformation in vitro. When LMP-1 is expressed in cells it results in the 
induction of cell-surface adhesion molecules and activation antigens, and 
upregulation of anti-apoptotic proteins (Eliopoulos and Young, 2001). 
Furthermore it has been shown to function as a constitutively activated 
member of the tumour necrosis factor (TNF) receptor, leading to activation of 
several signalling pathways. EBV protein also activates several downstream 
signalling pathways that contribute to many phenotypic consequences of 
LMP-1 expression, including the induction of various genes that encode anti- 
apoptotic proteins and cytokines (Young and Rickinson, 2004). In addition, 
the EBV nuclear antigen (EBVNA-LP) has been shown to interfere with wild
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type p53 and pRb functions, resulting in dysregulation of the cell cycle 
(Goldenberg etal., 2001).
1.21.3 EBV in salivary gland lesions
Although it is known that EBV can be transmitted via saliva, the 
cellular source of the virus is still unclear. Some have suggested that the oral 
epithelium is a putative reservoir as well as the salivary glands. Various 
studies have observed no relation between EBV and salivary glands lesions 
(Karja et al., 1997; Laane et al., 2002), while others suggested EBV to be 
associated with salivary gland tumours, including a lymphoepithelioma-like 
carcinoma (Tsai etal., 1996), undifferentiated carcinoma of the salivary gland 
(Wen et al., 1997a), lymphoma of the parotid gland and pleomorphic 
adenoma arising in the nasal cavity (Atula et al., 1998). The association of 
lymphoepithelial carcinoma of the salivary glands has been reported to be 
limited to Eskimos and Southern Chinese populations (Saemundsen et al., 
1982; Goldenberg et al., 2001). Furthermore, it has been occassionaly 
reported in Arabs in Saudi Arabia (Abdulla and Mian, 1996) and Greek 
Caucasians (Kotsianti etal., 1996).
A recent study detected the presence of EBV-DNA in the labial minor 
salivary gland of HIV infected patients who had diffuse infiltrative 
lymphocytosis syndrome (DILS), suggesting the involvement of EBV in this 
unusal disease (Rivera etal., 2003).
1.21.4 EBV in oral lesions
Epstein-Barr virus gives rise to infection monoclueosis, which can give 
rise to short-term oral manifestations such as palatal peteachia and
74
Chapter 1 Introduction. Human herpesvirus
superficial oral ulcerations (Ebell, 2004). However by far, the most common 
and significant chronic EBV-associated disease of the mouth is hairy oral 
leukoplakia (OHL). Oral hairy leukoplakia arises in almost all groups of long­
term immunocopmromised individuals, but particularly those with untreated 
HIV disease. It is clinically characterized by asymptomatic bilateral (often- 
elevated) white patches of the lateral borders and dorsum of tongue. EBV- 
DNA is abundant in OHL tissue (Hille et al., 2002; Walling et al., 2004; 
Komatsu et al., 2005), yet, OHL has no known malignant potential, thus 
perhaps suggesting that EBV is unlikely to play a strong role in the 
development of OSCC in HIV cases (Scully and Porter, 2000).
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1.22 Human Herpesvirus-8
1.22.1 Virology
Chang et al first identified human herpesvirus-8 (HHV-8) or Kaposi’s 
sarcoma herpesvirus (KSHV) in 1994 based upon DNA sequences detected 
in tissues from patients with AIDS-KS.. Human herpesvirus-8 DNA or RNA 
has been localised by PCR in-situ hybridisation and in-situ hybridisation to 
spindle cells, endothelial cells and monocytes in nodular KS. It has been 
postulated that HHV-8 infected T cells and monocytes may be responsible for 
the circulation of HHV-8, accounting for the multicentric nature of some KS 
lesions (Hengge et al., 2002b). Several clinical manifestations of KS have 
been distinguished including classic KS, endemic African KS, iatrogenic 
immunosuppressive KS and AIDS-related KS (Schulz, 2000; Hengge et al., 
2002a).
Figure 1.11 Schematic diagram of Human Herpesvirus-8 
Adapted from: http://www.herpes.ru/her/pat/hhv8/
It has been demonstrated that HHV-8 has a tropism for lymphocytes, 
endothelial cell, keratinocytes and possibly marrow stromal cells. Its protein 
capsid structure is surrounded by an amorphous tegument and a lipid bilayer
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for a general size of 120-150 nm. The HHV-8 genome is ~ 165 kb long and 
similar to that of other y -herpesviruses (Figure 1.11). The L-DNA segment of 
HHV-8 has many open reading frames with significant homology to human 
genes. The genome is circular during latent infection and linear during the 
lytic phase. Like other herpesviruses, replication is by the rolling circle 
mechanism within the nucleus of the host cells (Hengge etal., 2002b).
Human herpesvirus-8 has been phylogenetically classified into strains 
A, B, C, D and E, and further divided into 13 subgroups based on amino acid 
differences (Biggar et al., 2000). Subtypes A and C are very similar, while 
subtype B is the most divergent subtype. The A and C subtypes have a wide 
distribution throughout Europe, US, Asia and the Middle East. American 
patients with acquired immunodeficiency syndrome (AIDS) are usually 
infected with subgroup A1, A4 and C3, while subgroup A5 has been found in 
some African samples (Zong et al., 1999). The B subtype is found 
predominantly in sub-Saharan Africa or in persons of African heritage and 
has only 3 subgroups (B1, B2 and B3) (Zong et al., 2002). The D subtype 
appears to be rare and isolated to the Pacific Island region (Poole et al.,
1999). Sequences recovered from a Brazilian Amerindian population 
demonstrated a new type named type E (Biggar et al., 2000). On the amino- 
acid level, HHV-8 has 30-50% homology to Epstein-Barr virus and 
herpesvirus saimiri sequences for 30-50% (Hengge etal., 2002b).
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1.22.2 Human herpesvirus-8 and malignancies
Human herpesvirus-8 (HHV-8) has been aetiologically linked to 
Kaposi’s sarcoma (KS), primary effusion lymphomas (PELs) and multicentric 
Castleman’s disease (MCD).
Kaposi’s sarcoma is a vascular proliferation tumour that typically 
manifests as a mucocutaneous lesion. HHV-8 has been detected in spindle 
cells of KS tumours originating from endothelial cells. The four known types 
of KS are Classic KS (a generally benign cutaneous disease common among 
males resident around the Mediterranean), AIDS-associated KS (highly 
aggressive, attaking mucocutaneous surfaces and viscera), endemic KS 
(prevalent in non-HIV infected persons in some regions of Africa such as 
Uganda, and known to be more aggressive than the classic type of KS) and 
iatrogenic KS that has a variable clinical presentation related to the degree of 
therapy. It has been demonstrated that the prevalence of HHV-8 DNA among 
KS lesions is at least 95% (Cathomas, 2000; Cathomas, 2003; Wilkins et 
al., 2006).
When HHV-8 infects the B-lymphocytes it causes two different types 
of malignancies, primary effusion lymphomas (PEL) and multicentric 
Castleman’s disease (MCD).
Primary effusion lymphomas are malignant B cell lymphomas 
manifesting as body cavity effusions. The most significant criterion of the PEL 
is the positivity of HHV-8 DNA. It has been demonstrated that the prevalence 
of HHV-8 DNA reaches 100%, irrespective of the presence or absence of 
HIV disease (Nador etal., 1996; Cathomas, 2000; Ablashi etal., 2002)
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Multicentric Castleman’s disease is another B cell lymphoproliferative 
disease associated with HHV-8. Although MCD is considered as a 
prelymphoma state, it is not known whether there is a pathogenetic link 
between MCD and PEL. All examined AIDS-associated MCD lesions have 
detectable HHV-8, but only 50% of lesions of MCD in the absence of HIV 
contain HHV-8 (Ascoli et al., 2001; Pagano et al., 2004; Waterston and 
Bower, 2004).
In the last few years, oral plasmablastic lymphoma (PBL) has been 
suggested to be linked to HHV-8. Plasmablastic lymphoma is an aggressive 
neoplasm and has been listed in the WHO classification as a variant of 
diffuse large B cell lymphoma, although this classification has been denied 
recently by Vega et al.,2005. However, the link between HHV-8 and PBL was 
under investigation by many researchers (Delecluse et al., 1997; Lin et al., 
2004; Folk et al., 2006) suggesting that oral PBL in AIDS patients is strongly 
associated with HHV-8 and EBV (Cioc et al., 2004). Furthermore, some 
studies have suggested that HHV-8 and EBV may have a possible 
pathological role in PBL in sites other than the oral cavity (Verma etal., 2005) 
Of note, a case report of oral PBL in immunocompetent HIV-negative 
individuals did not detect any presence of HHV-8 or EBV (Lee et al., 2006)
HHV-8 associated tumours initiation and progression is linked with 
cytokine-mediated reactivation of HHV-8, and may arise only in individuals 
with specific immunogenetic phenotype (Cathomas, 2003). HHV-8 tightly 
regulates expression of its genes; these genes can be divided into latent or 
lytic infection. HHV-8 genes expressed during latent infection can induce cell 
growth by activation of cell cycle genes and block apoptosis in virally infected
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tumour cells. The functions of these virus proteins ensure life-long viral 
persistence in the host. Only small subset of tumour cells show evidence of 
viral lytic infection by expressing the whole range of putative oncogenes as 
detailed elsewhere (Schulz, 2000; Cathomas, 2003).
1.22.3 HHV-8 in salivary gland lesions
As with the previously mentioned herpesviruses, there are few data of 
the involvement of HHV-8 in the pathogenesis of salivary gland tumours. One 
early study did not detect HHV-8 in the tumour of pleomorphic-adenoma or 
malignant salivary gland tumours (Atula et al., 1998). A more recent study did 
not find HHV-8 to be associated with benign lymphoepithelial cysts of the 
parotid gland (Yen et al., 2004). Of note, however HHV-8 was detected in 
major salivary glands KS of HIV-disease although this of course is not 
unexpected (Castle and Thompson, 2000).
1.22.4 HHV-8 in oral lesions
Epidemiological and molecular studies have demonstrated the 
relationship of HHV-8 to Kaposi’s sarcoma and plasmablastic lymphoma of 
the oral cavity (Castle and Thompson, 2000) in the mouth of HIV/KS patients 
(Chang etal., 1994; Huang eta l., 1996; Hille etal., 2002). Furthermore, 
HHV-8 has also been found in oral ulcer tissues of HIV-infected individuals 
who did not have KS (Di Alberti L. et al., 1997). However, a recent study of 
Taiwanese patients did not find any association between HHV-8 and OSCC 
(Yang etal., 2004).
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1.23 Viruses in normal oral mucosa
The detection rates of HPV in normal oral mucosa in the literature 
range from 0% (Eike et al., 1995; Cruz et al., 1996; Bouda et al., 2000; 
Sand et al., 2000) to 70 % (Terai et al., 1999). In one study up to 60% of 
normal volunteers had some form of HPV in their oral mucosa (43% with 
either type 16 or 18), although the detection rate varied depending upon 
whether buccal scrapings, biopsy tissues or mouthwash were examined 
(Lawton et al., 1992). The number of the examined samples of healthy oral 
mucosa have sometimes been low or have comprised histopathologically 
normal tissue from patients with OSCC (Maitland etal., 1987; Shindoh etal., 
1995). Furthermore, in some large surveys, normal epithelium has been 
collected by scraping normal mucosa and such samples may not include the 
basal layers which may contain latent HPVs (Sugiyama etal., 2003).
Studies involving larger sample sizes than the aforementioned 
investigations have reported low (1-2%) prevalence rates of HPV-DNA in 
normal individuals (Lambropoulos et al., 1997; Smith et al., 1998), these 
studies have utilized PCR detection method, one of the most sensitive 
assays for HPV detection. Using similar techniques, investigators conducting 
a recent study in India of betel nut users found a detection rate of 33.6% 
among the normal control group (Nagpal et al., 2002), raising the possibility 
that there are geographic, exposure-related or other behavioural influences 
that play a role in the acquisition of HPV within the normal oral mucosa (Ha 
and Califano, 2004).
Studies of herpesviruses such as EBV, CMV and HHV-8 have also 
yielded variable detection rates in normal oral mucosa. The presence of
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HHV-8 has been investigated in different control groups including healthy 
blood donors (Bigoni et al., 1996; Decker et al., 1996; Blackbourn et al.,
1997). HHV-8 was assessed among healthy populations by seroprevalence 
of the virus, the highest being found in Sub-Saharan Africa whereby 
approximately 40% were seropositive for antibodies to HHV-8 (Ablashi et al., 
1999; Schulz, 2000). However, other studies did not detect HHV-8 in the 
saliva of healthy controls (Lucht et al., 1998) or in the saliva of any HIV- 
negative patients (Boldogh etal., 1996).
The detection of EBV-DNA was highly variable among normal healthy 
samples. EBV-DNA was not detected in samples from normal oral epithelium 
(Lin etal., 2005), nor in the nasopharyngeal space of healthy control samples 
(Hao et al., 2003), whilst it was found in 40% of healthy adults throat washing 
in Taiwan (Jeng et al., 1994), and in 46.6% of the oral scrapes of a group of 
immunocompetent subjects resident in Brazil (Braz-Silva etal., 2006).
Although cytomegalovirus seems to be rarely detected in normal 
healthy oral mucosa and healthy salivary glands (Ammatuna et al., 2001; 
Laane etal., 2002; Yang etal., 2004), it has been present in the oral fluids of 
immunocompetent individuals (Beyari etal., 2005).
In a recent study of the presence of EBV, CMV, HHV-8 and HPV in 
ulcerated oral tissues (Lin et al., 2005), specimens of fresh normal oral 
mucosal tissues and sera were used as controls, no viral DNA being 
detected among the control samples. Another study has investigated the 
presence of EBV, CMV, HHV-8 and HPV among OSCC patients from 
Taiwan, no detection of any virus in the control group being reported (Yang et 
al., 2004).
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The cause of the differences in the detection rates of HPV and some 
herpesviruses remains to be clearly determined, nevertheless the majority of 
recent studies have used very careful and accurate techniques, and overall it 
seems that these studies suggest that HPV, CMV, EBV and HHV-8 are 
commonly present in healthy normal mucosa.
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1.24 Viral interactions in OSCC
Interactions between viruses have the potential to decrease or more 
likely, enhance the potential pathogenic effects of individual viruses (Mbopi- 
Keou et al., 2002). In particular, synergism between viruses may have the 
potential to increase any liability to clinical disease. For example, in HIV 
disease, HIV driven cell-mediated immunosuppression will increase the 
likelihood of other viral infections, particularly herpes group infections of the 
mouth (e.g. EBV and HHV-8). However, HIV infection may itself be enhanced 
by CMV and EBV and reduced by HHV-8, while HHV-6 and HHV-7 possess 
mechanisms that could either enhance or reduce HIV infection (Mbopi-Keou 
et al., 2002). Recent studies using human epithelial culture tissues 
(organotypic graft) reveal that HSV (1 or 2) increased the copy number of 
HPV and that herpetic infection did not affect episomal status of HPV 
genomic DNA. Furthermore, HSV infection maintains expression of HPV E6 
and E7 (essential for oncogenesis) but suppresses E1 and E2 (essential for 
HPV-DNA replication) (Meyers et al., 2003). While these results do not 
suggest that HSV is a co-factor for HPV oncogenesis, they do indicate that 
there is the potential for a dynamic relationship between herpesviruses and 
HPV.
With respect to the oral mucosa, the demonstration of co-infection with 
CMV, HHV-8 in HPV infected individuals might suggest a synergistic 
oncogenic role of these viruses (Tsuhako et al., 2000). Epstein-Barr virus is 
known to be able to encode a specific protein which suppresses cellular 
immune-responses, thus the simultaneous infection of epithelial cells by EBV 
and HPV (combined with reduced immune status) could increase the risk of
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the development of potentially-malignant and malignant oral mucosa 
diseases compared with single viral infection (Rassekh et al., 1998). Indeed 
infection with EBV, CMV and HPV has been suggested to play some role in 
the pathogenesis of some malignancies such as genital tract malignancy in 
females (Gradilone et al., 1996), and bladder malignancy (Gazzaniga et al.,
1998).
1.25 Summary of herpesviruses and OSCC
Human herpesviruses have not yet been consistently detected in 
OSCC, although may be associated with a number of other head and neck 
malignancies. Hence, the evidence to suggest that such herpesviruses are 
associated with OSCC is limited and a causal association has not been 
demonstrated. Nevertheless, these viruses might have a role as a minor co­
factor in the pathogenesis of OSCC.
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1.26 Aims
Molecular and epidemiological data indicate that HPV may be a causal 
factor in a subset of oral, oropharyngeal and laryngeal carcinomas, and may 
cause malignant disease via the same mechanisms of oncogenesis as those 
of cervical malignancy (Lakshmi etal., 1993; Gillison etal., 1999; Gillison, 
2004; Syrjanen, 2005; Szentirmay et al., 2005; Kreimer et al., 2005).
Associations of herpesviruses and oral potentially malignant and 
malignant tumours have been previously proposed, but there are little 
consistent data to suggest that these viruses commonly residing within the 
mouth may give rise to oral tumours (Yang etal., 2004).
The aim of the present study was to investigate the DNA prevalence of 
HPV, CMV, EBV and HHV-8 in potentially malignant and malignant oral 
lesions of patients with a range of relevant diseases. In addition, the 
prevalence of these viruses was examined in salivary gland malignant 
diseases to establish if they may play any role in the development or 
perpetuation of such disease. Samples from two geographic locales were 
examined to establish whether there is any consistency in any observed 
associations.
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2.1 Patients
Eighty two archival, paraffin embedded tissues (PET), 
histopathologically confirmed oral specimens consisting of oral squamous 
cell carcinoma (30 samples), oral lichen planus (32 samples), 
mucoepidermoid carcinoma (10 samples), adenoidcystic carcinoma (4 
samples) and pleomorphic adenoma (6 samples), were obtained from 
College of Dentistry, King Saud University and Riyadh Central Hospital 
(Kingdom of Saudi Arabia).
Another 196 archival samples were obtained from the pathology 
archives of the Eastman Dental Institute (EDI) UK consisting of oral epithelial 
dysplasia (45 samples), proliferative verrucous leukoplakia (12 samples), 
erosive/non-erosive oral lichen planus (30), oral squamous cell carcinoma 
(34), human immunodeficiency virus positive samples (25) and 50 samples of 
histologically diagnosed normal oral mucosa (Table 2.1).
The biopsy samples had been taken from different sites in the head 
and neck area including tongue (all aspects), hard and soft palate, upper and 
lower lip, submandibular region, retro-molar area, buccal mucosa, floor of the 
mouth, salivary glands, oropharynx, pre-maxilla and interdental papilla area.
The characteristics of the different tissue samples are summarized in 
tables 2.2 and 2.3.
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T ab le  2.1 Sum m ary of the lesional tissues and patients sources
Country Lesion (No) Gender (No.) Median age
, (year)
Age range 
(year) Ethnicity
OK s ’ * \  . xV ’ ' " -
PVL (12)
F (6) 69 48:80 C= 4, N/A=2
M (6) 72 57:85 C=1, N/A=5
OLP (30)
F (14) 58 42:79 C=8, SEA=3, N/A=3
M (16) 60 40:79 C=8, SEA=2, N/A=6
OED (45)
F (22) 62 35:77 C=14, SEA=4, N/A=4
M (23) 56 29:72 C=16, SEA=2, N/A= 5
OSCC (34)
F (12) 70 56:90 C=6, SEA=6
M (22) 68 31:96 C=20, SEA=1, N/A=1
HIV (25)
F (3) 40 35:50 C=2, SEA=1
M (22) 42 31:53 C=20, AF=1, N/A=1
Total =146 (F = 57. M = 89) 58.5 29:96 C=99, SEA=19, N/A=27, AF=1
KSA" •
OLP (32)
F (19) 43 23:65 AR=19
M (13) 47 28:60 AR=10, SEA=1, FEA=2
OSCC (30)
F (7) 66 45:80 AR=7
M (23) 59 30:81 AR=21, C=2
Salivary (20)
F (7) 42 25:61 AR=7
M (13) 42 20:65 AR=11, SEA=1, FEA=1
Total = 82 ( F = 33, M = 49) 50 20:81 AR= 75. SEA=2, FEA=3, C=2
Normal Controls
F (29) 37 14:84 C= 23. SEA=5. AF=1
M (21) 44 18:105 C=14, SEA=5, AR=2
Total = 50 (F= 29, M= 21) 39.5 14:105 C=37. SEA=10, AF=1, AR=1
C=Caucasian, SEA=South East Asia, FEA=Far East Asia, AR-Arab, AF-African,
N/A= Data Not available, PVL= Proliferative verrucous leukoplakias, OLP= Oral lichen planus 
OED=Oral epithelial dysplasia, OSCC= Oral squamous cell carcinoma,
HIV* Human immunodeficiency virus
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T ab le  2 .2  Characteristics of patients from the United Kingdom
Characteristics OSCC OED PVL OLP HIV
F(% ) M (%) F(%) M
4(66)
1 (17)
1 (17)
2(33)
1 (17) 
1 (17)
6(100) 4(67) 
2(33) 
6(100) 4(67)
2(33)
6(100) 5(83)
1 (17)
6(100) 5(83)
1 (17) 
6(100) 6(100)
6(100) 6(100)
2(33) 1(17)
1 (17)
3(50) 3(50) 
1 (17) 1 (17)
F(%) M(%) F(%) M(%)
Buccal mucosa 
Lat. of tongue * 
Attached gingiva 
Hard palate 
Soft palate 
Lip
Commisure 
Floor of 
mouth 
Ant 2/3 
Tongue** 
Retromolar 
Salivary 
Other sites*** 
Cigarette 
None
Ex-smoker 
Current smoker 
Smoldng/dsiy 
None 
<5
10-15/day 
>20/day 
Paan 
None
Current user 
Alcohol 
None 
<5 u/wH 
5-20 u/w 
>20u/w 
N/A*** 
Corticosteroids
None
the
of
4(33)
2(17) 
1 (8)
2 (9 )
5(23)
1(5)
1 (5) 
3(14)
5(23)
2(17)
1 (5)
4 (18) 
19(86) 
3(14) 
12(100) 19(86)
3(25) 
12 (100)
10(83)
2(17)
2(9)
1,(5J
20(91)
.2(9)
12(100) 18(81) 
1(5)
3 (14)
1 2 (100) 22(100)
Topical 
Systemic 
Immunologlcally related diseases
None 10(83) 22(100)
Systemic 
disease)
Immunosuppressi 
ve drugs 
Relevant medical history
2(17)
None 
H RTff 
Asthma 
Candida 
Cutaneous 
disease
Diabetes mellitus 
OSCCH
Penicillin allergy 
Submucous 
fibrosis 
Arthritis 
Therapies 
None
Chemotherapy 
Radiotherapy 
Triple therapy
4(33) 11(50)
1(5)
8(67) 10(45)
8(67) 18(81) 
3(25) 3(14)
1 (8) 1(5)
3(14) 5(22) 
6(27) 6(26) 
1 (4.5)
2(9)
2(9)
1 (4.5) 1 (4) 
3(14) 6(26)
2 (9 ) 1(4)
4(18)
1 (4.5)
1 (4.5)
15(68) 9(39)
3(13)
7(32) 11 (48)
15(68) 9(39)
4 (18) 8(35) 
3(14) 6 (26)
19(86) 21(91) 
3 ( 1 4 )2 (9 )
11(50) 12(52) 
3(14) 1 (4)
1 (4.5) 2 (9) 
6(27) 6(26) 
1(4-5) 2(9)
Z2^ ° 23(100)
21(95) 22(96) 
1 (5) 1 (4)
11(50) 9(39) 
5(23)
2(9) 
2(9 ) 3(13)
1 (4) 
2(9 ) 5(22)
2(9) 2(9)
1 (4)
18(82) 23(100) 
4(18)
2(33)
11 (79) 14(88) 4(18)
2 (14) 1 (6) 2 (9)
1 (7) 1 (6) 2 (9)
2(67) 3(13.5)
1 (33) 5 (23) 
3(13.5)
1 (5)
2(9) 
3(100) 15(68)
7 t?2)
3(100) 15(68)
7(32) 
3(100) 22(100)
13(93) 13(81)
1 (6)
1 (7) 2 (13)
13(93) 13(81)
1 (7)
2(13)
1(6)
13(93) 16(100) 
1(7)
12(86) 11(69) 3(100) 21(96)
1 (7) 1 (6)
2 (12.5) 
1(7) 2(12.5)
11(67) 15(94)
1 (7)
2(14) 1 (6)
9(65) 12(75) 
2(14) 2(12.5)
3(21) 2(12.5)
5(37) 12(75) 
2(14)
2(14)
1 (7) 2(12.5)
2(14) 2(12.5)
2(14)
1 (4)
2(67) 16(73) 
1 (33) 6 (27)
1(4) 
3(100) 21(96)
3(100) 17(77)
4(18)
1 (5)
5(83) 6(100) 14(100) 16(100) 3(100) 16(100)
1(17)
6(27)
Total 12 22 22 23 6 6 14 16 3 22
* Lt. of tongue= lateral border of the tongue, ** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** Other sites= Data not available, UOSCC= Second-primary Oral Squamous Cell Carcinoma, HU HRT= Hormone 
replacement therapy
(Systemic immune disease=e.g. Stevens Johnson's syndrome, Benign mucous membrane pemphigoid.!!u/w= units 
per week
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Table 2.3 Characteristics of patients from the Kingdom of Saudi Arabia
Characteristics OSCC OLP Salivary diseases
F(%) , M(%) F(%) M(%0 F(%) M(%)
Biopsy sites .
Buccal mucosa 2(29) 4(18) 17(90) 10(76) 1(14) 4(30)
Lt. of tongue* 1(14) 6(26) 1(8)
Attached gingiva 1(5)
Hard palate 3(44) 6(46)
Soft palate
Lip 1(4) 1(8) 1(14)
Floor of the mouth 2(9) 1(8)
Ant 2/3 of Tongue 1(14) 1(8)
Retromolar 1(14) 7(30) 1(14) 1(18)
Other sites** 2(29) 303) 1(5) 1(14) 1(18)
Cigarette
None 7(100) 22(96) 19 (100) 13(100) 7(100) 13(100)
Current smoker 1(4)
Smoking/day
None 7(100) 22(96) 18(95) 13(100) 7(100) 13(100)
10-15/day 1(4) 1(5)
Paah
None 7(100) 23(100) 19(100) 13(100) 7(100) 13(100)
Alcohol v *1
None 7(100) 23(100) 19(100) 13(100) 7(100) 13(100)
W f l  U U vV tO fU IV o
None 7(100) 23(100) 19 (100) 13(100) 7(100) 13(100)
fmmunoidgk^ly’reiated disease
None 7(1°0) 23(100) 19 (100) 13(100) 7(100) 13(100)
Releyantntedidath^ory ♦ - V / *  V,' f *
None 5(72) 20(88) 12 (63) 8(62) 7(100) 13(100)
Asthma 1(5)
Cutaneous Disease 3(16) 3(23)
Diabe.tes mellitus 1(14) 1(4) 3(16) 2(15)
Second/primary OSCC 1(14) 1(4)
Penicillin allergy 1(4)
Therapies
None 7(100) 23(100) 19 (100) 13(100) 7(100) 13(100)
Total 7 23 19 13 7 13
* Lt of tongue= lateral border of tongue
‘ "other sites No recorded data
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2.2 Materials
2.2.1 Laboratory accommodation
PCR-related procedures were performed in four separate laboratory 
areas in the Health Protection Agency, Colindale, London-UK:
• A clean room used for preparing reagents (except DNA)
•  An amplification room used to run the PCRs
• A gel room for the detection of PCR amplicons by gel 
electrophoresis
The workflow was strictly unidirectional in order to prevent contamination with 
PCR products. Samples and plasmids containing high copy numbers of HPV 
DNA were handled in a separate laboratory remote from the designated 
areas.
2.3 Methods
2.3.1 DNA Extractions
Paraffin embedded tissue (PET) were sectioned using a sledge 
microtome (AS300, Shandon, UK), serial sections of *  5 -8  pm thickness, 
folded and inserted in 1.5 ml eppendroff tubes (Sarstedt, Germany).
Samples were sent to Genovar Company. DNA was extracted using a 
commercially available kit “Genovar Nucleic Acid Extraction Kit for Paraffin 
Embedded Tissue” Genovar, UK. The kit is designed to extract total nucleic 
acid from formalin-fixed, paraffin embedded tissue, and is optimised for
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extraction of DNA from one section of the tissue up to 20 pm thickness. 
(Appendix 2.1)
2.3.2 PCR amplification of j3-globin DNA
The presence of DNA in extracts from PET was verified by the 
amplification and detection of a 268 bp fragment of the housekeeping /3- 
globin gene as an indicator for the successful extraction. The PCR was 
carried out in a 25 pi reaction mixture containing 2.5 pi PCR buffer 
(Invitrogen, Paisley U.K, 10X buffer II), 0.75 pi of 50 mM MgCfe, 1 pi dNTP’s 
(Invitrogen, Paisley U.K), 1 pi (20 pmol) of each /8-globin primers “PC04 and 
GH20” (Cruachem Ltd, Glasgow UK) was added, 0.2 pi of Taq DNA 
polymerase (5U/pl) (Life technologies), and16.55 pi of water. Twenty three pi 
of the mix was added with 2 pi of DNA extract. Single round PCR was then 
applied, thermal cycler (Biometra T3 Thermocycler, Germany) being 
programmed to 94fiC for 5 m, followed by 942C for 1 m (denaturation), 55fiC 
for 1 m (annealing), and 72fiC for 1 m (extension), and the cycle being 
repeated for 34 times (Gravitt et al., 1998; Fredricks and Reiman, 1999; 
Sato etal., 2001).
2.3.2.1 Oligonucleotide primers for the amplification of (3-globin DNA
PC04:5'- CAACTTCATCCACGTTCACC-3'
GH20:5'- GAAGAGCCAAGGACAGGTAC-3'
The length of the /3—globin product *  268 bp (Gravitt et al., 1998; Fredricks 
and Reiman, 1999; Sato etal., 2001)
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2.3.3 PCR detection of HPV L1 DNA
The viral genome encompasses three main segments of unequal 
sizes. About 10% of the HPV genome corresponds to the long control region 
(LCR), and its function is the regulation of viral gene expression. The other 
part of the genome contains the early (E) or the late (L) genes. The L1 and 
L2 genes encode the major and minor capsid proteins, which are only 
expressed in terminally differentiated squamous epithelial cells. The DNA 
base sequence of L1 gene diverges only slightly in different HPV species, 
giving the molecular basis to detect different virus species by single 
polymerase chain reaction. The L1 consensus primers detect the presence 
of episomal forms of the HPV, predominantly present in oral cancers 
(Maitland et al., 1987). The integrated form of the virus is generally 
associated with cervical cancers, and often results in disruption of the L1 
gene (de Villiers et al., 1985; Maitland et al., 1987; Jeon et al., 1995). In 
addition, L1 gene regulates levels of HPV E6 and E7 gene expression, which 
are important in tumourogenesis, due to interaction and inactivation of the 
growth suppressor genes p53 and Rbp proteins (D'Costa etal., 1998).
2.3.3.1 Oligonucleotide primers of HPV
The high degree of sequence diversity between HPV types prevents 
the selection of common oligonucleotide primers for the simultaneous 
detection of all HPV types by PCR. A PCR with the “degenerate” consensus 
primers MY09/MY11 (Cruachem Ltd, Glasgow UK) initially described by 
Manos et al (1998), for the detection of genital HPVs, is also widely used to 
analyse skin lesions (McGregor et al., 1994). The “general” primers
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GP5+/GP6+ (Cruachem Ltd, Glasgow UK), (Roda Husman etal., 1995) have 
proved to be successful for the detection of a broad spectrum of HPV 
genotypes in cervical samples (Qu et al., 1997). A significant increase in 
sensitivity of detection was observed when all four primers (MY09/MY11, 
GP5+/GP6+) were used in a nested PCR (Evander et al., 1992; Strauss et 
al., 2000).
All optimisations of PCRs were performed using CaSki cells which 
contain 600 copies of HPV type 16 DNA per cell ((cell lines were obtained 
from the European Collection of Cell Culture, (ECACC, cat No.87020501)). A 
limited number of experiments were performed using HeLa cells which 
contain 1 copy of HPV type 18 DNA per cell (ECACC, cat No. 93021013) 
(Strauss etal., 2000).
2.3.3.2 PCR amplification of HPV (ORF-L1) DNA
A nested protocol was performed to amplify subgenomic HPV (ORF- 
L1) DNA. First round PCR was carried out using degenerate primers MY09 
and MY11 for the initial amplification (with an expected product size of about 
450 bp). Fifty pi of reaction mix was prepared, each contains 4 pi of PCR 
buffer (Invitrogen, Paisley U.K), 1 pi of 50 mM MgCI2, 0.4 pi of dNTP’s 
(Invitrogen, Paisley U.K). Then L1 primers (20 pmol each) 1 pi of MY 09 and 
1 pi of MY 11 were added, followed by 0.25 pi of Taq DNA polymerase 
(5U/pl) (Life Technologies) and 32.35 pi of water. Forty pi of the mix was 
added to 10 pi of the DNA extract, covered with a drop of mineral oil and then 
subjected to the thermal cycler. The mixtures were incubated for 5 m at 94*0 
for DNA denaturation followed by 40 cycles of amplification. Each cycle
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consisted of a denaturation step at 94 *C for 1 m, an annealing step at 55 *€ 
for 2 m and an elongation step at 72 *C for 3 m. The last cycle was extended 
7 m for elongation at 72 °C. The second round of amplification with the 
general primers GP5+ and GP6+ (Roda Husman et al., 1995) positioned 
inside of the MY09 and MY11 primers was performed on aliquot of the first 
round product; these amplified a 150 bp products. PCR was carried out in 50 
pi reactions each containing 4 pi of PCR buffer, 7 pi of 50 mM MgCb, 0.7 pi 
of dNTP’s, and then add L1 primers (20 pmol each) 1 pi of GP5+ and 1 pi of 
GP6+ were added, followed by 0.2 pi of Taq DNA polymerase (5U/pl), and
35.1 pi of water. Forty-eight pi of the mix was added to 2 pi of the previous 
PCR product, covered with one drop of mineral oil and subjected to the 
thermal cycler. Forty cycles of amplification were carried out; each cycle 
consists of a 1 m denaturation step at 94 °C and annealing step at 40*0 for 2 
m and an elongation step at 72 °C for 1.5 m. The first cycle was preceded by 
4 m of denaturation at 94 °C and the last cycle was extended by 4 m 
elongation at 72*0.
2.3.3.3 Oligonucleotide primers for the amplification of HPV-L1
MY 09: 5'-CGTCCMARRGGAWACTGATC-3'
MY 11: 5'-GCMCAGGGWCATAAYAATGG-3'
GP 5+: 5'- TTTGTT ACT GTG GTAG AT ACT AC-3'
GP 6+: 5'- G A AA AATA AACTGT A AAT CAT ATT C-3'
The length of the HPV DNA product was 450 bp at the 1st round and 150 bp
at the nested round.
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2.3.4 PCR amplification of the HHV-8 ORF-K1
First round PCR amplification of the first variable region of KSHV 
ORF-K1 was carried out in a 50 pi reaction mixture containing 33.8 pi of 
nuclease free water, 5pl buffer number 8 (Stratagene Europe, The 
Netherlands) containing 3.2 mM MgCfe, 1pl of each outer primer, 1 pi of each 
dNTP’s and 0.2 pi of Taq DNA polymerase. To this mixture 5 pi of extracted 
DNA was added. The second round conditions were the same as the first 
with the addition of 1 pi of each inner primer and 2 pi of the primary product 
as template. Amplification of both regions was carried out under the same 
PCR thermocycling conditions. Samples were heated to 9 4 ^  for 5 m 
followed by 35 cycles of 94*0 for 1 m, 60° for 1 m and 72°C for 1 m followed 
by 5 m of extension period at 72°C (Raab etal., 1998; Cook etal., 2002a)
2.3.4.1 Oligonucleotide primers for the amplification of KSHV -K1
K1 inn 5: 5'- CCCTGGAGTGATTTCAACGC-3'
K1 inn 6: 5'- ACATGCTGACCACAAGTGAC-3'
K1-1: 5'- GAGTGATTTCAACGCCTTAC-3'
K1 -N: 5'- TGCT G ACC AC AAGT G ACT GT-3'
The ORF-K1 outer primers produced a 255 bp fragment, and the inner 
primers produced a 247 bp fragment. (Cook etal., 2002a).
2.3.5 PCR amplification of the CMV-gN DNA
A nested protocol was performed to amplify subgenomic CMV-gN 
region DNA. First round PCR was carried out in 50 pi reactions each 
containing, 5 pi of PCR buffer, 8 pi of 50 mM MgC^, 4 pi of dNTP’s, then first 
round gN primers (20 pmol each) 2 pi of gN-up, 2 pi of gN-low were added,
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followed by 0.38 pi of Taq DNA polymerase (5U/pl), and 23.62 pi of water. 
Forty-five pi of the mix was added to 5 pi of the DNA extract covered with a 
drop of mineral oil, the nested round is identical to the first one except in 
26.62 pi of water was added followed by second round gN primers(20 pmol 
each), 2 pi of gN-3 and 2 pi gN-4. Forty-eight pi of the mix was added to 2 pi 
of the first round as template, and then subjected to the second round PCR. 
The thermal cycler (both rounds have the same protocols) at 962C for 1 m, 
then at 962C for 1 m, then at 552C for 1 m, then at 722C for 1 m, then the 
cycle was repeated for 35 times, finally at 722C for 10 m (Pignatelli et al., 
2001; Pignatelli etal., 2003).
2.3.5.1 Oligonucleotide primers for the amplification of CMV-gN
gN-up: 5'- TGGTGTGATGGAGTGGAAC-3'
gN-lw: 5'- TAGCCTTTGGTGGTGGTTGC-3'
gN-3: 5'- GTAGTGGCAGAGAGTTCTGG-3'
gN-4: 5'- GT AC A AT AC A AA AAG CT CCC-3'
The second round product was 304 bp in length.
2.3.6 PCR amplification of the (EBV-SamHI K) DNA
Primers were selected to allow amplification of BamHl K region. PCR 
was performed on 50 pi reaction mixture, first round consisted of 5pl of PCR
buffer, 2pl of each primer at 20 pmol, 1.5 pi of 50 mM MgCI2, 0.25 of Taq
DNA polymerase, 1 pi of dNTP’s and 33.25pl of water, topped with 5pl of 
DNA template. PCR was performed for 35 cycles (denaturation at 94 °C for 1 
m, annealing at 68 °C for 40 s and extension at 72 °C for 1 m). Before the 
start of each reaction, the samples were denatured for 5 m at 94 °C; after the 
last cycle, the extension step was extended by 10 m. Further amplification
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was carried out by adding 2 pi of the first round to 48 pi of second round PCR 
mix, which contained the inner primers of the BamHI K amplicons. PCR was 
carried out for 1 m at 94 °C, 40 s at 60 °C, 1 m at 72 °C for 25 cycles 
(Triantos etal., 1998).
2.3.6.1 Oligonucleotide primers for the amplification of EBV BAMHI-K
Outer, sense TGATGGAGGCAGGCGCAAAAAAG
Outer, anti-sense GAAACCAGGGAGGCAAATCTACT
Inner, sense CGCAAAAAAGGAGGGTGGTTT
Inner, anti-sense CATCGTCAAAGCTGCACACAG
The first round product was 469 bp, second round product was 433 bp in
length.
2.3.7 Detection of PCR product
Eight pi of the PCR product was mixed with 2 pi of Orange G loading 
dye and loaded onto 2% agarose gel (SB fine gel, Severn Biotech Ltd.) along 
with 1 pg of 1 kb DNA ladder marker (Invitrogen, Paisley U.K) on one side of 
the gel. A positive and a negative controls were also been added. 
Electrophoresis took place in a 1X tris-borate EDTA buffer (TBE supplied as 
10X stock) (Invitrogen, Paisley U.K). The gels were then stained with 5pg/ml 
ethidium bromide solution (Sigma, UK) in TBE buffer. DNA fragments were 
visualised using a short wave ultra-violet trans-illuminator and photographed 
using a photo printer.
2.3.8 Reverse Line Blotting for HPV typing
The method was based on the use of HPV-specific primers containing 
a hairpin loop structure in which fluorescent donor and quencher groups are
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held in close proximity such that fluorescence is quenched. Amplification of 
the target sequence results in the opening of the loop. Fluorescent amplicons 
were typed by a single hybridization with specific probes immobilised in lines 
on a nylon membrane and detected by fluorescent scanner (Jordens et al., 
2000)
2.3.8.1 Molecular beacon primer-based PCR amplification and detection
Molecular beacon labelled primers was first used by Nazarenko et al., 
1997, and has been modified by developing a PCR method which permits the 
real-time detection of any HPV Infection (Jordens et al., 2000), the 
fluorescent amplicons detected in positive samples were suitably labelled for 
direct testing against a panel of HPV genotype-specific probes. PCR using 
second round primers (GP5+, GP6+) for all the HPV positive samples was 
performed. The GP6+ primer sequence was:
GP6+: 5’ F-GAAAAATAAACTGTAAATCATATTC 3’
F= Fluorescein.
The same conditions and protocols for the second round PCR in 
thermal cycler were used. The hairpin loop of a DNA sequence was added to 
the 5’ end of the antisense GP6+ primer sequence to give maximum 
fluorescence above background when incorporated into an amplicon 
(Nazarenko et al., 1997). The primer sequence that contained a 5’ 
fluorescein residue (F) and a quencher (Q) was synthesized by Oswel DNA 
services (Eurogenetc.UK). (Figure 2.1)
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Figure 2.1 Showing the incorporation and opening out of molecular beacon primers during 
amplification, leading to fluorescence. (1), annealing of unlabelled and molecular beacon 
primers; (2), annealing and extension from primers; (3), annealing of uniabelled primer to 
molecular beacon primed DNA with extension leading to fluorescence (4) Q, quencher; F, 
fluorescein.
(Adapted from Jordens et a/., 2000)
2.3.8.2 Probe design and attachment to nylon membranes
Type-specific probes for 25 common HPV types were designed within 
the GP5+/GP6+ amplification regions of the L1 gene (sense) (Jordens et al., 
2000). The sequences (and references) of the probes are shown in Table 
2.4. Probes were attached to the Biodyne nylon membranes (Pall 
BioSupport, UK) immediately before use. The denatured products were 
added to the prepared membrane, which has been activated in 16% EDAC 
(Sigma, UK) for 15 m, rinsed in water and placed in a mini-blotter (Biometra 
Ltd, UK). Optimum coupling of probes to the membrane was achieved by 
adding 14 pi of thawed amino-linked oligonucleotide probes to 346 pi fresh 
probe buffer (500 mM NaHC03= 0.84g NaHc03 + 20 ml DW), add 180 of 
diluted probe to the bottom slots of the mini-blotter for 1 m only, and then 
aspirated from the top slots, until all the probes finished. The membrane was 
then removed from the blotter, inactivated in 100 ml of 100 mM NaOH for 10 
m, rinsed in water and then incubated in preheated sample buffer, 2x SSPE;
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0.1% SDS (200 ml of sample buffer = 198 ml 2XSSPE + 2 ml 10% SDS) for 
10 m at SB'C. After a final rinse in 2x SSPE membranes were used 
immediately or stored at 4°C for subsequent use (Jordens et a!., 2000).
Table 2.4 Probe sequences for reverse line blotting
HPV type Probe sequences (5'*3') References
6 ATCCGT AACT AC AT CTT CC AC ATAC ACC AA Jacobs et a/.,1995
11 ATCTGTGTCT A AAT CTGCT AC AT AC ACT AA Jacobs etal., 1995
16 GTCATTATGTGCTGCCATATCTACTTCAGA Jacobs etal., 1995
18 TGCTT CT ACACAGT CTCCTGTACCT GGGCA Jacobs eta l.,1995
31 TGTTTGTGCTGCAATTGCAAACAGTGATAC Jacobs etal., 1995
33 TTTAT GC ACAC AAGT AACTAGT G AC AGT AC Jacobs etal.,1995
35 GTCTGTGTGTTCTGCTGTGTCTTCTAGTGA Jacobs etal., 1995
39 T CT ACCT CT AT AG AGT CTT CC AT ACCTT CT Jacobs etal., 1995
42 CT G C AAC AT CTGG TG ATAC AT AT AC AG CTG Jacobs etal.,1995
43 T CT ACT G ACCCTACT GTGCCC AGT AC ATAT Jacobs etal., 1995
45 ACAC AAAAT CCTGTG CC AAGT ACAT ATG AC Jacobs eta l.,1995
51 AGCACTGCCACTGCTGCGGTTTCCCCAACA Jacobs etal.,1995
52 TGCTG AGGTTAAAAAGG AAAG C ACAT AT AA Jacobs etal.,1995
53 CCGCAACC AC ACAGT CTATGTCTACATATA Jordens et a!. ,2000
54 TACAGC AT CC ACG C AGG AT AGCTTT AAT AA Jordens et al.,2000
56 GTACTGCT AC AG AAC AGTT AAGT AAAT AT G Jordens et al. ,2000
58 ATT ATGC ACT G AAGT AACT AAGG AAGGTAC Jordens et al.,2000
59 GTGCTT CTACT ACTT CTT CT ATTCCT AAT GTAT Jordens efa/.,2000
62 CTGCTGCAGCAGAATACACGGC Jordens efa/.,2000
66 ATT AAT G C AGCT AAA AG C AC ATT Hildeshein etal., 1994
67 CTGAGGGAAAATCAGAGGCTAC Qu etal., 1997
70 CTGCACCG AAACGGCCAT AC Jordens et al. ,2000
72 GCC AC AG CGTCCTCTGTAT C AG A Jordens et al.,2000
han831 GTG CCACACAAACACCCTCTGA Jordens et al.,2000
CP8304 CAC AGCT ACAT CT GCTG CT GCAG A Jordens etal.,2000
(Adapted from Jordens et.al., 2000)
2.3.8.3 Hybridisation and detection by reverse line blotting
Twelve pi of amplification products were added immediately before 
use to 168 pi of preheated sample buffer (2x SSPE;0.1% SDS), denatured 
by boiling for 10 m in 100 °C heating block, then placed immediately on ice for 
1 m. After a brief spin, samples were brought to room temperature. The 
prepared membrane was placed in the mini-blotter, turned through 90° 
relative to its original position so that each slot crossed all the probes. Then 
180 pi of the denatured products were added to the slots, the mini-blotter 
placed in a plastic bag with damp tissue and incubated for 1 to 1.5 h at 60°C
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to allow hybridisation. Samples were then removed by aspiration. The 
membrane removed from the blotter and washed twice with 150 ml wash 
buffer, 2x SSPE; 0.5% SDS (for 500 ml= 475 ml 2x SSPE+ 25 ml 10% SDS). 
Then rinsed in wash buffer B, 100 mM Tris-HCL, 150 Mm NaCI pH 7.5 (for 1 
L= 12.1 g Tris +8.77g NaCI) and incubated with Anti-fluorescein-peroxidase 
conjugate (Boehringer Ingelheim Limited, U.K) diluted in Liquid Blocking 
Reagent (1 in 2333) (Amersham Biosciences UK) and Wash buffer B (30 pi, 
7 ml, and 63 ml respectively) for 30 m. The conjugate was then aspirated, 
followed by three washes with Wash Buffer B containing 0.3% Tween 20. 
Probe-target hybrids were detected by enzyme-linked chemifluorescence 
using the Opti-4CN (Bio RAD, UK) by mixing 2 ml of Opti-4CN Diluent, 18 ml 
DW and 400 pi of substrate. Then the liquid was poured into the mini-blotter 
with the membrane, left for a while until the dots appear and visually 
interpreted. The membrane was then photocopied by photo-printer (Figure 
2.2). (Jordens etal., 2000)
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Figure 2.2 An exam ple of a reverse line blot, showing single and mixed infections. The  
num bers indicate the probes (arranged vertically) and the letters represent the clinical 
sam ples (arranged horizontally), e.g., sample (I) has mixed infection of H P V  types 16, 39  
and 52
104
Chapter 2 Materials and Methods
2.4 Statistical analysis
• Data entry and analysis were performed using the SPSS for Windows 
(Statistical Package of Social Science) software, version 12.0.
Corporate Headquarters 
SPSS Inc.
2335 Waker Drive, 11th Floor 
Chicago, IL
• Frequency distribution and cross-tabulation tables were constructed in 
order to analyze the demographic information, showing median age, mean 
age, age range and percentages of gender and ethnicity.
• A logistic regression model was used to determine the strength of any 
viral associations. Crude and adjusted (for risk factors) odds ratios (OR), and 
their 95% confidence intervals (Cl) were calculated where possible. P-values 
have only been presented on those occasions where it was either not- 
possible or not-appropriate to present 95% Cl for the parameter estimate, for 
example, where there was a zero in any of the cells of a 2x2 table.
•  Bivariate correlation (Spearman’s rank correlation coefficient) was used to 
test for viral interactions within OSCC.
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Table 3.1 Frequency of detection of human papillomavirus in examined oral and salivary 
glands lesions
Country Lesion Gender -veNo. (%)
+ve 
No. (%)
UK
OSCC All 7/34 (20.6) 27/34 (79.4)
F 2/12(16.7) 10/12(83.3)
M 5/22 (22.7) 17/22 (77.3)
PVL All 5/12(41.7) 7/12(58.3)
F 26 (33.3) 4/6 (66.7)
M 3/6 (50.0) 3/6 (50.0)
OED All 26/45 (57.8) 19/45 (42.2)
F 12/22 (54.5) 10/22 (45.5)
M 14/23 (60.9) 9/23 (39.1)
OLP All 21/30 (70.0) 9/30 (30.0)
F 10/14(71.4) 4/14 (28.6)
M 11/16 (68.8) 5/16(31.3)
HIV All 16/25 (64.0) 9/25 (36.0)
F 2/3 (66.7) 1/3 (33.3)
M 14/22 (63.6) 8/22 (36.4)
KSA
OSCC All 13/30(43.3) 17/30 (56.7)
F 2/7 (28.6) 5/7 (71.4)
M 11/23 (47.8) 12/23 (52.2)
OLP All 23/32 (71.9) 9/32 (28.1)
F 14/19(73.7) 5/19(26.3)
M 9/13(69.2) 4/13(30.38)
Salivary All 15/25 (75.0) 5/25 (25.0)
F 5/7 (71.4) 2/7 (28.6)
M 10/13 (76.9) 3/13(23.1)
Normal Controls
UK All 50/50 (100.0) 0/50 (0.0)
F 29/29 (100.0) 0/29 (0.0)
M 21/21 (100.0) 0/21(0.0)
OSCC = Oral squamous cell carcinoma
PVL = Proliferative verrucous leukoplakia
OED = Oral epithelial dysplasia
OLP = Oral lichen planus
HIV = Human immunodeficiency virus
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Table 3.2 Detection of human papillomavirus versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with oral epithelial dysplasia
Characteristic -ve. NO. (%)
+ ve. 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female
Male
2/12(16.7)
5/22(22.7)
10/12(83.3) 
17/22 (77.2)
. f ’ ..... . ;•
Age (years) . . • i*-
30-40 1/1(100) 0/1 (0.0) - 1/1 (100.0) 0/1(0.0)
50-60 2/8(25.0) 6/8(75.0) 0/4(0.0) 4/4(100.0) 2/4(50.0) 2/4(50.0)
60-70 1/5(20.0) 4/5(80.0) 0/2(0.0) 2/2(100.0) 1/3(33.3) 2/3(66.7)
70-80 1/12(8.3) 11/12(91.7) 1/2(50.0) 1/2(50.0) 0/10(0.0) 10/10(100.0)
>80 2/8(25.0) 6/8(75.0) 1/4(25.0) 3/4(75.0) 1/4(25.0) 3/4(75.0)
Ethnicity
Caucasian 5/26(19.2) 21/26(80.8) 1/6(16.7) 5/6(83.3) 4/20(20.0) 16/20(80.0)
SEA* 1/7(14.2) 6/7 (85.7) 1/6(16.7) 5/6(83.3) 0/1 (0.0) 1/1(100.0)
N/A 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
TobaCco ** ■
None 7/31(22.5) 24/31(77.4) 2/12(16.7) 10/12(83.3) 5/19(26.3) 14/19(73.7)
Current
Smoking
0/3(0.0) 3/3(100.0) - “ 0/3(0.0) 3/3(100.0)
None 7/31(22.5) 24/31(77.4) 2/12(16.7) 10/12(83.3) 5/19(26.3) 14/19(73.7)
10-15/day 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
>20/day
Paan
0/1(0.0) 1/1(100.0) ■ " 0/1(0.0) 1/1(100.0)
None 6/30(20.0) 24/30 (80.0) 2/10(20.0) 8/10(80.0) 4/20(20.0) 16/20(80.0)
Current
Alcohol
1/4(25.0) 3/4 (75.0) 0/2(0.0) 2/2(100.0) 1/2(50.0) 1/2 (50.0)
None 6/30(20.0) 24/30(80.0) 2/12(16.7) 10/12(83.3) 4/18(22.2) 14/18(77.8)
5-20 u/w** 0/1(0.0) 1/1(100.0) - - 0/1(0.0) 1/1(100.0)
N/A*** 1/3(33.3) 2/3(66.7) - - 1/3(33.3) 2/3(66.7)
Total 7/34(20.6) 27/34(79.4) 2/12(16.7) 10/12(833) 5/22(22.7) 17/22(77.3)
*SEA=South East Asian
** u/w = units /week
*** N/A= Data not available
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Table 3.3 Cross tabulation for human papillomavirus in UK-oral squamous cell carcinoma 
samples according to biopsy site, relevant medical note, corticosteroids, immune status and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve Female 
No. (%)
+ve Female 
No. (%)
-ve Male 
No. (%)
+ve Male 
No. (%)
Biopsy site
Buccal mucosa 2/6(33.3) 4/6 (66.7) 2/4(50.0) 2/4 (50.0) 0/2(0.0) 2/2(100.0)
Lt. of tongue* 2/5(40.0) 3/5(60.0) - - 2/5(40.0) 3/5(60.0)
Floor of mouth 1/5(20.0) 4/5(80.0) - - 1/5(20.0) 4/5(80.0)
Soft palate 0/1 (0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Hard palate 0/1 (0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Ant. 2/3 ol 
tongue** ' 0/2(0.0) 2/2(100.0) 0/2(0.0) 2/2(100.0) - -
Lip 0/5(0.0) 5/5(100.0) 0/2(0.0) 2/2(100.0) 0/3(0.0) 3/3(100.0)
Commisure 0/1 (0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) - -
Retromolar 0/1 (0.0) 1/1(100.0) - 0/1(0.0) 1/1(100.0)
Other sites*** 2/7(28.6) 5/7(71.4) 0/3(0.0) 3/3(100.0) 2/4(50.0) 2/4(50.0)
Relevant medical history
None 2/15(13.3) 13/15(86.7) 0/4(0.0) 4/4(100.0) 2/11(18.2) 9/11(81.8)
SCCf 5/18(27.8) 13/18(72.2) 2/8(25.0) 6/8(75.0) 3/10(30.0) 7/10(70.0)
Candidal
infection 0/1(0.0) 1/1(100.0) " 0/1(0.0) 1/1(100.0)
Corticosteroids
None 7/34(20.6) 27/34(79.4) 2/12(16.7) 10/12(83.3) 5/22(22.7) 17/22(77.3)
Immune status
None 7/32(21.9) 25/32(78.1) 2/10(20.0) 8/10(80.0) 5/22(22.7) 17/22(77.3)
Systemic 0/2(0.0) 2/2(100.0) 0/2(0.0) 2/2(100.0) - -
Therapies
None 4/26(15.4) 22/26(84.6) 1/8(12.5) 7/8(87.5) 3/18(16.7) 15/18(83.3)
Chemotherapy 2/6(33.3) 4/6(66.7) 1/3(33.3) 2/3(66.7) 2/3(66.7) 2/3(66.7)
Radiotherapy 1/2(50.0) 1/2(50.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) 0/1(0.0)
Total 7/34(20.6) 27/34(79.4) 2/12(16.7) 10/12(83.3) 5/22(22.7) 17/22(77.3)
* Lt. of tongue= lateral border of tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** Other sites= Data not available 
HSCC= Second-primary Squamous Cell Carcinoma
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Table 3.4 Human papillomavirus infection in relation to UK-oral squamous cell carcinoma
UK Gender Odds Ratio 
(95 % Cl)
P-value*
OSCC' '
ALL Cancer
+
-\ HPV 50 7
+ 0 27
F Cancer
+
- 29 2
+ 0 10
M Cancer
+
21 5HPV
17
N/C <0.001
+ 0
N/C: could not be calculated because none of the normal controls were HPV +ve 
* Calculated from Fisher’s exact test
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3.1 Human papillomavirus in oral squamous cell carcinoma -UK
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1. An overall HPV-DNA positive proportion of 27/34 
(79.4%) was detected in OSCC-UK patients. Demographic characteristics 
and risk factors for OSCC in the UK patients are summarised in Table 3.2.
3.1.1 Gender
Human papillomavirus-DNA was detected in 10/12 (83.3%) of females 
compared with 17/22 (77.3%) in males.
3.1.2 Age groups
When HPV-DNA was examined in the different age groups, HPV 
infection showed a peak in the 70-80 year age group. Human papillomavirus- 
DNA was detected in 6/8 (75.0%) in the 50-60 year age group, and 4/5 
(80.0%) in the 60-70 year age group, reaching a peak of 11/12 (91.7%) in the 
70-80 year age group, the frequency then falling to 6/8 (75.0%) in those over 
80 years of age. When stratified according to gender and age, all 10 of males 
aged 70-80 years were HPV infected, while 1/2 (50.0%) of females in this 
age range were infected with HPV.
3.1.3 Ethnic origins
The results show no statistical difference between the Caucasian and 
South Asian groups infected with HPV. Human papillomavirus-DNA was 
detected in 21/26 (80.8%) of Caucasians compared with 6/7 (85.7%) in South 
East Asian descendents. When stratified according to gender and ethnicity, 
HPV-DNA was detected in 5/6 (83.3%) of females in both ethnic groups.
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However, in contrast, 16/20 (80.0%) of the Caucasian males were HPV 
infected compared with 1/1 (100.0%) of the South East Asian males.
3.1.4 Association with tobacco, alcohol and Paan
The association between HPV and other major risk factors for OSCC 
(e.g., tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Human papillomavirus-DNA was detected in 3/3 (100.0%) of 
current smokers compared with 24/31 (77.4%) of non-smokers. Among the 
smokers group, HPV-DNA was detected in 2/2 (100.0%) of individuals 
smoking 10-15/day, and in 1/1 (100.0%) of individuals smoking >20/day. 
When stratified according to gender and smoking, none of the females in this 
group were current smokers. HPV-DNA was found in 3/3 (100.0%) of male 
current smokers. Human papillomavirus-DNA was detected in 10/12 (83.3%) 
of the female non-smokers group compared with 14/19 (73.7%) of male 
individuals.
When the use of Paan was examined, HPV-DNA was found in 24/30 
(80.0%) of non-Paan users compared with 3/4 (75.0%) of Paan users. The 
results show no evidence of statistical variation between both groups. When 
stratified according to gender and current use of Paan, HPV-DNA was 
detected in 2/2 (100.0%) of females compared with 1/2 (50.0%) in male 
individuals.
HPV-DNA was detected in 24/30 (80.0%) of non-alcohol drinkers 
compared with 1/1 (100.0%) of individuals currently consuming 5-20 units of 
alcohol per week. When stratified to gender and alcohol intake, the results 
show that HPV was detected in 14/18 (77.8%) of non-alcohol drinking males 
compared with 10/12 (83.3%) of females within the same group. Among the
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male alcohol drinking groups, HPV-DNA found in 1/1 (100.0%) of individuals 
consuming 5-20 units of alcohol per week, none of the females in the 
samples were current alcohol consumers. Of note, three male individuals did 
not report their alcohol consumption and HPV-DNA was detected in 2/3 
(66.7%) of these individuals.
3.1.5 Site of oral squamous cell carcinoma samples
Cross tabulation for HPV-DNA frequency and other characteristics are 
summarised in Table 3.3. Although only small numbers were present in the 
samples, HPV-DNA was detected in the soft palate, hard palate, anterior two 
thirds of tongue, lip, commisure and retromolar area, and to a lesser extent, 
the buccal mucosa, lateral border of the tongue and floor of mouth. HPV- 
DNA was detected in 5/7 (71.4%) of patients where no data was available 
regarding the biopsy site. No difference was readily apparent as regards the 
biopsy site.
3.1.6 Relevant medical history
Human papillomavirus-DNA was detected in 13/15 (86.7%) of patients 
with no relevant medical history and in 13/18 (72.2%) of patients with second 
primary OSCC . In addition, HPV-DNA was found in 1/1 (100.0%) of male 
individuals with candidal infection. When stratified according to gender and 
medical history HPV was detected in 4/4 (100.0%) of female patients with no 
relevant medical history, compared with 6/8 (75.0%) of female patients with 
second primary OSCC. Human papillomavirus DNA was also detected in 
9/11 (81.8%) of male patients with no relevant medical history compared with 
7/10 (70.0%) of males with second primary OSCC.
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The results show that none of the individuals infected with HPV-DNA 
were receiving any corticosteroid therapy. Human papillomavirus DNA was 
found in 25/32 (78.1%) of patients with no known immunodeficiency disease 
compared with 2/2 (100.0%) of patients with systemic immune disease. 
When stratified according to gender and immune status, HPV was detected 
in 2/2 (100.0%) of female patients with systemic immune disease.
Human papillomavirus-DNA was detected in 4/6 (66.7%) of patients 
who had received chemotherapy, in 1/2 (50.0%) of patients who had received 
radiotherapy and in 22/26 (84.6%) of individuals who had received no 
therapy. When stratified according to gender and therapy received, HPV was 
found in 7/8 (87.5%) of female individuals who received no treatment 
compared with 15/18 (83.3%) of male individuals within the same group. 
Human papillomavirus DNA was detected in 2/3 (66.7%) of both genders 
received chemotherapy and in 1/1 (100.0%) in female patients received 
radiotherapy.
3.1.7 HPV infection in relation to UK-OSCC
The results for HPV infection in relation to OSCC are summarised in 
Table 3.4. In the sample of people, none of the normal controls was HPV+ve. 
However, some of the OSCC patients were HPV+ve. Thus, the OSCC 
patients were highly significantly more likely than normal controls to be 
HPV+ve in this sample (P<0.001, Fisher’s exact test). However, since none 
of the controls was HPV+ve, it was not possible to calculate an odds ratio. 
Therefore, it was also not possible to control for the effects of any other risk 
factors in the analysis.
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Table 3.5 Detection of human papillomavirus versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with proliferative verrucous leukoplakia
Characteristic - veNo. (%)
+ ve 
No. (%)
■ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female
Male
Age(yearg)
2/6(33.3)
3/6(50.0)
4/6 (66.7) 
3/6 (50.0)
40-50 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
50-60 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
60-70 1/3(33.3) 2/3(66.7) 0/2(0.0) 2/2(100.0) 1/1(100.0) 0/1 (0.0)
70-80 1/6(16.7) 5/6 (83.3) 1/3(33.3) 2/3 (66.7) 0/3(0.0) 3/3(100.0)
>80
Ethnicity
1/1(100.0) 0/1(0.0) " " 1/1(100.0) 0/1(0.0)
Caucasian 1/5(20.0) 4/5 (80.0) 1/4(25.0) 3/4 (75.0) 0/1 (0.0) 1/1 (100.0)
N/A* 4/7(57.1) 3/7 (42.9) 1/2(50.0) 1/2(50.0) 3/5(60.0) 2/5(40.0)
Tobacco
None 5/10(50.0) 5/10 (50.0) 2/6 (33.3) 4/6 (66.7) 3/4(75.0) 1/4 (25.0)
current
Smoking
0/2(0.0) 2/2(100.0) " * 0/2(0.0) 2/2(100.0)
None 5/10(50.0) 5/10(50.0) 2/6 (33.3) 4/6 (66.7) 3/4(75.0) 1/4 (25.0)
>20/day
Paan
0/2(0.0) 2/2 (100.0) - 0/2(0.0) 2/2 (100.0)
None 4/11(36.4) 7/11 (63.6) 2/6 (33.3) 4/6 (66.7) 2/5(40.0) 3/5 (60.0)
Current user
Alcohol
1/1 (100.0) 0/1 /0 01 * - 1/1(100.0) 0/1 (0.0)
None 5/11(45.5) 6/11 (54.5) 2/6 (33.3) 4/6 (66.7) 3/5(60.0) 2/5 (40.0)
>20 u/w** 0/1(0.0) 1/1 (100.0) - - 0/1(0.0) 1/1 (100.0)
Total 5/12(41.7) 7/12(58.3) 2/6(33.3) 4/6 (66.7) 3/6(50.0) 3/6(50.0)
*N/A= Data not available
**u/w = Units / week
115
Chapter 3 Human papillomavirus-Results
Table 3.6 Cross tabulation for human papillomavirus in UK-proliferative verrucous 
leukoplakia samples according to biopsy site, relevant medical note, corticosteroids, immune 
status, and therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%))
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal mucosa 
Lt.of tongue*
1/4(25.0)
1/2(50.0)
3/4(75.0)
1/2(50.0)
1/4(25.0) 3/4(75.0)
1/2(50.0) 1/2(50.0)
Floor of mouth 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
Hard palate 0/1(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) - -
Ant. 2/3 of 
tongue** 0/1 (0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Lip 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Retromolar 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Medical note
None 2/3(66.7) 1/3(33.3) 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1(0.0)
s ee*** 2/6(33.3) 4/6(66.7) 1/3(33.3) 2/3(66.7) 1/3(33.3) 2/3(66.7)
Candidal
infection
0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Penicillin
allergy
Corticosteroids
None
1/2(50.0) 1/2(50.0) 0/1 (0.0) 1/1(100.0) 1/1(100.0) 0/1(0.0)
5/12(41.7) 7/12(58.3) 2/6(33.3) 4/6(66.7) 3/6(50.0) 3/6(50.0)
Immune status
None 5/12(41.7) 7/12(58.3) 2/6(33.3) 4/6(66.7) 3/6(50.0) 3/6(50.0)
Therapies
None 5/11(54.5) 6/11(45.5) 2/5(40.0) 3/5(60.0) 3/6(50.0) 3/6(50.0)
Chemotherapy 0/1(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) - -
Total 5/12(41.7) 7/12(58.3) 2/6(33.3) 4/6(66.7) 3/6(50.0) 3/6(50.0)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** SCC= Second-primary Squamous Cell Carcinoma
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Table 3.7 Human papillomavirus infection in relation to UK-proliferative verrucous 
leukoplakia samples
UK Gender Odds Ratio (95 % Cl) P-value*
PVL • * t *■' ' " \
Ail PVL
+
HPV
+
50 5 
0 7 N/C <0.001
PVL
+
F
HPV
+
29 2 
0 4 N/C <0.001
PVL
+
M
HPV
+
21 3 
0 3
N/C <0.001
N/C: Could not be calculated because none of the normal controls was HPV+ve 
* Calculated from Fisher’s exact test
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3.2 Human papillomavirus in proliferative verrucous leukoplakia-UK
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1. An overall HPV-DNA positive proportion of 7/12 
(58.3%) was detected in PVL-UK patients. Demographic characteristics and 
risk factors for PVL in the UK patients are summarised in Table 3.5.
3.2.1 Gender
Human papillomavirus-DNA was detected in 4/6 (66.7%) of females 
compared with 3/6 (50.0%) in males.
3.2.2 Age groups
Human papillomavirus-DNA detection was 2/3 (66.7%) in the 60-70 
year age group and 5/6 (83.3%) in the 70-80 year age group. When stratified 
according to age and gender, HPV-DNA was detected in 2/2 (100.0%) of 
females aged 60-70 years, and in 2/3 (66.7%) of females aged 70-80 years 
compared with 3/3 (100.0%) of males within the same age group.
3.2.3 Ethnic origins
Human papillomavirus-DNA was detected in 4/5 (80.0%) of 
Caucasians compared with 3/7 (42.9%) in patients where ethnicity was not 
recorded. When further stratified according to gender and ethnicity, HPV- 
DNA was detected in 3/4 (75.0%) of Caucasian females compared with 1/1 
(100.0%) of males of the same ethnicity.
3.2.4 Associations with tobacco/alcohol and Paan
The association between HPV and other major risk factors for PVL 
(e.g., tobacco smoking, frequency of smoking, Paan use and alcohol intake)
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was examined. Human papillomavirus-DNA was found in 2/2 (100.0%) of 
current smokers compared with 5/10 (50.0%) of non-smokers. Among the 
smokers group, HPV-DNA was detected in 2/2 (100.0%) of individuals 
smoking >20/day. When further stratified according to gender and smoking, 
none of the females in this group were current smokers. Human 
papillomavirus-DNA was found in 1/4 (25.0%) of male non-smokers 
compared with 2/2 (100.0%) of male individuals smoking >20/day group.
When the use of Paan was examined, HPV-DNA was found only in 
7/11 (63.6%) of non-Paan users. When stratified according to gender and 
use of Paan, HPV-DNA was found in non-Paan users in 4/6 (66.7%) of 
females compared with 3/5 (60.0%) of male individuals not using Paan.
Human papillomavirus-DNA was detected in 6/11 (54.5%) of non­
alcohol drinkers compared with 1/1 (100.0%) of individuals currently 
consuming >20 units per week. When stratified according to gender and 
alcohol intake, HPV-DNA was found 4/6 (66.7%) of female non-alcohol 
drinkers. Human papillomavirus-DNA was detected in 1/1 (100.0%) of male 
individuals consuming >20 units per week compared with 2/5 (40.0%) of 
male non-alcohol drinkers.
3.2.5 Site of proliferative verrucous leukoplakia samples
Cross tabulation for HPV-DNA frequency and other characteristics are 
summarised in Table 3.6. Human papillomavirus-DNA was detected in the 
buccal mucosa, lateral border of the tongue, floor of mouth, hard palate and 
in the anterior 2/3 of the tongue. When stratified according to gender and 
biopsy site, no difference was readily apparent as regards the biopsy site.
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3.2.6 Relevant medical history
Human papillomavirus-DNA was detected in 1/3 (33.3%) of patients 
with no relevant medical history. In addition, HPV-DNA was found in 4/6 
(66.7%) of patients with second primary OSCC, in 1/1 (100.0%) of patients 
with candidal infection and in 1/2 (50.0%) of patients allergic to penicillin. 
When stratified according to gender and medical history, HPV-DNA was 
found in 1/2 (50.0%) of females with no relevant medical history, in 2/3 
(66.7%) with second primary OSCC, and in 1/1 (100.0%) of patients allergic 
to penicillin. Human papillomavirus-DNA was found in 2/3 (66.7%) of male 
patients with second primary OSCC, and in 1/1 (100.0%) of those with 
previous candidal infection.
The results show that none of the individuals infected with HPV-DNA 
had received any cortico-steroid therapy or had any known immune disease. 
In patients receiving chemotherapy, HPV-DNA was found in 1/1 (100.0%) of 
female individuals compared with 3/5 (60.0%) of female individual received 
no therapy. Human papillomavirus-DNA was detected in 3/6 (50.0%) of male 
individuals recieved no therapy.
3.2.7 HPV infection in relation to UK-PVL
The results for HPV infection in relation to PVL are summarised in 
Table 3.7. In the sample of people, none of the normal controls was HPV+ve. 
However, some of the PVL patients were HPV+ve. Thus the PVL patients 
were highly significantly more likely than normal controls to be HPV+ve in 
this sample (P<0.001, Fisher’s exact test). However, since none of the 
controls were HPV+ve, it was not possible to calculate an odds ratio.
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Therefore, it was also not possible to control for the effects of any other risk 
factors in this analysis.
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Table 3.8 Detection of human papillomavirus versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with oral epithelial dysplasia
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female
Male
12/22(54.5)
14/23(60.9)
?*** *< 
10/22(45.5) 
9/23 (39.1)
; v;*
Age (years) .... * * (V*
20-30 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0)
30-40 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0)
40-50 2/3(66.7) 1/3 (33.3) - - 1/2(50.0) 1//2 (50.0)
50-60 10/16(62.5) 6/16 (37.5) 4/6(66.7) 2/6(33.3) 6/10(60.0) 4/10(40.0)
60-70 6/14(42.9) 8/14 (57.4) 2/7(28.6) 5/7(71.4) 4/7(57.1) 3/7 (42.9)
70-80
Ethnicity
5/9(55.6) 4/9 (44.4) 4/7(57.1) 3/7(42.9) 1/2(50.0) 1/2(50.0)
Caucasian 20/30(66.7) 10/30 (33.3) 10/14(71.4) 4/14 (28.6) 10/16(62.5) 6/16(37.5)
SEA* 2/6(33.3) 4/6 (66.7) 1/4(25.0) 3/4 (75.0) 1/2 (50.0) 1/2(50.0)
N/A** 4/9(44.4) 5/9 (55.6) 1/4(25.0) 3/4 (75.0) 3/5(60.0) 2/5(40.0)
Tobacco
None 13/24(54.2) 11/24(45.8) 7/15(46.7) 8/15(53.3) 6/9(66.7) 3/9(33.3)
Ex-smoker 1/3(33.3) 2/3 (66.7) - - 1/3(33.3) 2/3(66.7)
Current
Smoking
12/18(66.7) 6/18 (33.3) 5/7(71.4) 2/7(28.6) 7/11(63.6) 4/11(36.4)
None 13/24(54.2) 11/24 (45.8) 7/15(46.7) 8/15(53.3) 6/9(66.7) 3/9(33.3)
10-15/day 6/12(50.0) 6/12(50.0) 2/4(50.0) 2/4(50.0) 4/8(50.0) 4/8 (50.0)
>20/day
Paan
7/9(77.8) 2/9 (22.2) 3/3(100.0) 0/3(0.0) 4/6(66.7) 2/6(33.3)
None 24/40(60.0) 16/40 (40.0) 11/19(57.9) 8/19(42.1) 13/21(61.9) 8/21(38.1)
Current
Alcohol
2/5(40.0) 3/5 (60.0) 1/3(33.3) 2/3(66.6) 1/2(50.0) 1/2(50.0)
None 13/23(56.5) 10/23 (43.5) 5/11(45.5) 6/11(54.5) 8/12(66.7) 4/12(33.3)
<5 u/w*** 3/4(75.0) 1/4 (25.0) 2/3(66.7) 1/3 (33.3) 1/1(100.0) 0/1(0.0)
5-20 u/w 0/3(0.0) 3/3(100.0) 0/1 (0.0) 1/1 (100.0) 0/2(0.0) 2/2(100.0)
> 20 u/w 7/12(58.3) 5/12(41.7) 4/6(66.6) 2/6 (33.3) 3/6/50.01 3/6(50.0)
N/A 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0) 2/2(100.0) 0/2(0.0)
Total 26/45(57.8) 19/45(42.2) 12/22(54.5) 10/22(45.5) 14/23(50.9) 9/23 (39.1)
*SEA= South East Asian
**N/A= Data not available
***u/w= units per week
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Table 3.9 Cross tabulation for human papillomavirus in UK-oral epithelial dysplasia samples 
according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies.
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site . - T < •
Buccal m ucosa 4/8(50.0) 4/8(50.0) 1/3(33.3) 2/3(66.7) 3/5(60.0) 2/5(40.0)
Lt. of tongue* 7/12(58.3) 5/12(41.7) 2/6(33.3) 4/6(66.7) 5/6(83.3) 1/6(16.7)
Floor of mouth 2/3(66.7) 1/3(33.3) 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1 (0.0)
Hard palate 0/2(0.0) 2/2 (100.0) - - 0/2(0.0) 2/2(100.0)
Soft palate 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
Ant. 2/3 of 
tongue**
3/4(75.0) 1/4 (25.0) 3/4(75.0) 1/4(25.0) - -
Lip 1/2(50.0) 1/2 (50.0) 1/1(100.0) 0/1 (0.0) 0/1(0.0) 1/1(100.0)
Com m isure 8/9(88.9) 1/9(11.1) 3/3(100.0) 0/3(0.0) 5/6(83.3) 1/6(16.7)
Retromolar 0/1 (0.0) 1/1 (100.0) 0/1 (0.0) 1/1(100.0) - -
Salivary 0/1(0.0) 1/1 (100.0) 0/1 (0.0) 1/1(100.0) - -
Attacnea 1/1(100.0) 
gingiva 
Relevant medical note
0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
None 13/20(65.0) 7/20(35.0) 7/11(63.6) 4/11(36.4) 6/9(66.7) 3/9(33.3)
. see***
Candidal
2/7(28.6) 5/7(71.4) 0/2(0.0) 2/2(100.0) 2/5(40.0) 3/5(60.0)
infection
4/5(80.0) 1/5(20.0) 2/2(100.0) 0/2(0.0) 2/3(66.7) 1/3(33.3)
Submucous
fibrosis
1/4(25.0) 3/4 (75.0) 0/2(0.0) 2/2(100.0) 1/2(50.0) 1/2 (50.0)
HRT**** 3/5(60.0) 2/5(40.0) 3/5(60.0) 2/5(40.0) - -
Arthritis 0/1(0.0) 1/1(100.0) - - 0/1(0.0) 1/1(100.0)
Asthm a
Diabetes
2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
mellitus
Corticosteroids
1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0)
None 
immune status
26/45(57.8) 19/45(42.2) 12/22(54.5) 10/22(45.5) 14/23(60.9) 9/23(39.1)
None 25/43(58.1) 18/43(41.9) 11/21(52.4) 10/21(47.6) 14/22(63.6) 8/22(36.4)
Systemic
Therapies
1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1(0.0) 0/1 (0.0) 1/1(100.0)
None 24/41(58.5) 17/41(41.5) 10/18(55.6) 8/18(44.4) 14/23(60.9) 9/23(39.1)
C hem otherapy 2/4(50.0) 2/4 (50.0) 2/4(50.0) 2/4(50.0) - -
Total 26/45(57.8) 19/45(42.2) 12/22(54.5) 10/22(45.5) 14/23(60.9) 9/23(39.1)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** SCC= Second-primary Squamous Cell Carcinoma
****HRT=Hormone replacement therapy
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Table 3.10 Human papillomavirus infection in relation to UK-oral epithelial dysplasia samples
UK Gender Odds Ratio (95% Cl) P-value*
OED
All OED
+
HPV
+
50 26 
0 19
N/C <0.001
OED
+
F
HPV
+
29 12 
0 10 N/C <0.001
OED
+
M
HPV
+
21 14 
0 9
N/C <0.001
N/C: could not be calculated because none of the normal controls were HPV +ve 
* Calculated from Fisher’s exact test
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3.3 Human papillomavirus in oral epithelial dysplasia-UK
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1. An overall HPV-DNA positive proportion of 19/45 
(42.2%) was detected in OED-UK patients. Demographic characteristics and 
risk factors for OED in the UK patients are summarised in Table 3.8.
3.3.1 Gender
Human papillomavirus-DNA was detected in 10/22 (45.5%) of females 
compared with 9/23 (39.1%) in males.
3.3.2 Age groups
When HPV-DNA was examined in different age groups the proportion 
was 1/3 (33.3%) in the 40-50 year age group, 6/16 (37.5%) in the 50-60 year 
age group, 8/14 (57.4%) in the 60-70 year age group and 4/9 (44.4%) in the 
70-80 year age group. When stratified according to gender and age groups, 
HPV-DNA was found in 2/6 (33.3%) of the female group aged 50-60 years 
compared with 4/10 (40.0%) of males within the same age group. Human 
papillomavirus-DNA was detected in 5/7 (71.4%) of the female group aged 
60-70 years compared with 3/7 (42.9%) of males within the same age group. 
In addition, HPV-DNA was found in 3/7 (42.9%) of the female aged 70-80 
years compared with 1/2 (50.0%) of males within the same age group.
3.3.3 Ethnic origins
Human papillomavirus-DNA was detected in 10/30 (33.3%) of 
Caucasians compared with 4/6 (66.7%) in South East Asians. When stratified 
according to gender and ethnicity, HPV-DNA was found in 4/14 (28.6%) of 
female Caucasians compared with 6/16 (37.5%) of the male Caucasians.
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However, in South East Asians HPV-DNA was found in 3/4 (75.0%) of 
females compared with 1/2 (50.0%) of males. HPV-DNA was found in 5/9 
(55.6%) of patients with no recorded ethnicity.
3.3.4 Associations with tobacco, alcohol and Paan
The association between HPV and other major risk factors for PVL 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Human papillomavirus-DNA was found in 6/18 (33.3%) of 
current smokers compared with 11/24 (45.8%) in non-smokers. In addition, 
HPV was positive in 2/3 (66.7%) of ex-smokers. Among the smokers group, 
HPV-DNA was detected in 6/12 (50.0%) of individuals smoking 10-15/day 
and in 2/9 (22.2%) of individuals smoking >20/day. When further stratified 
according to gender and smoking, HPV-DNA was detected in none of the 
female ex-smoking group compared with 2/3 (66.7%) of male ex-smokers. 
Human papillomavirus-DNA was found in 4/8 (50.0%) of male smoking 10- 
15/day compared with 2/6 (33.3%) of male smoking >20 /day.
When the use of Paan was examined, HPV-DNA was found in 16/40 
(40.0%) of non-Paan users compared with 2/5 (40.0%) of current Paan 
users. When stratified according to gender and use of Paan, HPV-DNA was 
found in 8/19 (42.1%) of female non-Paan users compared with 8/21 (38.1%) 
of male individuals. In current Paan users, HPV-DNA was found in 2/3 
(66.7%) of females compared with 1/2 (50.0%) of male individuals currently 
using Paan.
Human papillomavirus-DNA was detected in 10/23 (43.5%) of non­
alcohol drinkers. However, HPV-DNA was detected in 1/4 (25.0%) of 
individuals currently consuming < 5 units per week, in 3/3 (100.0%) of
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individuals currently consuming 5-20 units per week and in 5/12 (41.7%) of 
individuals consuming >20 units per week. When stratified according to 
gender and alcohol intake, HPV-DNA was found 6/11 (54.5%) of female non­
alcohol drinkers compared with 4/12 (33.3%) of male individuals. Human 
papillomavirus-DNA was detected in all two male individuals consuming 5-20 
units per week compared with 1/1 (100.0%) of female individuals. In addition, 
HPV-DNA was detected in 3/6 (50.0%) of male individuals consuming >20 
units per week compared with 2/6 (33.3%) of females within the same group.
3.3.5 Site of oral epithelial dysplasia samples
Cross tabulation for HPV-DNA frequency and other characteristics are 
summarised in Table 3.9. Human papillomavirus-DNA was detected in the 
buccal mucosa, lateral border of the tongue, soft palate, hard palate, and to a 
lesser extent, anterior two thirds of tongue, lip, commisure, retromolar area, 
and floor of mouth. No difference was readily apparent as regards the biopsy 
site and HPV infection. Similar proportions were found in both genders.
3.3.6 Relevant medical history
Human papillomavirus-DNA was detected in 7/20 (35.0%) of patients 
with no relevant medical history and in 5/7 (71.4%) of patients with second 
primary OSCC. In addition, HPV-DNA was found in 1/5 (20.0%) of individuals 
with candidal infection, in 3/4 (75.0%) of patients with submucous fibrosis, in 
2/5 (40.0%) of female patients receiving HRT and in 1/1 (100.0%) of male 
individuals with a history of arthritis. When stratified according to gender and 
medical history, HPV was detected in 4/11 (36.4%) of females with no 
relevant medical history compared with 3/9 (33.3%) of male individuals within
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same group, and in 2/2 (100.0%) of females with second primary compared 
with 3/5 (60.0%) of male individuals within the same group. In addition, HPV 
was positive in 2/2 (100.0%) of females with submucous fibrosis compared 
with 1/2(50.0%) of males with the same disease.
The results show that none of the individuals infected with HPV-DNA 
had received any corticosteroid therapy. Human papillomavirus was found in 
18/43 (41.9%) of patients of both genders without any known immune 
disease compared with 1/1 (100.0%) of males with systemic immune 
disease.
Human papillomavirus-DNA was detected in 2/4 (50.0%) of patients 
received chemotherapy compared with 17/41 (41.5%) of patients who had 
received no such treatment. When stratified according to gender and 
receiving chemotherapy, HPV was found in 2/4 (50.0%) of female individuals.
3.3.7 HPV infection in relation to UK-OED
The results for HPV infection in relation to OED are summarised in 
Table 3.10. In the sample of people, none of the normal controls was 
HPV+ve. However, some of the OED patients were HPV+ve. Thus the OED 
patients Were highly significantly more likely than normal controls to be 
HPV+ve in this sample, (Pc.0001, Fisher’s exact test). However, since none 
of the controls was HPV+ve, it was not possible to calculate an odds rsatio. 
Therefore, it was also not possible to control for the effects of any other risk 
factors in this analysis.
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Table 3.11 Detection of human papillomavirus versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with oral lichen planus
Characteristic -ve No. (%)
+ve 
No. (%)
-ve
Female
No.J%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female 
Male 
Age (years)
10/14(71.4)
11/16(68.8)
4/14(28.6)
5/16(31.3)
40-50 5/7(71.4) 2/7(28.6) 3/4(75.0) 1/4(25.0) 2/3(66.7) 1/3(33.3)
50-60 6/10(60.0) 4/10(40.0) 3/5(40.0) 2/5(40.0) 3/5(60.0) 2/5(40.0)
60-70 5/8(62.5) 3/8(37.5) 2/3(66.7) 1/3(33.3) 3/5(60.0) 2/5(40.0)
70-80 5/5(100.0) 0/5(0.0) 2/2(100.0) 0/2(0.0) 3/3(100.0) 0/3(0.0)
Ethnicity Y ' • - • ' '  V  ' . r. '  * '
Caucasian 12/16(75.0) 4/16(25.0) 6/8(75.0) 2/8(25.0) 6/8(75.0) 2/8(25.0)
SEA* 5/5(100.0) 0/5(0.0) 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0)
N/A** 4/9(44.4) 5/9(55.6) 1/3(33.3) 2/3(66.7) 3/6(50.01 3/6(50.0)
Tobacco
None 19/26(73.1) 7/26(26.9) 9/13(69.2) 4/13(30.8) 10/13\76.9; 3/13(23.1)
Ex-smoker 0/1 (0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Current 2/3(66.7) 1/3(33.3) 1/1(100.0) 0/1(0.0) 1/2(50.0) 1/2(50.0)
Smoking
None 19/26(73.1) 7/26(26.9) 9/13(69.2) 4/13 (30.8) 10/13(76*9) 3/13(23.1)
<5 /day 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) - -
10-15/day 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
>20/day 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Paan
None 20/29(69.0) 9/29(31.0) 9/13(69.2) 4/13(30.8) 11/16(68.8) 5/16(31.3)
Current 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) - -
Alcohol
None 16/23(69.6) 7/23(30.4) 8/12(66.7) 4/12(33.3) 8/11(72.7) 3/11(27.3)
5-20u/w *** 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1(0.0) 0/1 (0.0) 1/1(100.0)
>20 u/ w 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
N/A 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
Total 21/30(70.0) 9/30(30.0) 10/14(71.4) 4/14(28.6) 11/16(68.8) 5/16(31.3)
*SEA=South East Asian
**N/A= Data not available
*** u/w = units per week
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Table 3.12 Cross tabulation for human papillomavirus in UK-oral lichen planus samples 
according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -veNo. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
.... v „ , ...j ,.. *
Buccal mucosa 18/25(72.0) 7/25(28.0) 9/11(81.8) 2/11(18.2) 9/14(64.2) 5/14(35.7)
Lt. of tongue* 2/3(66.7) 1/3 (33.3) 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1(0.0)
Attached gingiva 
Medical note
1/2(50.0) 1/2(50.0) 0/1 (0.0) 1/1(100.0) 1/1(100.0) 0/1 (0.0)
None 10/17(58.8) 7/17(41.2) 2/5(40.0) 3/5(60.0) 8/12(66.7) 4/12(33.3)
Cutaneous
disease 3/4(75.0) 1/4(25.0) 2/2(100.0) 0/2(0.0) 1/2(50.0) 1/2(50.0)
Diabetes mellitus 1/2(50.0) 1/2(50.0) 1/2(50.0) 1/2(50.0) - -
HRT** 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0) - -
Asthma 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0) - -
Candida
Corticosteroids
3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
None 18/26(69.2) 8/26(30.8) 8/11(72.7) 3/11(27.3) 10/15(66.7) 5/15(33.3)
Topical 0/1 (0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) - -
Systemic 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0)
immune status
None 13/21(61.9) 8/21(38.1) 5/9(55.6) 4/9(44.4) 8/12(66.7) 4/12(33.3)
Drugs 4/5(80.0) 1/5 (20.0) 2/2(100.0) 0/2(0.0) 1/2 (50.0) 1/2(50.0)
Systematic
TheTspies
4/4(100.0) 0/4(0.0) 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0)
None 21/30(70 0) 9//30(30.0) 10/14(71.4) 4/14(28.6) 11/16(68.8) 5/16(31.3)
Total 21/30(70.0) 9/30(30.0) 10/14(71.4) 4/14(28.6) 11/16(68.8) 5/16(31.3)
* Lt. of tongue= lateral border of the tongue
**HRT=Hormone replacement therapy
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Table 3.13 Human papillomavirus infection in relation to UK-oral lichen planus samples
UK Gender Odds Ratio (95% Cl) P-value*
OLP '
ALL OLP
+
HPV +
50 21 
0 9
N/C <0.001
F OLP
+
HPV +
29 10 
0 4
N/C <0.001
M OLP
+
HPV +
21 11 
0 5
N/C <0.001
N/C: could not be calculated because none of the normal controls were HPV +ve 
* Calculated from Fisher’s exact test
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3.4 Human papillomavirus in oral lichen planus - UK
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1 An overall HPV-DNA positive proportion of 9/30 
(30.0%) was detected in OLP-UK patients. Demographic characteristics and 
risk factors for OLP in the UK pateints are summarised in Table 3.11.
3.4.1 Gender
Human papillomavirus-DNA was detected in 4/14 (28.6%) of females 
compared with 5/16 (31.3%) of males.
3.4.2 Age groups
When HPV-DNA was examined in different age groups, HPV-DNA 
was detected in 2/7 (28.6%) in the 40-50 year age group, 4/10 (40.0%) of the 
50-60 year age group and 3/8 (37.5%) of the 60-70 year age group. When 
stratified according to gender and age groups, HPV-DNA was found in 1/4 
(25.0%) of the female 40-50 years age group compared with 1/3 (33.3%) of 
males within the same age group, HPV-DNA was found in 2/5 (40.0%) of the 
50-60 year age group in both genders. In addition, HPV-DNA was found in 
1/3 (33.3%) of females aged 60-70 years compared with 2/5 (40.0%) of 
males within the same age group.
3.4.3 Ethnic origins
Human papillomavirus-DNA was detected in 4/16 (25.0%) of 
Caucasians compared with 4/9 (44.4%) in patients with no recorded ethnicity. 
When stratified according to gender and ethnicity, HPV-DNA was found in 
2/8 (25.0%) of both genders in Caucasian. However, HPV-DNA was found in
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2/3 (66.7%) of the females with no recorded ethnicity compared with 3/6 
(50.0%) of the males within the same group.
3.4.4 Associations with tobacco, alcohol and Paan
The association between HPV and other major risk factors for OLP 
(e.g., tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. HPV-DNA was found in 1/3 (33.3%) of current smokers 
compared with 7/26 (26.9%) of non-smokers. In addition, HPV was positive in 
1/1 (100.0%) of ex-smokers. Among the smokers group, HPV-DNA was 
detected in both 2/2 (100%) individuals smoking 10-15/day. When further 
stratified according to gender and smoking, none of the females in this group 
were ex-smokers while 1/1 (100.0%) of HPV positive males was ex-smoker.
When the use of Paan was examined, HPV-DNA was found in 9/29 
(31.0%) of non-Paan users. When stratified according to gender and use of 
Paan, HPV-DNA was found in 4/13 (30.8%) of non-Paan users female 
individuals compared with 5/16 (31.3%) of non-Paaan users males.
Human papillomavirus-DNA was detected in 7/23 (30.4%) of non­
alcohol drinkers. However, HPV-DNA was detected in 1/2 (50.0%) of both 
groups of individuals currently consuming 5-20 units per week and of 
individuals consuming >20 units per week. When stratified according to 
gender and alcohol intake, human papillomavirus-DNA was found in 4/12 
(33.3%) of non-alcohol drinking females compared with 3/11 (27.3%) of male 
individuals within the same group. Among the male alcohol drinking group, 
HPV-DNA was detected in 1/1 (100.0%) of male consuming 5-20 units per 
week compared with 1/2 (50.0%) of males consuming >20 units per week.
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3.4.5 Site of oral lichen planus samples
Cross tabulation for HPV-DNA frequency and other characteristics are 
summarised in Table 3.12. Human papillomavirus-DNA was detected in the 
buccal mucosa, lateral border of the tongue and attached gingiva, no 
differences in HPV infection were readily apparent as regards the biopsy site. 
When further stratified according to gender and biopsy site, HPV-DNA was 
found in the buccal mucosa of 5/14 (35.7%) of males compared with 2/11 
(18.2%) of females within the same group.
3.4.6 Relevant medical history
Human papillomavirus-DNA was detected in 7/17 (41.2%) of patients 
with no relevant medical history, in 1/2 (50.0%) of male patients with a skin 
lesion and in 1/2 (50.0%) of diabetic female patients. The results show that 
HPV-DNA was found in 8/26 (30.8%) of patients who received no cortico­
steroids compared with 1/1 (100.0%) female receiving topical steroids. 
Human papillomavirus was found in 8/21 (38.1%) of patients without any 
immune disease compared with 1/2 (50.0%) of male patients receiving 
immunosuppressive drugs. None of the patients’ detected positive for HPV- 
DNA had received chemotherapy or radiotherapy.
3.4.7 HPV infection in relation to OLP
The results for HPV infection in relation to OLP are summarised in 
Table 3.13. In the sample of people, none of the normal controls was 
HPV+ve. However, some of the OLP patients were HPV+ve. Thus the OLP 
patients were highly significantly more likely to be HPV+ve than normal 
controls in this sample. (P<0.001, Fisher’s exact test). However, since none
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of the controls were HPV+ve it was not possible to calculate an odds ratio. 
Therefore, it was also not possible to control for the effects of any other risk 
factors in this analysis.
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Table 3.14 Detection of human papillomavirus versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with human immunodeficiency virus
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender • .
Female 
Male 
Age (years)
2/3 (66.7) 
14/22(63.6)
1/3(33.3)
8/22(36.4)
30-40 6/8(75.0) 2/8(25.0) 1/2(50.0) 1/2(50.0) 5/6(83.3) 1/6(16.7)
40-50 8/13(61.5) 5/13(38.5) - - 8/13(61.5) 5/13(38.5)
50-60 2/4(50.0) 2/4(50.0) 1/1(100.0) 0/1 (0.0) 1/3(33.3) 2/3 (66.7)
Ethnicity • " " V  " '■ ’ / * .  '
Caucasian 15/22(68.2) 7/22(31.8) 1/2(50.0) 1/2(50.0) 14/20(70.0) 6/20(30.0)
African 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
SEA* 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) - -
N/A** 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Tobacco
None 9/18(50.0) 9/18(50.0) 2/3(66.7) 1/3(33.3) 7/15(46.7) 8/15(53.3)
Current 7/7(100.0) 0/7(0.0) - ■ - 7/7(100.0) 0/7(0.0)
Smoking
None 9/18(50.0) 9/18(50.0) 2/3(66.7) 1/3(33.3) 7/15(46.7) 8/15(53.3)
>20/day 7/7(100.0) 0/7(0.0) - - 7/7(100.0) 0/7(0.0)
Paan
None 16/25(64.0) 9/25(36.0) 2/3(66.7) 1/3(33.3) 14/22(63.6) 8/22(36.4)
Alcohol
None 15/25(60.0) 9/24(37.5) 2/3(66.7) 1/3(33.3) 13/22(59.1) 8/21(38.1)
>20 u/w*** 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Total 16/25(64.0) 9/25(36.0) 2/3(66.7) 1/3(33.3) 14/22(63.6) 8/22(36.4)
* SEA=South East Asian
**N/A= Data not available
*** u/w= Units per week
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Table 3.15 Cross tabulation for human papillomavirus in human immunodeficiency virus 
samples according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal mucosa 3/4(75.0) 1/4(25.0) - - 3/4(75.0) 1/4(25.0)
Lt. of tongue* 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
Attached
gingiva 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
Hard palate 3/5(60.0) 2/5(40.0) 1/2(50.0) 1/2(50.0) 2/3(66.7) 1/3(33.3)
Ant. 2/3 of 
tongue** 0/1 (0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0)
Lip 6/6(100.0) 0/6(0.0) 1/1(100.0) 0/1 (0.0) 5/5(100.0) 0/5(0.0)
Commisure 3/3(100.0) 0/3(0.0) - - 3/3(100.0) 0/3(0.0)
Retromolar 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Other sites*** 0/1(0.0) 1/1(100.0) - - 0/1(0.0) 1/1(100.0)
Relevant medical note
None 12/20(60.0) 8/20(40.0) 2/3(66.7) 1/3(33.3) 10/17(58.8) 7/17(41.2)
Candidal
infection 3/4(75.0) 1/4(25.0) - - 3/4 (75.0) 1/4 (25.0)
Cutaneous
disease 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Cortlcosteroide
None 14/18(77.8) 4/18(22.2) 1/2 (50.0) 1/2(50.0) 13/16(81.3) 3/16(18.8)
Systemic 2/7(28.6) 5/7(71.4) 1/1(100.0) 0/1 (0.0) 1/6(16.7) 5/6(31.3)
Immune status
None 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Systemic 15/24(62.5) 9/24(37.5) 2/3(66.71 1/3(33.3) 13/21(61.9) 8/21(38.1)
Therapies
None 10/19(52.6) 9/19(47.4) 2/3(66.7) 1/3(33.3) 8/16(50.0) 8/16(50.0)
Triple therapy 6/6(100.0) 0/6(0.0) - - 6/6(100.0) 0/6(0.0)
Totaf 16/25(64.0) 9/25(36.0) 2/3(66.7) 1/3(33.3) 14/22(63.6) 8/22(36.4)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** Other sites= Data not available
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Table 3.16 Human papillomavirus infection in relation to UK- human immunodeficiency virus 
samples
UK Gender Odds Ratio 
(95% Cl)
P-value*
HIV x  ;
ALL HIV
+
HPV
+
50 16 
0 9
N/C <0.001
F HIV
+
HPV
+
29 2 
0 1
N/C <0.001
M HIV
+
HPV
+
21 14 
0 8
N/C <0.001
N/C: could not be calculated because none of the normal controls were HPV +ve 
* Calculated from Fisher’s exact test
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3.5Human papillomavirus in Human immunodeficiency virus individuals
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1. An overall HPV-DNA positive proportion of 9/25 
(36.0%) was detected in HIV-UK patients. Demographic characteristics and 
risk factors for HIV in the UK patients are summarised in Table 3.14.
3.5.1 Gender
Human papillomavirus-DNA was detected in 1/3 (33.3%) of females 
compared with 8/22 (36.4%) in males.
3.5.2 Age groups
When HPV-DNA was examined in different age groups, the proportion 
was 2/8 (25.0%) in the 30-40 year age group, 5/13 (38.5%) in the 40-50 year 
age group and 2/4 (50.0%) in the 50-60 year age group. When stratified 
according to gender and age, HPV-DNA was found in 1/2 (50.0%) of the 
female group aged 30-40 years compared with 1/6 (16.7%) of the males 
within the same age group. Human papillomavirus-DNA was detected in 5/13 
(38.5%) of the male group aged 40-50 years and in 2/3 (66.7%) of the male 
group aged 50-60 years.
3.5.3 Ethnic origins
Human papillomavirus-DNA was detected in 7/22 (31.8%) of 
Caucasians compared with 1/1 (100.0%) African. When stratified according 
to gender and ethnicity, HPV-DNA was found in 1/2 (50.0%) of Caucasian 
females compared with 6/20 (30.0%) of the Caucasian males. HPV-DNA was 
found in 1/1 (100.0%) of male patient with no recorded ethnicity.
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3.5.4 Association with tobacco, alcohol and Paan
The association between HPV and other major risk factors for HIV 
(e.g., tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined and HPV-DNA was found only in 9/18 (50.0%) of non- 
smokers.
When the use of Paan was examined, HPV-DNA was found in 9/25 
(36.0%) of non-Paan users. In addition, HPV-DNA was detected in 9/24 
(37.5%) of non-alcohol drinkers.
3.5.5 Site of human immunodeficiency virus oral sample
Cross tabulation for HPV-DNA frequency and other characteristics are 
summarised in Table 3.15. Human papillomavirus-DNA was detected in the 
buccal mucosa, lateral border of the tongue, attached gingiva, hard palate 
and anterior two thirds of tongue.
3.5.6 Relevant medical history
Human papillomavirus-DNA was detected in 8/20 (40.0%) of patients 
with no relevant medical history, in addition, HPV-DNA was found in 1/4 
(25.0%) of males with candidal infection. The results show that HPV-DNA 
was found in 4/18 (22.2%) of individuals who received no corticosteroid 
therapy compared with 5/7 (71.4%) of those who received systemic 
corticosteroids. HPV was found in 9/24 (37.5%) of patients with systemic 
immune disease. When further stratified according to gender and immune 
status, HPV-DNA was detected in 1/3 (33.3%) of females compared with 
8/21 (38.1%) of males. No HPV-DNA was detected in patients who had
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received triple therapy. In addition, HPV-DNA was detected in 9/19 (47.4%) 
of patients who had received no other therapy.
3.5.7 HPV infection in relation to HIV-patients
The results for HPV infection in relation to HIV are summarised in 
Table 3.16. In the sample of people, none of the normal controls was 
HPV+ve. However, some of the HIV patients were HPV+ve. Thus the HIV 
patients were highly significantly more likely than normal controls to be 
HPV+ve in this sample (P<0.001, Fisher’s exact test). However, since none 
of the controls were HPV+ve, it was not possible to calculate an odds ratio. 
Therefore, it was also not possible to control for the effects of any other risk 
factors in this analysis.
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Table 3.17 Demographic details of UK normal patients
Characteristic -veNo. (%)
-ve
Female
No.(%)
-ve 
Male 
No. (%)
Gender . ,t  ' W  1"! 'i 1 Jl‘ ' " v 1 '
Female 29/50 (58.0)
Male 21/50 (42.0)
Age (years) . / ,•
<20 6/50(12.0) 5/29(17.2) 1/21(4.8)
20-30 11/50(22.0) 6/29(20.7) 5/21(23.8)
30-40 8/50(16.0) 4/29(13.8) 4/21(19.0)
40-50 6/50(12.0) 4/29(13.8) 2/21(9.5)
50-60 8/50(16.0) 3/29(10.3) 5/21(23.8)
60-70 4/50(8.0) 4/29(13.8) -
70-80 4/50(8.0) 2/29(6.9) 2/21(9.5)
>80 3/50(6.0) 1/29(3.4) 2/21(9.5)
Ethnicity
Caucasian 37/50(74.0) 23/29(79.3) 14/21(66.7)
SEA* 10/50(20.0) 5/29(17.2) 5/21(23.8)
Arab 2/50(4.0) - 2/21(9.5)
African 1/50(2.0) 1/29(3.4) -
Tobacco
None 49/50(98.0) 29/29(100.0) 20/21(95.2)
Ex-smoker 1/50(2.0) - 1/21(4.8)
Smoking
None 49/50(98.0) 29/29(100.0) 20/21(95.2)
10-15/day 1/50(2.0) 1/21(4.8)
Paan
None 48/50(96.0) 29/29(100.0) 19/21(90.5)
Ex-user 2/50(4.0) 2/21(9.5)
Alcohol
None 46/50(92.0) 26/29(89.7) 20/21(95.2)
5-20u/w 4/50(8.0) 3/29(10.3) 1/21(4.8)
Total 50/50(100.0) 29/29(100.0) 21/21(100.0)
**SEA= South East Asian
N.B. All subjects were HPV-ve
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Table 3.18 Cross tabulation for human papillomavirus in UK normal oral mucosa, according 
to biopsy site, relevant medical note, corticosteroids, immune status and therapies
Characteristic -ve No. (%)
-ve 
Female 
No. (%)
-ve 
Male 
No. (%)
Biopsy site *- . •
Buccal mucosa 11/50(22.0) 7/29(24.1) 4/21(19.0)
Lt. of tongue* 1/50(2.0) 1/29(3.4) -
Floor of mouth 12/50(24.0) 7/29(24.1) 5/21(23.8)
Attached gingiva 1/50(2.0) - 1/21(4.8)
Soft palate 1/50(2.0) 1/29(3.4) -
Hard palate 4/50(8.0) 3/29(10.3) 1/21(4.8)
Ant. 2/3 of 
tongue** 1/50(2.0) - 1/21(4.8)
Lip 17/50(34.0) 10/29(34.5) 7/21(33.3)
Retromolar 2/50(4.0) - 2/21(9.5)
Relevant medical note
None 47/50(94.0) 27/29(93.1) 20/21(95.2)
HRT*** 1/50(2.0) 1/29(3.4) -
Asthma 1/50(2.0) - 1/21(4.8)
Penicillin allergy 1/50(2.0) 1/29(3.4) -
Corticosteroids
None 49/50(98.0) 28/29(96.6) 21/21(100.0)
Systemic 1/50(2.0) 1/29(3.4) -
Immune status
None 50/50(100.0) 29/29(100.0) 21/21(100.0)
Therapies
None 50/50(100.0) 29/29(100.0)) 21/21(100.0)
Total 50/50(100.0) 29/29(100.0) 21/21(100.0)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** HRT: Hormone replacement therapy 
N.B. All subjects were HPV -ve
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3.6 Human papillomavirus in normal control oral mucosa-UK
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1. There was no HPV+ve detected in normal control 
oral mucosa samples. Demographic characteristics and risk factors of normal 
control oral mucosa samples are summarised in Table 3.17 and 3.18.
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Table 3.19 Detection of human papillomavirus versus demographics and risk factors for oral 
squamous cell carcinoma of KSA patients with oral squamous cell carcinoma
Characteristic
-ve
No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female
Male
2/7(28.6)
11/23(437.8)
"  5/7(71.4) 
12/23(52.2)
••
Age (years) • •> ‘ .
30-40 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
40-50 2/2(100.0 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0)
50-60 4/7(57.1) 3/7(42.9) 0/1(0.0) 1/1(100.0) 4/6(66.7) 2/6(33.3)
60-70 2/11(18.2) 9/11(81.8) 0/2(0.0) 2/2(100.0) 2/9(22.2) 7/9(77.8)
70-80 1/3(33.3) 2/3(66.7) - - 1/3(33.3) 2/3(66.7)
>80 3/5(60.0) 2/5(40.0) 1/3(33.3) 2/3(66.7) 2/2(100.0) 0/2(0.0)
c in n iv iiy
Caucasian 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
Arab
Tobacco
13/28(46.4) 15/28(53.6) 2/7(28.6) 5/7(71.4) 11/21(52.4) 10/21(47.6)
None 13/29(44.8) 16/29(55.2) 2/7(28.6) 5/7(71.4) 11/22(50.0) 11/22(50.0)
Current 0/1(0.0) 1/1(100.0) - 0/1 (0.0) 1/1(100.0)
Smoking
None 13/29(44.8) 16/29(55.2) 2/7(28.6) 5/7(71.4) 11/22(50.0) 11/22(50.0)
10-15/day
Paan
0/1 (0.0) 1/1(100.0) " 0/1 (0.0) 1/1(100.0)
None
Alcohol
13/30(43.3) 17/30(56.7) 2/7(28.6) 5/7(71.4) 11/23(47.8) 12/23(52.2)
None 13/30(43.3) 17/30(56.7) 2/7(28.6) 5/7(71.4) 11/23(47.8) 12/23(52.2)
Total 13/30(43.3) 17/30(56.7) 2/7(28.6) 5/7(71.4) 11/23(47.8) 12/23(52.2)
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Table 3.20 Cross tabulation for human papillomavirus in KSA- oral squamous cell carcinoma 
samples according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal mucosa 2/6(33.3) 4/6(66.7) 1/2(50.0) 1/2(50.0) 1/4(25.0) 3/4(75.0)
Lt. of tongue* 3/7(42.9) 4/7(57.1) 0/1 (0.0) 1/1(100.0) 3/6(50.0) 3/6(50.0)
Floor of mouth 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Ant. 2/3 
tongue** 0f 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) - -
Lip 0/1 (0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Retromolar 4/8(50.0) 4/8(50.0) 0/1 (0.0) 1/1(100.0) 4/7(57.1) 3/7(42.9)
Other * " 1/5(20.0) 4/5(80.0) 0/2(0.0) 2/2(100.0) 1/3(33.3) 2/3(66.7)
Relevant medical note
None 12/25(48.0) 13/25(52.0) 2/5(40.0) 3/5(60.0) 10/20(50.0) 10/20(50.0)
seen 0/2(0.0) 2/2(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0)
Diabetes mellitus 1/2(50.0) 1/2(50.0) 0/1 (0.0) 1/1(100.0) 1/1(100.0) 0/1 (0.0)
Penicillin allergy 0/1(0.0) 1/1(100.0) - - 0/1(0.0) 1/1(100.0)
Corticosteroids
Nqne 13/30(43.3) 17/30(56.7) 2/7(28.6) 5/7(71.4) 11/23(47.8) 12/23(52.2)
Immune status
None 13/30(43.3) 17/30(56.7) 2/7(28.6) 5/7(71.4) 11/23(47.8) 12/23(52.2)
Therapies
None 13/30(43.3) 17/30(56.7) 2/7(28.6) 5/7(71.4) 11/23(47.8) 12/23(52.2)
Total 13/30(43.3) 17/30(56.7) 2/7(28.6) 5/7(71.4) 11/23(47.8) 12/23(52.2)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** Other sites= Data not available 
HSCC= Second primary Squamous Cell Carcinoma
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Table 3.21 Human papillomavirus infection in relation to KSA-oral squamous cell carcinoma
KSA Gender Odds Ratio 
(95% Cl)
P-value*
OSCC , -j, ^ •_ ' . . . . .  .
ALL OSCC
+
HPV
+
50 13 
0 17
N/C <0.001
F OSCC
+
HPV
+
29 2 
0 5
N/C <0.001
M OSCC
+
HPV
+
21 11 
0 12
N/C <0.001
.N/C: could not be calculated because none of the normal controls were HPV +ve 
* Calculated from Fisher’s exact test
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3.7 Human papillomavirus in oral squamous cell carcinoma - KSA
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1. An overall HPV-DNA positive proportion of 17/30 
(56.7%) was detected in OSCC-KSA patients. Demographic characteristics 
and risk factors for OSCC in the KSA patients are summarised in Table 3.19
3.7.1 Gender
Human papillomavirus-DNA was detected in 5/7 (71.4%) of females 
compared with 12/23 (52.2%) males.
3.7.2 Age groups
When HPV-DNA was examined in different age groups, HPV infection 
showed a peak in the 60-70 year age group. The rate of HPV-DNA was 1/2 
(50.0%) in the 30-40 year age group, and 3/7 (42.9%) in the 50-60 year age 
group, reaching a peak of 9/11 (81.8%) in the 60-70 year age group. The 
proportion falls to 2/3 (66.7%) in the 70-80 year age group and to 2/5 (40.0%) 
in those over 80 years of age. When stratified according to gender and age, 
7/9 (77.8%) of the men aged 60-70 years were HPV infected, while 2/2 
(100.0%) of the females in this age range were infected with HPV.
3.7.3 Ethnic origins
The results show that HPV-DNA was detected in both Caucasians in 
the samples and in 15/28 (53.6%) of Arabs. When stratified according to 
gender and ethnicity, HPV-DNA was detected in 5/7 (71.4%) of Arab 
females. However, both of the Caucasian males were HPV infected 
compared with 10/21 (47.6%) of the Arab males.
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3.7.4 Associations with tobacco, alcohol and Paan
The association between HPV and other major risk factors for OSCC 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Human papillomavirus-DNA was detected in 16/29 (55.2%) of 
non-smokers compared with 1/1 (100.0%) of individuals smoking 10-15/day. 
When stratified according to gender and smoking, none of the females in this 
group were current smokers, HPV-DNA was found in 11/22 (50.0%) of male 
non-smokers. No HPV positive samples were observed in Paan-users or 
alcohol drinkers of either gender.
3.7.5 Site of squamous cell carcinoma sample
Cross tabulation for HPV-DNA frequency and other characteristics are 
summarised in Table 3.20. Although only small numbers were present in the 
samples, HPV-DNA was detected in the buccal mucosa, lateral border of the 
tongue, lip and retromolar area. In addition, HPV-DNA was detected in 4/5 
(80.0%) of patients where no data was available regarding the biopsy site.
3.7.6 Relevant medical history
Human papillomavirus-DNA was detected in 13/25 (52.0%) of patients 
with no relevant medical history and in 2/2 (100.0%) of patients with second- 
primary OSCC. In addition, HPV-DNA was found in 1/1 (100.0%) diabetic 
female individual and in 1/1 (100.0%) male allergic to penicillin. The results 
show that none of the individuals infected with HPV-DNA had received any 
corticosteroid therapy or had any systemic immune disease. In addition, 
HPV-DNA was found in 17/30 (56.7%) of patients who had received no 
therapy.
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3.7.7 HPV infection in relation to KSA-OSCC
The results for HPV infection in relation to OSCC are summarised in 
Table 3.21. In the sample of people, none of the normal controls was 
HPV+ve. However, some of the OSCC patients were HPV+ve. Thus the 
OSCC patients were highly significantly more likely than normal controls to 
be HPV+ve in this sample (P<0.001, Fisher’s exact test). However, since 
none of the controls were HPV+ve, it was not possible to calculate an odds 
ratio. Therefore, it was also not possible to control for the effects of any other 
risk factors in this analysis.
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Table 3.22 Detection of human papillomavirus versus demographics and risk factors for oral 
squamous cell carcinoma of KSA patients with oral lichen planus
-ve 
No. (%)
+ve 
No. (%)
-ve +ve -ve +ve
Characteristic Female Female Male Male
No. (%) No. (%) No.(%) No. (%)
Gender
Female 14/19(73.7) 5/19(26.3)
Male 9/13(69.2) 4/13(30.8)
Age (years) , v .. „ ' .* ♦ * V r
20-30 2/3(66.6) 1/3(33.3) 1/1(100.0) 0/1 (0.0) 1/2(50.0) 1/2(50.0)
30-40 4/7(57.1) 3/7(42.9) 4/6(66.7) 2/6(33.3) 0/1 (0.0) 1/1(100.0)
40-50 7/9(77.8) 2/9(22.2) 5/7(71.4) 2/7(28.6) 2/2(100.0) 0/2(0.0)
50-60 6/8(75.0) 2/8(25.0) 1/2(50.0) 1/2(50.0) 5/6(83.3) 1/6(16.7)
60-70 4/5(80.0) 1/5(20.0) 3/3(100.0) 0/3(0.0) 1/2(50.0) 1/2(50.0)
Ethnicity
SEA* 0/1(0.0) 1/1(100.0) - - 0/1(0.0) 1/1(100.0)
FEA** 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Arab 21/29(72.4) 8/29(27.9) 14/19(73.7) 5/19(26.3) 7/10(70.0) 3/10(30.0)
Tobacco
None 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13(69.2) 4/13(30.8)
Smoking
None 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13(69.2) 4/13(30.8)
Paan
None 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13(69.2) 4/13(30.8)
Alcohol
None 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13(rq 2' 4/13(30.8)
Total 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13169 2) 4/13(30.8)
*SEA=South East Asian
** FEA= Far East Asian
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Table 3.23 Cross tabulation for human papillomavirus in KSA-oral lichen planus samples 
according to biopsy site, relevant medical note, corticosteroids, immune status and therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal
mucosa 20/27(74.1) 7/27(25.9) 13/17(76.5) 4/17(23.5) 7/10(70.0) 3/10(30.0)
Lt. of tongue* 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Attached
gingiva 0/1 (0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) - •
Ant. 2/3 of 
tongue** 0/1 (0.0) 1/1(100.0) - . - 0/1 (0.0) 1/1(100.0)
Lip 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Other *** 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) - -
Relevant medical note
None 14/20(70.0) 6/20(30.0) 8/12(66.7) 4/12(33.3) 6/8(75.0) 2/8(25.0)
uutaneous
disease 4/6(66.7) 2/6(33.3) 2/3(66.7) 1/3(33.3) 2/3(66.7) 1/3(33.3)
D ia b e te s
mellitus 4/5(80.0) 1/5(20.0) 3/3(100.0) 0/3(0.0) 1/2(50.0) 1/2(50,0)
Asthma 1/1(100.0) 0/1(0.0) 1/1(100.0) 01/(0.0) - -
Corticosteroids
None 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13(69.2) 4/13(30.8)
Immune status
None 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13(69.2) 4/13(30.8)
Therapies
None 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13(69.2) 4/13(30.8)
Total 23/32(71.9) 9/32(28.1) 14/19(73.7) 5/19(26.3) 9/13(69.2) 4/13(30.8)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** Other sites= Data not available
152
Chapter 3 Human papillomavirus-Results
Table 3.24 Human papillomavirus infection in relation to KSA-oral lichen planus samples
KSA Gender Odds Ratio 
(95% Cl)
P-value*
OLP - -
ALL OLP
+
HPV
+
50 23 
0 9
N/C <0.001
F OLP
+
HPV
+
29 14 
0 5
N/C <0.001
M OLP
+
HPV
+
21 9 
0 4
N/C <0.001
N/C: could not be calculated because none of the normal controls were HPV +ve 
* Calculated from Fisher’s exact test
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3.8 Human papillomavirus in oral lichen planus - KSA
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1. An overall HPV-DNA positive proportion of 9/32 
(28.1%) was detected in OLP-KSA patients. Demographic characteristics and 
risk factors for OLP in the KSA pateints are summarised in Table 3.22
3.8.1 Gender
Human papillomavirus-DNA was detected in 5/19 (26.3%) of females 
compared with 4/13 (30.8%) of males.
3.8.2 Age groups
When HPV-DNA was examined in different age groups, the proportion 
was 1/3 (33.3%) in the 20-30 year age group, 3/7 (42.9%) in the 30-40 year 
age group, 2/9 (22.2%) in the 40-50 year age group and 2/8 (25.0%) in the 
50-60 year age group. In addition, HPV-DNA was found in 1/5 (20.0%) in the 
60-70 year age group. When stratified according to gender and age, HPV- 
DNA was found in 2/6 (33.3%) of the female group aged 30-40 years 
compared with 1/1 (100.0%) of the male group within the same age group. 
Human papillomavirus-DNA was detected in 1/2 (50.0%) of the female group 
aged 50-60 years compared with 1/6 (16.7%) of the male within the same 
age group.
3.8.3 Ethnic origins
Human papillomavirus-DNA was detected in 8/29 (27.9%) of Arabs 
compared with 1/1 (100.0%) of South East Asians. When stratified according 
to gender and ethnicity, HPV-DNA was found in 5/19 (26.3%) of Arab 
females compared with 3/10 (30.0%) of males within the same ethnic group.
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3.8.4 Associations with tobacco, alcohol and Paan
The association between HPV and other major risk factors for OLP 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Human papillomavirus-DNA was found in 9/32 (28.1%) of 
non-smokers, non-Paan users and non-alcohol drinkers.
3.8.5 Site of oral lichen planus samples
Cross tabulation for HPV-DNA frequency and other characteristics are 
summarised in Table 3.23. Human papillomavirus-DNA was found mostley 
in the buccal mucosa, and to a lesser extent, in attached gingiva and anterior 
two thirds of the tongue. When further stratified according to gender and 
biopsy site, HPV-DNA was found in 4/17 (23.5%) of females compared with 
3/10 (30.0%) of males in the buccal mucosa site.
3.8.6 Relevant medical history
Human papillomavirus-DNA was detected in 6/20 (30.0%) of patients 
with no relevant medical history, in 2/6 (33.3%) of patients with a skin lesion 
and in 1/2 (50.0%) of male diabetic patients. The results show that none of 
the individuals infected with HPV-DNA had received any corticosteroid 
therapy or had any systemic immune disease. HPV-DNA was found in 9/32 
(28.1%) of patients who had received no therapy.
3.8.7 HPV infection in relation to KSA-OLP
The results for HPV infection in relation to OLP are summarised in 
Table 3.24. In the sample of people, none of the normal controls were 
HPV+ve. However, some of the OLP patients were HPV+ve. Thus the OLP 
patients were highly significantly more likely than normal controls to be
155
Chapter 3 Human papillomavirus-Results
HPV+ve in this sample (PcO.001, Fisher’s exact test). Since none of the 
controls were HPV+ve, it was not possible to calculate an odds ratio. 
Therefore, it was also not possible to control for the effects of any other risk 
factors in this analysis.
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Table 3.25 Detection of human papillomavirus versus demographics and risk factors for oral 
squamous cell carcinoma of KSA patients with salivary gland lesions
Characteristic -veNo. (%)
+ve
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female
Male
5/7(71.4)
10/13(76.9)
2/7(28.6)
3/13(23.1)
r *■. f-r'
Age (years) ‘ * 1 tf
20-30 2/3(66.7) 1/3(33.3) 1/1(100.0) 0/1 (0.0) 1/2(50.0) 1/2(50.0)
30-40 3/5(60.0) 2/5(40.0) 0/1(0.0) 1/1(100.0) 3/4(75.0) 1/4(25.0)
40-50 5/5(100.0) 0/5(0.0) 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0)
50-60 3/4(75.0) 1/4(25.0) 0/1(0.0) 1/1(100.0) 3/3(100.0) 0/3(0.0)
60-70 2/3(66.7) 1/3(33.3) 1/1(100.0) 0/1 (0.0) 1/2(50.0) 1/2(50.0)
Ethnicity
SEA* 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1(0.0)
FEA** 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1(0.0)
Arab
Tobacco
13/18(72.2) 5/18(27.8) 5/7(71.4) 2/7(28.6) 8/11(72.7) 3/11(27.3)
None
Smoking
15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
None
Daait ■
15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
r'ctan ■
None
Alcohol
15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/1 J)
Total 15/20(75.0) 5/20(25.0) 5/7(71.4) M (28.61 10/13(76.9) 3/13(231)
*SEA=South East Asian
** FEA= Far East Asian
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Table 3.26 Cross tabulation for human papillomavirus in KSA-salivary gland samples 
according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve
Male
No. (%)
Biopsy site , . < , ; -
Buccal
mucosa 4/5(80.0) 1/5(20.0) 1/1(100.0) 0/1 (0.0) 3/4(75.0) 1/4(25.0)
Floor of mouth 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Hard palate 5/9(55.6) 4/9(44.4) 1/3(33.3) 2/3(66.7) 4/6(66.7) 2/6(33.3)
Lip 1/1(100.0) 0/1 (0.0) 1/1(100.01) 0/1 (0.0) - -
Retromolar 2/2(100.0) 0/2(0.0) 1/1(100.01) 0/1 (0.0) 1/1(100.0) 0/1(0.0)
Other* 2/2(100.0) 0/2(0.0) 1/1(100.01) 0/1 (0.0) 1/1(100.0) 0/1(0.0)
Relevant medical note
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Corticosteroids
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Immune status
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Therapies
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Total 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
* Other sites= Data not available
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Table 3.27 Human papillomavirus infection in relation to KSA salivary gland samples
KSA Gender Odds Ratio (95% Cl) P-value
Salivary - . -V ! .-Xtkd’i,, >. . t: ,** *
N/C <0.001
N/C <0.001
N/C <0.001
N/C: could not be calculated because none of the normal controls were HPV +ve 
* Calculated from Fisher’s exact test
ALL
HPV
Salivary
+
- 50 15
+ 0 5
HPV
Salivary
+
29
0
HPV
Salivary
+
10
3
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3.9 Human papillomavirus in salivary gland samples from KSA
The frequency of human papillomavirus DNA among oral lesions is 
summarised in Table 3.1. An overall HPV-DNA positive proportion of 5/25 
(25.0%) was detected in salivary gland lesions-KSA patients. Demographic 
characteristics and risk factors for salivary gland lesions in the KSA pateints 
are summarised in Table 3.25
3.9.1 Gender
Human papillomavirus-DNA was detected in 2/7 (28.6%) of females 
compared with 3/13 (23.1%) of males.
3.9.2 Age groups
When HPV-DNA was examined in different age groups, HPV-DNA 
was 1/3 (33.3%) in patients in the 20-30 year age group, 1/4 (25.0%) in the 
30-40 year age group and 1/3 (33.3%) in the 60-70 year age group. 
However, HPV was positive in 1/1 (100.0%) female aged 30-40 years 
compared with 1/4 (25.0%) of males within the same age group.
3.9.3 Ethnic origins
Human papillomavirus-DNA was detected in 5/18 (27.8%) of Arabs. 
When stratified according to gender and ethnicity, HPV-DNA was found in 
2/7 (28.6%) of female Arab descendents compared with 3/11 (27.3%) of 
males individuals within the same ethnic group.
3.9.4 Association with tobacco, alcohol and Paan
The association between HPV and other major risk factors for salivary 
gland lesions (e.g. tobacco smoking, frequency of smoking, Paan use and
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alcohol intake) was examined. Human papillomavirus-DNA was found in 5/20 
(25.0%) of non-smokers, non-Paan users and non-alcohol drinkers.
3.9.5 Site of salivary gland samples
Cross tabulation for HPV-DNA frequency and other characteristics are 
summarised in Table 3.26. Human papillomavirus-DNA was found mostly in 
the hard palate and, to a lesser extent, in the buccal mucosa. When further 
stratified according to gender and biopsy site, HPV-DNA was found in 2/3 
(66.7%) of the hard palate of females compared with 2/6 (33.3%) of males.
3.9.6 Relevant medical history
The results show that none of the individuals infected with HPV-DNA 
had received any corticosteroid therapy or had any systemic immune 
disease. In addition, HPV-DNA was found in patients who had received no 
therapy.
3.9.7 HPV infection in relation to KSA-salivary lesions
The results for HPV infection in relation to salivary gland samples are 
summarised in Table 3.27. In the sample of people, none of the normal 
controls was HPV+ve. However, some of the salivary gland samples were 
HPV+ve. Thus the salivary gland lesions patients were highly significantly 
more likely than normal controls to be HPV+ve in this sample (P<0.001, 
Fisher’s exact test). Since none of the controls were HPV+ve, it was not 
possible to calculate an odds ratio. Therefore, it was also not possible to 
control for the effects of any other risk factors in this analysis.
161
Chapter 3 Human papillomavirus-Results
Table 3.28 The relative risk (OR) of human papillomavirus infection in oral epithelial 
dysplasia compared to oral squamous cell carcinoma
UK Gender Odds Ratio 
(95 % Ci)
P-value
■ %
ALL
OED OSCC
HPV
+
26
19
7
27
5.278(1.90,14.64) <0.001
HPV
OED OSCC
- 12 2
+ 10 10
6.00(1.059,34.0) 0.043
M
OED OSCC
HPV
+
14
9
5 5.289(1.44,19.45) 0.012
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3.10 Relative risk of HPV in OED compared to OSCC
Table 3.28 compares the viral prevalence of HPV in OED and OSCC. 
The OR results indicate that OSCC patients are approximately 5.3 times 
more likely to be infected with HPV than OED patients (95% Cl = 1.9, 14.6). 
When stratified according to gender, the results were essentially unchanged.
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Table 3.29 Single and double infection of HPV and HHV-8 in oral squamous cell carcinoma
Non-infected 
No. (%)
Single HPV 
Infection 
No. (%)
Single HHV-8 
Infection 
No. (%)
Double 
infections 
No. (%)
Total 
No. (%)
UK-OSCC 7(20.6) 24(70.6) 0(0.0) 3(8.8) 34(100.0)
KSA-OSCC 12(40.0) 11(36.7) 1(3.3) 6(20.0) 30(100.0)
AII-OSCC 19(29.7) 35(54.7) 1(1.6) 9(14.0) 64(100.0)
UK-OSCC (a) KSA-OSCC (b)
HHV-8HPV
n=24
Non-infected= 7 Non-infected=12
Non-infected=19
HPV HHV-8
n=35
All cases of OSCC (c)
Figure 3.1
(a) details the single and double infections in UK-OSCC
(b) details the single and double infections in KSA-OSCC
(c) details the single and double infections in ALL cases of OSCC
164
Chapter 3 Human papillomavirus-Results
Table 3.30 Single and double infection of EBV and CMV in normal control samples from the
UK
Single EBV Single CMV Double
Non-infected infection infection infections Total
No. (%) No. (%) No. (%) No. (%) No. (%)
Normal control 43(86.0) 6(12.0) 1(2.0) 0(0.0) 50(100.0)
Non-infected=43 
EBV 
n=6
UK normal controls
Figure 3.2 details the single and double infection in UK cases of normal control
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3.11 Single and double infections
Table 3.29 shows that HPV was present as a single infection in 24 
(70.6%) of UK-OSCC samples, 11 (36.7%) of KSA-OSCC samples and 35 
* (54.7%) in all OSCC samples, while HHV-8 was present as a single infection
in 0 (0.0%) of UK-OSCC samples, 1(3.3%) of KSA-OSCC samples and in 
1(1.6%) of all OSCC samples. However, 3 people (8.8%) were co-infected
\
with both HPV and HHV-8 viruses of UK-OSCC. Similarly, 6 people (20.0%) 
were co-infected in KSA-OSCC samples. The combined presence of co- 
infection in all OSCC samples was 9 (14.0%).
Table 3.30 illustrates that 6 (12.0%) people of the normal control 
samples were infected with EBV as a single infection, while 1(2.0%) was 
infected with CMV as a single infection. None of the normal control samples 
were co-infected with both viruses.
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Table 4.1 Frequency of human herpesvirus-8 in examined oral mucosal and salivary gland 
lesions
Country Lesion Gender -ve 
No. (%)
+ve 
No. (%)
UK .
OSCC a h ' 31/34(91.2) 3/34 (8.8)
F 10/12(83.3) 2/12(16.7)
M 21/22 (95.5) 1/22 (4.5)
PVL All 9/12(75.0) 3/12(25.0)
F 3/6 (50.0) 3/6 (50.0)
M 6/6(100) -
OED All 44/45 (97.8) 1/45 (2.2)
F 22/22 (100.0) -
M 22/23 (95.7) 1/23 (4.3)
OLP All 27/30 (90.0) 3/30 (10.0)
F 12/14(85.7) 2/14(14.3)
M 15/16(93.8) 1/16(6.3)
HIV All 13/25 (52.0) 12/25 (48.0)
F 1/3 (33.3) 2/3 (66.7)
M 12//22 (54.5) 10/22 (45.5)
KSA :
OSCC All 23/30 (76.7) 7/30 (23.3)
F 6/7 (85.7) 1/7(14.3)
M 17/23 (73.9) 6/23 (26.1)
OLP All 20/32 (62.5) 12/32(37.5)
F 11/19(57.9) 8/19(42.1)
M 9/13 (69.2) 4/13(30.8)
Salivary All 15/25 (75.0) 5/25 (25.0)
F 5/7 (71.4) 2/7 (28.6)
M 10/13(76.9) 3/13 (23.1)
Normal- control
UK All 50/50(100.0) 0/50(0.0)
F 29/29(100.0) 0/21(0.0)
M 21/21(100.0) 0/21(0.0)
OSCC = Oral squamous cell carcinoma
PVL = Proliferative verrucous leukoplakia
OED = Oral epithelial dysplasia
OLP = Oral lichen planus
HIV = Human immunodeficiency virus
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Table 4.2 Detection of human herpes virus-8 versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with oral squamous cell carcinoma
-ve
No. (%)
+ve 
NO. (%)
-ve +ve -ve +ve
Characteristic Female Female Male Male
No. (%) No. (%) No. (%) No. (%)
Gender
Fem ale 10/12(83.3) 2/12(16.7)
M ale 21/22(95.5) 1/22(4.5)
Age (years), • "
30-40 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
50-60 8/8(100.0) 0/8(0.0) 4/4(100.0) 0/4(0.0) 4/4(100.0) 0/4(0.0)
60-70 5/5(100.0) 0/5(0.0) 2/2(100.0) 0/2(0.0) 3/3(100.0) 0/3(0.0)
70-80 10/12(83.3) 2/12(16.7) 1/2(50.0) 1/2(50.0) 9/10(90.0) 1/10(10.0)
>80 7/8(87.5) 1/8(12.5) 3/4(75.0) 1/4(25.0) 4/4(100.01 0/4(0.0)
Ethnicity
C aucasian 24/26(92.3) 2/26(7.7) 5/6(83.3) 1/6(16.7) 19/20(95.0) 1/20(5.0)
S E A * 6/7(85.7) 1/7(14.3) 5/6(83.3) 1/6(16.7) 1/1(100.0) 0/1 (0.0)
N /A ** 1/1(110.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Tobacco
None 28/31(90.3) 3/31(9.7) 10/12(83.3) 2/12(16.7) 18/19(94.7) 1/19(5.3)
Current 3/3(100.0) 0/3(0.0) - - 3/3(100.0) 0/3(0.0)
Smoking
None 28/31(90.3) 3/31(9.7) 10/12(83.3) 2/112(16.7) 18/19(94.7) 1/19(5.3)
10 -15 /day 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
>20 /d ay 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Paan
None 28/30(93.3) 2/30(6.7) 9/10(90.0) 1/10(10.0) 19/20(95.0) 1/20(5.0)
Current 3/4(75.0) 1/4(25.0) 1/2(50.0) 1/2(50.0) 2/2(100.0) 0/2(0.0)
Alcohol
None 27/30(90.0) 3/30(10.0) 10/12(83.3) 2/112(16.7) 17/18(94.4) 1/18(5.6)
5-20 u/w*** 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
N /A 3/3(100.0) 0/3(0.0) - - 3/3(100.0) 0/3(0.0)
Total 31/34(91.2) 3/34(8.8) 10/12(83.3) 2/12(16.7) 21/22(95.5) 1/22(4.5)
*SEA=South East Asian
** N/A= Data not available
*** u/w = units per week
169
Chapter 4 Human herpesvirus-8 Results
Table 4.3 Cross tabulation for human herpesvirus-8 in UK-oral squamous cell carcinoma 
samples according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve
Male
No. (%)
+ve 
Male 
No. (%)
Biopsy alto
Buccal mucosa 5/6(83.3) 1/6(16.7) 3/4(75.0) 1/4(25.0) 2/2(100.0) 0/2(0.0)
Lt. of tongue* 5/5(100.0) 0/5(0.0) - - 5/5(100.0) 0/5(0.0)
Floor of mouth 5/5(100.0) 0/5(0.0) - - 5/5(100.0) 0/5(0.0)
Soft palate 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Hard palate 0/1 (0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Ant. 2/3 of 
tongue** 1/2(50.0) 1/2(50.0) 1/2(50.0) 1/2(50.0) - -
Lip 5/5(100.0) 0/5(0.0) 2/2(100.0) 0/2(0.0) 3/3(100.0) 0/3(0.0)
Commisure 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
Retromolar 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Other *** 7/7(100.0) 0/7(0.0) 3/3(100.0) 0/3(0.00 4/4(100.00 0/4(0.0)
Relevant medical note
None 15/ 15(1 oo.o) 0/15(0.0) 4/4(100.0) 0/4(0.0) 11/11(100.0) 0/11(0.0)
SCCf 15/18(83.3) 3/18(16.7) 6/8(75.0) 2/8(25.0) 9/10(90.0) 1/10(10.0)
Candida 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Corticosteroids
None 31/34(91.2) 3/34(8.8) 10/12(16.7) 2/12(16.7) 21/22(95.5) 1/22(4.5)
Immune status
None 29/32(90.6) 3/32(9.4) 8/10(80.0) 2/10(20.0) 21/22(95.5) 1/22(4.5)
Systemic 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0) - -
Therapies
None 25/26(96.2) 1/26(3.8) 8/8(100.0) 0/8(0.0) 17/18(94.4) 1/18(5.6)
Chemotherapy 5/6(83.3) 1/6(16.7) 2/3(66.7) 1/3(33.3) 3/3(100.0) 0/3(0.0)
Radiotherapy 1/2(50.0) 1/2(50.0) 0/1 (0.0) 1/1(100.0) 1/1(100.0) 0/1(0.0)
Total 31/34(91.2) 3/34(8.8) 10/12(83.3) 2/12(18.7) 21/22(95.5) 1/22(4.5)
* Lt. of tongue® lateral border of the tongue
** Ant. 2/3 of tongue® anterior 2/3 of tongue
*** Other sites® Data not available 
fSCC® Second primary Squamous Cell Carcinoma
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Table 4.4 Human herpesvirus-8 infection in relation to UK-oral squamous cell carcinoma 
samples
UK Gender Odds Ratio (95% Cl) P-value*
OSCC
. . .  .
ALL OSCC
+
HHV8 +
50 31 
0 3 N/C <0.001
F OSCC
+
HHV8 +
29 10 
0 2 N/C <0.001
M OSCC
+
HHV8 +
21 21 
0 1 N/C <0.001
N/C: could not be calculated because none of the normal controls were HHV-8 +ve 
Calculated from Fisher’s exact test
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4.1 Human herpesvirus- 8 in oral squamous cell carcinoma - UK
The frequency of human herpesvirus-8 DNA among oral lesions is 
summarised in Table 4.1. An overall HHV-8 DNA positive proportion of 3/34 
(8.8%) was detected in OSCC-UK patients. Demographic characteristics and 
risk factors for OSCC in the UK patients are summarised in Table 4.2.
4.1.1 Gender
Human herpesvirus-8 DNA was detected in 2/12 (16.7%) of females 
compared with 1/22 (4.5%) iof males.
4.1.2 Age groups
When HHV-8 DNA was examined in different age groups, the 
proportion of HHV-8 DNA was 2/12 (16.7%) of 70-80 year age group, and 1/4 
(25.0%) in the > 80 years female group. HHV-8 was found in 1/2 (50.0%) of 
the females aged 70-80 years compared with 1/10 (10.0%) of males within 
the same age group.
4.1.3 Ethnic origins
Human herpesvirus-8 DNA was detected in 2/26 (7.7%) of Caucasians 
compared with 1/6 (16.7%) in female South East Asians. When stratified 
according to gender and ethnicity, HHV-8 DNA was detected in 1/6 (16.7%) 
of females in both ethnic groups. HHV-8 DNA was detected in 1/20 (5.0%) of 
the Caucasian males.
4.1.4 Association with tobacco, alcohol and Paan
The association between HHV-8 and other major risk factors for 
OSCC (e.g. tobacco smoking, frequency of smoking, Paan use and alcohol
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intake) was examined. Human herpesvirus-8 DNA was detected only in 3/31 
(9.7%) of non-smokers. When the use of Paan was examined, HHV-8 DNA 
was found in 2/30 (6.7%) of non-Paan users compared with 1/2 (50.0%) of 
female Paan users. Human herpesvirus-8 DNA was detected in only 3/30 
(10.0%) of non-alcohol drinkers.
4.1.5 Site of oral squamous cell carcinoma samples
Cross tabulation for HHV-8 DNA frequency and other characteristics 
are summarised in Table 4.3. Only small numbers were present in the 
samples, HHV-8 DNA was detected in the buccal mucosa, hard palate and 
anterior two thirds of tongue. No difference was readily apparent as regards 
the biopsy site and HHV-8 infection was found in similar proportions in both 
genders.
4.1.6 Relevant medical history
Human herpesvirus-8 DNA was detected in 3/18 (16.7%) of patients 
with second-primary OSCC. When stratified according to gender and medical 
history, HHV-8 was detected in 2/8 (25.0%) of female patients with second- 
primary OSCC compared with 1/10 (10.0%) of males within the same group.
The results show that none of the individuals infected with HHV-8 DNA 
had received any corticosteroid therapy or had any immune diseases. In 
patients receiving chemotherapy or radiotherapy, HHV-8 DNA was detected 
only in female individuals receiving therapy. Human herpesvirus-8 DNA was 
found in 1/3 (33.3%) of female patients who had received chemotherapy and 
in 1/1 (100.0%) of female patients who had received radiotherapy. However,
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HHV-8 DNA was found in 1/18 (5.6%) of male patients who had received no 
therapy.
4.1.7 HHV-8 infection in relation to UK-OSCC
The results for HHV-8 infection in relation to OSCC are summarised in 
Table 4.4. In the sample of people, none of the normal controls was HHV- 
8+ve. However, some of the OSCC patients were HHV-8 +ve. Thus, the 
OSCC patients were highly significantly more likely than normal controls to 
be HHV-8+ve in this sample (P<0.001, Fisher’s exact test). Since none of the 
controls were HHV-8+ve, it is not possible to calculate an odds ratio. 
Therefore, it was also not possible to control for the effects of any of the risk 
factors in this analysis.
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Table 4.5 Detection of human herpesvirus-8 versus demographics and risk factors for oral 
squamous cell carcinoma of UK pateints with proliferative verrucous leukoplakia
Characteristic -ve No. (%)
+ve 
No. (%)
-ve
Female
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female 
Male 
Age (years)
3/6(50.0)
6/6(100.0)
3/6(50.0)
0/6(0.0)
40-50 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
50-60 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
60-70 1/3(33.3) 2/3(66.7) 0/2(0.0) 2/2(100.0) 1/1(100.0) 0/1(0.0)
70-80 5/6(83.3) 1/6(16.7) 2/3(66.7) 1/3(33.3) 3/3(100.0) 0/3(0.0)
>80 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Ethnicity
Caucasian 3/5(60.0) 2/5(40.0) 2/4(50.0) 2/4(50.0) 1/1(100.0) 0/1 (0.0)
N/A* 6/7(85.7) 1/7(14.3) 1/2(50.0) 1/2(50.0) 5/5(100.0) 0/5(0.0)
Tobacco
None 7/10(70.0) 3/10(30.0) 3/6(50.0) 3/6(50.0) 4/4(100.0) 0/4(0.0)
Current 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Smoking
None 7/10(70.0) 3/10(30.0) 3/6(50.0) 3/6(50.0) 4/4(100.0) 0/4(0.0)
>20/day 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Paan
None 8/11(72.7) 3/11(27.3) 3/6(50.0) 3/6(50.0) 5/5(100.0) 0/5(0.0)
Current 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Alcohol
None 8/11(72.7) 3/11(27.3) 3/6(50.0) 3/6(50.0) 5/5(100.0) 0/5(0.0)
>20 u/w** 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Total 9/12(75.0) 3/12(25.0) 3/6(50.0) 3/6(50.0) 6/6(100.0) 0/6(0,0)
* N/A= Data not available
** u/w = units per week
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Table 4.6 Cross tabulation for human herpesvirus-8 in UK-proliferative verrucous 
leukoplakia samples according to biopsy site, relevant medical note, corticosteroids, immune 
status, and therapies
Characteristic -veNo. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal mucosa 2/4(50.0) 2/4(50.0) 2/4(50.0) 2/4(50.0) _ .
Lt. of tongue* 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Floor of mouth 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Hard palate 0/1 (0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) - -
Ant. 2/3 of 
tongue** 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Lip 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
Retromolar 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Relevant medical note
None 2/3(66.7) 1/3(33.3) 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1(0.0)
see*** 4/6(66.7) 2/6(33.3) 1/3(33.3) 2/3(66.7) 3/3(100.0) 0/3(0.0)
Candida 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Penicillin allergy 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0)
Corticosteroids
None 9/12(75.0) 3/12(25.0) 3/6(50.0) 3/6(50.0) 6/6(100.0) 0/6(0.0)
Immune status
None 9/12(75.0) 3/12(25.0) 3/6(50.0) 3/6(50.0) 6/6(100.0) 0/6(0.0)
Therapies
None 9/11(81.8) 2/11(18.2) 3/5(60.0) 2/5(40.0) 6/6(100.0) 0/6(0.0)
Chemotherapy 0/1(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) - -
Total 9/12(75.0) 3/12(25.0) 3/6(50.0) 3/6(50.0) 6/6(100.0) 0/6(0.0)
* Lt. of tongue* lateral border of the tongue
** Ant. 2/3 of tongue* anterior 2/3 of tongue
*** SCC* Second primary Squamous Cell Carcinoma
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Table 4.7 Human herpesvirus-8 infection in relation to UK-proliferative verrucous leukoplakia 
samples
UK Gender Odds Ratio 
(95% Cl)
P-value*
PVL
ALL PVL
+
HHV8 +
50 9 
0 3 N/C <0.001
F PVL
+
HHV8 +
29 3 
0 3 N/C <0.001
M PVL
+
HHV8 +
21 6 
0 0 N/C <0.001
N/C: could not be calculated because none of the normal controls were HHV-8 +ve 
•Calculated from Fisher's exact test
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4.2 Human herpesvirus- 8 in proliferative verrucous leukoplakia - UK
The frequency of human herpesvirus-8 DNA among oral lesions is 
summarised in Table 4.1. An overall HHV-8 DNA positive proportion of 3/12 
(25.0%) was detected in PVL-UK patients. Demographic characteristics and 
risk factors for PVL in the UK pateints are summarised in Table 4.5.
4.2.1 Gender
Human herpesvirus-8 DNA was detected in 3/6 (50.0%) females only. 
None of the males were infected with HHV-8.
4.2.2 Age groups
When HHV-8 DNA was examined in different age groups, the 
proportion of HHV-8 DNA was 2/3 (66.7%) in the 60-70 year age group, and 
1/6 (16.7%) in the 70-80 year age female group, and it was not detected in 
any other age group.
4.2.3 Ethnic origins
Human herpesvirus-8 DNA was detected in 2/5 (40.0%) of female 
Caucasians compared with 1/7 (14.3%) in female with no recorded ethnicity.
4.2.4 Association with tobacco, alcohol and Paan
The association between HHV-8 and other major risk factors for PVL 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Human herpesvirus-8 was detected in 3/10 (30.0%) of non- 
smokers and no HHV-8 was detected among smokers group. When the use 
of Paan and alcohol drinking were examined, HHV-8 DNA was found in 3/11
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(27.3%) of both non-Paan users and non-alcohol drinkers. HHV-8 was not 
detected in any of the Paan-users nor alcohol drinkers.
4.2.5 Site of proliferative verrucous leukoplakia samples
Cross tabulation for HHV-8 DNA frequency and other characteristics 
are summarised in Table 4.6. Only small numbers were present in the 
samples, HHV-8 DNA was detected in the buccal mucosa and hard palate.
4.2.6 Relevant medical history
Human herpesvirus-8 DNA was detected in 2/6 (33.3%) of patients 
with second-primary OSCC, and in 1/3 (33.3%) of patients with no relevant 
medical history. The results show that none of the individuals infected with 
HHV-8 DNA had received any corticosteroid therapy or had any immune 
diseases. In patients receiving chemotherapy, HHV-8 DNA was detected in 
one of the females 1/1(100.0%) and in 2/5 (40.0%) of patients who had 
received no therapy.
4.2.7 HHV-8 infection in relation to UK-PVL
The results for HHV-8 infection in relation to PVL are summarised in 
Table 4.7. In the sample of people, none of the normal controls was HHV- 
8+ve. However, some of the PVL patients were HHV-8 +ve. Thus the PVL 
patients were highly significantly more likely than normal controls to be HHV- 
8+ve in this sample (P<0.001, Fishers exact test). Since none of the controls 
were HHV-8+ve, it was not possible to calculate an odds ratio. Therefore, it 
was also not possible to control for the effects of any of the risk factors in this 
analysis.
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Table 4.8 Detection of human herpesvirus-8 versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with oral epithelial dysplasia
Characteristic -veNo. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve
Male
No. (%)
Gender
Female 
Male 
Age (years)
22/22(100.0)
22/23(95.7)
0/22(0.0)
1/23(4.3)
20-30 1/1(100.0) 0/1 (0.0) - 1/1(100.0) 0/1(0.0)
30-40 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0)
40-50 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0) 2/2(100.0) 0/2(0.0)
50-60 16/16(110.0) 0/16(0.0) 6/6(100.0) 0/6(0.0) 10/10(100.0) 0/10(0.0)
60-70 13/14(92.9) 1/14(7.1) 7/7(100.0) 0/7(0.0) 6/7(85.7) 1/7(14.3)
70-80 9/9((100.0) 0/9(0.0) 7/7(100.0) 0/7(0.0) 2/2(100.0) Q/2(0.0)
Ethnicity
Caucasian 29/30(96.7) 1/30(3.3) 14/14(100.0) 0/14(0.0) 15/16(93.8) 1/16(6.3)
SEA* 6/6(100.0) 0/6(0.0) 4/4(100.0) 0/4(0.0) 2/2(100.0) 0/2(0.0)
N/A** 9/9(100.0) 0/9(0.0) 4/4(100.0) 0/4(0.0) 5/5(100.0) 0/5(0.0)
Tobacco
None 24/24(100.0) 0/24(0.0) 15/15(100.0) 0/15(0.0) 9/9(100.0) 0/9(0.0)
Ex-smoker 2/3(66.7) 1/3(33.3) - - 2/3(66.7) 1/3(33.3)
Current 18/18(100.0) 0/18(0.0) 7/7(100.0) 0/7(0.0) 11/11(100.0) 0/11(0.0)
Smoking
None 24/24(100.0) 0/24(0.0) 15/15(100.0) 0/15(0.0) 9/9(100.0) 0/9(0.0)
10-15/day 12/12(100.0) 0/12(0.0) 4/4(100.0) 0/4(0.0) 8/8(100.0) 0/8(0.0)
>20/day 8/9(88.9) 1/9(11.1) 3/3(100.0) 0/3(0.0) 5/6(83.3) 1/6(16.7)
Paan
None 39/40(97.5) 1/40(2.5) 19/19(100.0) 0/19(0.0) 20/21(95.2) 1/21(4.8)
Current 5/5(100.0) 0/5(0.0) 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0)
Alcohol
None 23/23(100.0) 0/23(0.0) 11/11(100.0) 0/11(0.0) 12/12(100.0) 0/12(0.0)
<5 4/4(100.0) 0/4(0.0) 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0)
5-20 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
>20 u/w*** 11/12(91.7) 1/12(8.3) 6/6(100.0) 0/6(0.0) 5/6(83.3) 1/6(16.7)
N/A 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
Total 44/45(97.8) 1/45(2.2) 22/22(100.0) 0/22(0.0) 22/23(95,7) 1/23(4.3)
*SEA=South East Asian
**N/A= Data not available
*** u/w = units per week
180
Chapter 4 Human herpesvirus-8 Results
Table 4.9 Cross tabulation for hum an herpesvirus-8 in UK-oral epithelial dysplasia samples  
according to biopsy site, relevant medical note, corticosteroids, im m une status, and  
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
-t-ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal mucosa 8/8(100.0) 0/8(0.0) 3/3(100.0) 0/3(0.0) 5/5(100.0) 0/5(0.0)
Lt. of tongue* 12/12(100.0) 0/12(0.0) 6/6(100.0) 0/6(0.0) 6/6(100.0) 0/6(0.0)
Floor of mouth 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0)
Attached gingiva 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Soft palate 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Hard palate 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
Ant. 2/3 of 
tongue** 4/4(100.0) 0/4(0.0) 4/4(100.0) 0/4(0.0) - -
Lip 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0)
Commisure 9/9(100.0) 0/9(0.0) 3/3(100.0) 0/3(0.0) 6/6(100.0) 0/6(0.0)
Retromolar 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Salivary 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) - -
Relevant medical note
None 20/20(100.0) 0/20(0.0) 11/11(100.0) 0/11(0.0) 9/9(100.0) 0/9(0.0)
SCCfl 7/7(100.0) 0/7(0.0) 2/2(100.0) 0/2(0.0) 5/5(100.0) 0/5(0.0)
HRT*** 5/5(100.0) 0/5(0.0) 5/5(100.0) 0/5(0.0) - -
Asthma 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Submucous fibrosis 4/4(100.0) 0/4(0.0) 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0)
Candida 4/5(80.0) 1/5(20.0) 2/2(100.0) 0/2(0.0) 2/3(66.7) 1/3(33.3)
Diabetes mellitus 1/1(0.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Arthritis 1/1(0.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Corticosteroids
None 44/45(97.8) 1/45(2.2) 22/22(100.0) 0/22(0.0) 22/23(95.7) 1/23(4.3)
Immune status
None 42/43(97.7) 1/43(2.3) 21/21(100.0) 0/21(0.0) 21/22(95.5) 1/22(4.5)
Systemic 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(0.0) 0/1 (0.0)
Therapies
None 40/41(97.6) 1/41(2.4) 18/18(100.0) 0/18(0.0) 22/23(95.7) 1/23(4.3)
Chemotherapy 4/4(100.0) 0/4(0.0) 4/4(100.0) 0/4(0.0) - -
Total 44/45(97.8) 1/45(2.2) 22/22(100.0) 0/22(0.0) 22/23(95.7) 1/23(4.3)
* Lt. of tongue= lateral border of the tongue
** A n t.'2 /3  of tongue= anterior 2 /3  of tongue
***H R T = H o rm o n e  rep lacem ent therapy  
|S C C =  second prim ary Squam ous Cell Carcinom a
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Table 4.10 Human herpesvirus-8 infection in relation to UK-oral epithelial dysplasia 
samples
UK Gender Odds Ratio (95% Cl) P-value*
OED ■m'rr-x- -.....................-
ALL OED
+
HHV8 +
50 44 
0 1 N/C <0.001
F OED
+
HHV8 +
29 22 
0 0 N/C <0.001
M OED
+
HHV8 +
21 22 
0 1 N/C <0.001
N/C: could not be calculated because none of the normal controls were HHV-8 +ve 
* Calculated from Fisher’s exact test
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4.3 Human herpesvirus- 8 in oral epithelial dysplasia - UK
The frequency of human herpesvirus-8 DNA among oral lesions is 
summarised in Table 4.1. An overall HHV-8 DNA positive proportion of 1/45 
(2.2%) was detected in OED-UK patients. Demographic characteristics and 
risk factors for OED in the UK pateints are summarised in Table 4.8.
4.3.1 Human herpesvirus-8 in OED demographic Characteristics
Human herpesvirus-8 was only detected in one sample. This person 
was a Caucasian male aged 60-70 who was an ex-smoker who drinks >20 
units of alcohol per week. He had no relevant medical history and the site of 
the lesion was the hard palate. Since only one sample had detectable HHV-8 
it was not possible to calculate ORs for infection and logistic regression was 
not undertaken.
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Table 4.11 Detection of human herpesvirus-8 versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with oral lichen planus
Characteristic -ve No. (%)
+ve 
No. (%)
-ve
Female
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female 
Male 
Age (years)
12/14(85.7)
15/16(93.8)
2/14(14.3)
1/16(6.3)
40-50 6/7(85.7) 1/7(14.3) 3/4(75.0) 1/4(25.0) 3/3(100.0) 0/3(0.0)
50-60 9/10(90.0) 1/10(10.0) 4/5(80.0) 1/5(20.0) 5/5(100.0) 0/5(0.0)
60-70 8/8(100.0) 0/8(0.0) 3/3(100.0) 0/3(0.0) 5/5(100.0) 0/5(0.0)
70-80 4/5(80.0) 1/5(20.0) 2/2(100.0) 0/2(0.0) 2/3(66.7) 1/3(33.3)
Ethnicity
Caucasian 15/16(93.8) 1/16(6.3) 7/8(87.5) 1/8(12.5) 8/8(100.0) 0/8(0.0)
SEA* 4/5(80.0) 1/5(20.0) 2/3(66.7) 1/3(33.3) 2/2(100.0) 0/2(0.0)
N/A** 8/9(88.9) 1/9(11.1) 3/3(100.0) 0/3(0.0) 5/6(83.3) 1/6(16.7)
Tobacco
None 23/26(88.5) 3/26(11.5) 11/13(84.6) 2/13(15.4) 12/13(92.3) 1/13(7.7)
Ex-smoker 1/1(100.0) 0/1(0.0) - - 2/2(100.0) 0/2(0.0)
Current 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0)
Smoking
None 23/26(88.5) 3/26(11.5) 11/13(84.6) 2/13(15.4) 12/13(92.3) 1/13(7.7)
<5 /day 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) - -
10-15/day 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
>20 /day 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Paan
None 26/29(89.7) 3/29(10.3) 11/13(84.6) 2/13(15.4) 15/16(93.7) 1/16(6.3)
Current 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
Alcohol
None 20/23(87.0) 3/23(13.0) 10/12(83.3) 2/12(16.7) 10/11(91.0) 1/11(9.0)
5-20 u/w*** 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0)
>20 u/w 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
N/A 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0) 2/2(100.0) 0/2(0.0)
Total 27/30(90.0) 3/30(10.0) 12/14(85.7) 2/14(14.3) 15/16(93.8) 1/16(6.3)
*SEA=South East Asian
**N/A= Data not available
*** u/w = units per week
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Table 4.12 Cross tabulation for human herpesvirus-8 in UK-oral lichen planus samples 
according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve
Male
No. (%)
Biopsy site
Buccal mucosa 22/25(88.0) 3/25(12.0) 9/11(81.8) 2/11(18.2) 12/13(92.3) 1/13(7.7)
Lt. of tongue* 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0)
Attached gingiva 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 2/2(100.0) 0/2(0.0)
Relevant medical note
None 15/17(88.2) 2/17(11.8) 4/5(80.0) 1/5(20.0) 11/12(91.7) 1/12(8.3)
HRT** 1/2(50.0) 1/2(50.0) 1/2(50.0) 1/2(50.0) - -
Asthma 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0) - -
Candida 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
Cutaneous
disease 4/4(100.0) 0/4(0.0) 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0)
Diabetes mellitus 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0) - -
Corticosteroids
None 23/26(88.5) 3/26(11.5) 9/11(81.8) 2/11(18.2) 14/15(93.3) 1/15(6.7)
Topical 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
Systemic 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0)
Immune status
None 18/21(85.7) 3/21(14.3) 7/9(77.8) 2/9(22.2) 11/12(91.7) 1/12(8.3)
Systemic 4/4(100.0) 0/4(0.0) 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0)
Drugs 5/5(100.0) 0/5(0.0) 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0)
Therapies
None 27/30(90.0) 3/30(10.0) 12/14(85.7) 2/14(14.3) 15/16(93.8) 1/16(6.3)
Total 27/30(90,0) 3/30(10.0) 12/14(85,7) 2/14(14.3) 15/16(93.8) 1/16(6.3)
* Lt. of tongue* lateral border of the tongue
** HRT= Hormone replacement therapy
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Table 4.13 Human herpesvirus-8 infection in relation to UK-oral lichen planus samples
UK Gender Odds Ratio (95% Cl) P-value*
OLP
ALL OLP
+
HHV8 +
50 27 
0 3 N/C <0.001
F OLP
+
HHV8 +
29 12 
0 2 N/C <0.001
M OLP
+
HHV8 +
21 15 
0 1 N/C <0.001
N/C: could not be calculated because none of the normal controls were HHV-8 +ve 
* Calculated from Fisher’s exact test
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4.4 Human herpesvirus- 8 in oral lichen planus of patients from UK
The frequency of human herpesvirus-8 DNA among oral lesions is 
summarised in Table 4.1. An overall HHV-8 DNA positive proportion of 3/30 
(10.0%) was detected in OLP-UK patients. Demographic characteristics and 
risk factors for OLP in the UK patients are summarised in Table 4.11.
4.4.1 Gender
Human herpesvirus-8 DNA was detected in 2/14 (14.3%) of females 
compared with 1/16 (6.3%) in males.
4.4.2 Age groups
When HHV-8 DNA was examined in different age groups, the 
proportion of HHV-8 DNA was 1/5 (20.0%) in the 70-80 year age group, 1/10 
(10.0%) in 50-60 year age group and 1/7 (14.3%) in 40-50 year age group. 
HHV-8 DNA was detected in 1/4 (25.0%) in females aged 40-50 years and in 
1/5 (20.0%) in 50-60 year age group compared with 1/3 (33.3%) in males 
aged 70-80 years.
4.4.3 Ethnic origins
Human herpesvirus-8 DNA was detected in 1/8 (12.5%) of female 
Caucasians compared with 1/3 (33.3%) of female South East Asians. HHV-8 
DNA was detected in 1/6 (16.7%) of the males with no recorded ethnicity 
data.
4.4.4 Association with tobacco, alcohol and Paan
The association between HHV-8 and other major risk factors for OLP 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake)
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was examined. Human herpesvirus-8 DNA was detected only in 3/26 (11.5%) 
of non-smokers. When the use of Paan was examined, HHV-8 DNA was 
found in 3/29 (10.3%) of non-Paan users. Human herpesvirus-8 DNA was 
detected in only 3/23 (13.0%) of non-alcohol drinkers.
4.4.5 Site of oral lichen planus smaples
Cross tabulation for HHV-8 DNA frequency and other characteristics 
are summarised in Table 4.12. Human herpesvirus-8 DNA was detected 
exclusively in the buccal mucosa.
4.4.6 Relevant medical history
Human herpesvirus-8 DNA was detected in 2/17 (11.8%) of patients 
with no relevant medical history. When stratified according to gender and 
medical history, HHV-8 was detected in 1/2 (50.0%) of female patients who 
had received HRT. The results show that none of the individuals infected with 
HHV-8 DNA had received any corticosteroid, chemo/radiotherapy or had any 
known immune diseases.
4.4.7 HHV-8 infection in relation to UK-OLP
The results for HHV-8 infection in relation to OLP are summarised in 
Table 4.13. In the sample of people, none of the normal controls was HHV- 
8+ve. However, some of the OLP patients were HHV-8 +ve. Thus the OLP 
patients were highly significantly more likely than normal controls to be HHV- 
8+ve in this sample (P<0.001, Fisher’s exact test). Since none of the controls 
were HHV-8+ve, it was not possible to calculate an odds ratio. Therefore, it 
was also not possible to control for the effects of any of the risk factors in this 
analysis.
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Table 4.14 Detection of human herpesvirus-8 versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with human imunodeficiency virus
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female 
Male 
Age (years)
30-40
1/3(33.3)
12/22(54.5)
6/8(75.0)
2/3(66.7)
10/22(45.5)
2/8(25.0) 1/2(50.0) 1/2(50.0) 5/6(83.3) 1/6(16.7)
40-50 7/13(53.8) 6/13(46.2) - - 7/13(53.8) 6/13(46.2)
50-60 0/4(0.0) 4/4(100.0) 0/1 (0.0) 1/1(100.0) 0/3(0.0) 3/3(100.0)
Ethnicity
Caucasian 13/22(59.1) 9/22(40.9) 1/2(50.0) 1/2(50.0) 12/20(60.0) 8/20(40.0)
SEA* 0/1(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) - -
African 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
N/A** 0/1 (0.0) 1/1(100.0) - - 0/1(0.0) 1/1(100.0)
Tobacco
None 7/18(38.9) 11/18(61.1) 1/3(33.3) 2/3(66.7) 6/15(40.0) 9/15(60.0)
Current 6/7(85.7) 1/7(14.3) - - 6/7(85.7) 1/7(14.3)
$moking
None 7/18(38.9) 11/18(61.1) 1/3(33.3) 2/3(66.7) 6/15(40.0) 9/15(60.0)
>20/day 6/7(85.7) 1/7(14.3) - - 6/7(85.7) 1/7(14.3)
Paan
None 13/25(52.0) 12/25(48.0) 1/3(33.3) 2/3(66.7) 12/22(54.5) 10/22(45.5)
Alcohol
None 12/24(50.0) 12/24(50.0) 1/3(33.3) 2/3(66.7) 11/2152.4) 10/21(47.6)
>20 u/w*** 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Total 13/25(52.0) 12/25(48.0) 1/3(33.3) 2/3(66.7) 12/22(54.5) 10/22(45.5)
*SEA*South East Asian
**N/A= Data not available
*** u/w « units per week
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Table 4.15 Cross tabulation for human herpesvirus-8 in human imunodeficiency virus UK 
samples according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -veNo. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsysite
Buccal mucosa 3/4(75.0) 1/4(25.0) 3/4(75.0) 1/4(25.0)
Lt. of tongue* 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
Attached
gingiva 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
Hard palate 2/5(40.0) 3/5(60.0) 0/2(0.0) 2/2(100.0) 2/3(66.7) 1/3(33.3)
Ant. 2/3 of 
tongue** 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Lip 6/6(100.0) 0/6(0.0) 1/1(100.0) 0/1 (0.0) 5/5(100.0) 0/5(0.0)
Commisure 2/3(66.7) 1/3(33.3) - - 2/3(66.7) 1/3(33.3)
Retromolar 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Other *** 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Relevant medical note
None 10/20(50.0) 10/20(50.0) 1/3(33.3) 2/3(66.7) 9/17(52.9) 8/17(47.1)
Candida 3/4(75.0) 1/4(25.0) - - 3/4(75.0) 1/4(25.0)
Cutarieous disease 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Corticosteroids
None 13/18(72.2) 5/18(27.8) 1/2(50.0) 1/2(50.0) 12/16(75.0) 4/16(25.0)
Systemic 0/7(0.0) 7/7(100.0) 0/1(0.0) 1/1(100.0) Q/6(0.0) 6/6(100.0)
Immune status
None 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0)
Systemic 12/24(50.0) 12/24(50.0) 1/3(33.3) 2/3(66.7) 11/21(52.4) 10/21(47.6)
Therapies
None 7/19(36.8) 12/19(63.2) 1/3(33.3) 2/3(66.7) 6/16(37.5) 10/16(62.5)
Triple therapy 6/6(100.0) 0/6(0.0) - - 6/6(100.0) 0/6(0.0)
Total 13/25(52.0) 12/25(48.0) 1/3(33.3) 2/3(66.7) 12/22(54.5) 10/22(45.5)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** Other sites= Data not available
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Table 4.16 Human herpesvirus-8 infection in relation to UK-human immunodeficiency virus 
samples
UK Gender Odds Ratio (95% Cl) P-value*
HIV
ALL HIV
+
HHV8 +
50
0
13
12 N/C <0.001
F HIV
+
HHV8 +
29
0
1
2 N/C <0.001
M HIV
+
HHV8 +
21
0
12
10 N/C <0.001
N/C: could not be calculated because none of the normal controls were HPV +ve 
* Calculated from Fisher’s exact test
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4.5 Human herpesvirus- 8 in HIV individuals-UK
The frequency of human herpesvirus-8 DNA among oral lesions is 
summarised in Table 4.1. An overall HHV-8 DNA positive proportion of 12/25 
(48.0%) was detected in HIV-UK patients. Demographic characteristics and 
risk factors for HIV in the UK patients are summarised in Table 4.14.
4.5.1 Gender
Human herpesvirus-8 DNA was detected in 2/3 (66.7%) of females 
compared with 10/22 (45.5%) in males.
4.5.2 Age groups
When HHV-8 DNA was examined in different age groups, the 
proportion was 2/8 (25.0%) in the 30-40 year age group, 6/13 (46.2%) in the 
40-50 year age group and in 4/4 (100.0%) in the 50-60 year age group. 
When stratified according to gender and age groups, HHV-8 DNA was found 
in 1/2 (50.0%) of the female group aged 30-40 years compared with 1/6 
(16.7%) of males within the same age group. Human herpesvirus-8 DNA was 
detected in 1/1 (100.0%) of the female group aged 50-60 years compared 
with 3/3 (100.0%) of male within the same age group. In addition, HHV-8 was 
positive in 6/13 (46.2%) of the male group aged 40-50 years.
4.5.3 Ethnic origins
Human herpesvirus-8 DNA was detected in 9/22 (40.9%) of 
Caucasians compared with 1/1 (100.0%) in Africans. In addition, HHV-8 was 
detected in other ethnic groups e.g. in 1/1 (100.0%) South East Asian. When 
stratified according to gender and ethnicity, HHV-8 DNA was found in 1/2 
(50.0%) of Caucasian females compared with 8/20 (40.0%) in male
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Caucasians. However, HHV-8 DNA was found in 1/1 (100.0%) of male 
patient with no recorded ethnicity.
4.5.4 Association with tobacco, alcohol and Paan
The association between HHV-8 and other major risk factors for HIV 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Human herpesvirus-8 DNA was found in 11/18 (61.1%) of 
non-smokers compared with 1/7 (14.3%) of males currently smoking 
>20/day. When the use of Paan was examined, HHV-8 DNA was found only 
in 12/25 (48.0%) of non-Paan users. The rate of HHV-8 DNA was detected in 
12/24 (50.0%) of non-alcohol drinkers.
4.5.5 Site of human immunodeficiency virus sample
Cross tabulation for HHV-8 DNA frequency and other characteristics 
are summarised in Table 4.15. Human herpesvirus-8 DNA was detected in 
the hard palate, lateral border of the tongue, attached gingiva and, to a lesser 
extent, the buccal mucosa, anterior two thirds of tongue, commisure, and 
retromolar area. No difference was readily apparent as regards the biopsy 
site and HHV-8 infection.
4.5.6 Relevant medical history
Human herpesvirus-8 DNA was detected in 10/20 (50.0%) of patients 
with no relevant medical history. In addition, HHV-8 DNA was found in 1/4 
(25.0%) of males with candidal infection and in 1/1 (100.0%) male with a 
cutaneous disease. The results show that HHV-8 DNA was found in 5/18 
(27.8%) of individuals who had received no corticosteroid therapy compared 
with 7/7 (100.0%) of patients who received systemic corticosteroids. Human
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herpesvirus-8 was found in 12/24 (50.0%) of patients with systemic immune 
disease. When further stratified according to gender and immune status, 
HHV-8 DNA was detected in 2/3 (66.7%) of female patients compared with 
10/21 (47.6%) in male individuals. No HHV-8 DNA was detected in patients 
who received triple therapy. In addition, HHV-8 DNA was detected in 12/19 
(63.2%) of patients received no therapy.
4.5.7 HHV-8 infection in relation to UK-HIV
The results for HHV-8 infection in relation to HIV are summarised in 
Table 4.16. In the sample of people, none of the normal controls was HHV- 
8+ve. However, some of the HIV patients were HHV-8 +ve. Thus the HIV 
patients were highly significantly more likely than normal controls to be HHV- 
8+ve in this sample (P<0.001, Fisher’s exact test). However, since none of 
the controls were HHV-8+ve, it was not possible to calculate an odds ratio. 
Therefore, it was also not possible to control for the effects of any of the risk 
factors in this analysis.
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4.6 Human herpesvirus-8 in normal control
None of the normal controls had detectable HHV-8. Thus, the 
demographic characteristics of this sample are as has already been 
described in the previous chapter (See tables 3.17 and 3.18)
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Table 4.17 Detection of human herpesvirus-8 versus demographics and risk factors for oral 
squamous cell carcinoma of KSA patients with oral squamous cell carcinoma
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve
Male
No. (%)
Gender
Female 
Male 
Age (years)
6/7(85.7)
17/23(73.9)
1/7(14.3)
6/23(26.1)
30-40 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
40-50 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0)
50-60 5/7(71.4) 2/7(28.6) 0/1 (0.0) 1/1(100.0) 5/6(83.3) 1/6(16.7)
60-70 7/11(63.6) 4/11(36.4) 2/2(100.0) 0/2(0.0) 5/9(55.6) 4/9(44.4)
70-80 2/3(66.7) 1/3(33.3) - - 2/3(66.7) 1/3(33.3)
>80 5/5(100.0) 0/5(0.0) 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0)
Ethnicity
Caucasian 1/2(50.0) 1/2(50.0) _ 1/2(50.0) 1/2(50.0)
Arab 22/28(78.6) 6/28(21.4) 6/7(85.7) 1/7(14.3) 16/21(76.2) 5/21(23.8)
Tobacco
None 23/29(78.3) 6/29(20.7) 6/7(85.7) 1/7(14.3) 17/22(77.3) 5/22(22.7)
Current 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Smoking
None 23/29(78.3) 6/29(20.7) 6/7(85.7) 1/7(14.3) 17/22(77.3) 5/22(22.7)
10-15/day 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Paan
None 23/30(76.7) 7/30(23.3) 6/7(85.7) 1/7(14.3) 17/23(73.9) 6/23(26.1)
Alcohol
None 23/30(76.7) 7/30(23.3) 6/7(85.7) 1/7(14.3) 17/23(73.9) 6/23(26.1)
Total 23/30(76.7) 7/30(23.3) 6/7(85.7) 1/7(14.3) 17/23(73.9) 6/23(26.1)
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Table 4.18 Cross tabulation for human herpesvirus-8 in KSA-oral squamous cell carcinoma 
samples according to biopsy site, relevant medical note, corticosteroids, immune status and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve
Male
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal mucosa 3/6(50.0) 3/6(50.0) 2/2(100.0) 0/2(0.0) 1/4(24.0) 3/4(75.0)
Lt. of tongue* 6/7(85.7) 1/7(14.3) 1/1(100.0) 0/1 (0.0) 5/6(83.3) 1/6(16.7)
Floor of mouth 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Ant. 2/3 of 
tongue** 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Lip 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1(0.0)
Retromolar 8/8(100.0) 0/8(0.0) 1/1(100.0) 0/1(0.0) 7/7(100.0) 0/7(0.0)
Other*** 2/5(40.0) 3/5(60.0) 1/2(50.0) 1/2(50.0) 1/3(33.3) 2/3(66.7)
Relevant medical note
None 19/25(76.0) 6/25(24.0) 4/5(80.0) 1/5(20.0) 15/20(75.0) 5/20(25.0)
s e e * * * * 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1 (0.0) 0/1 (0.0) 1/1(100.0)
Diabetes mellitus 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0)
Penicillin allergy 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Corticosteroids
None 23/30(76.7) 7/30(23.3) 6/7(85.7) 1/7(14.3) 17/23(73.9) 6/23(26.1)
Immune status
None 23/30(76.7) 7/30(23.3) 6/7(85.7) 1/7(14.3) 17/23(73.9) 6/23(26.1)
Therapies
None 23/30(76.7) 7/30(23.3) 6/7(85.7) 1/7(14.3) 17/23(73.9) 6/23(26.1)
Total 23/30(76.7) 7/30(23.3) 6/7(85.7) 1/7(14.3) 17/23(73.9) 6/23(26.1)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** Other sites= Data not available
**** SCC= Second primary Squamous Cell Carcinoma
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Table 4.19 Human herpesvirus-8 infection in relation to KSA-oral squamous cell carcinoma 
samples
KSA Gender Odds Ratio 
(95% Cl)
P-value*
OSCC
ALL OSCC
+
HHV8 +
50 23 
0 7 N/C <0.001
F OSCC
+
HHV8 +
29 6 
0 1 N/C <0.001
M OSCC
+
HHV8 +
21 17 
0 6 N/C <0.001
N/C: could not be calculated because none of the normal controls were HHV-8 +ve 
* Calculated from Fisher’s exact test
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4.7 Human herpesvirus- 8 in oral squamous cell carcinoma - KSA
The frequency of human herpesvirus-8 DNA among oral lesions is 
summarised in Table 4.1. An overall HHV-8 DNA positive proportion of 7/30 
(23.3%) was detected in OSCC-KSA patients. Demographic characteristics 
and risk factors for OSCC in the KSA patients are summarised in Table 4.17
4.7.1 Gender
Human herpesvirus-8 DNA was detected in 1/7 (14.3%) of females 
compared with 6/23 (26.1%) in males.
4.7.2 Age groups
When HHV-8 DNA was examined in different age groups, HHV-8 DNA 
was 2/7 (28.6%) in the 50-60 year age group compared with 4/11 (36.4%) in 
the 60-70 year age group. When stratified according to gender and age 
groups, HHV-8 DNA was found in 1/1 (100.0%) of females aged 50-60 years 
compared with 1/6 (16.7%%5) of males within the same age group. HHV-8 
was found in 4/9 (44.4%) of males in the 60-70 year age group.
4.7.3 Ethnic origins
Human herpesvirus-8 DNA was detected in 1/2 (50.0%) of male 
Caucasians compared with 5/21 (23.8%) Arab males. HHV-8 DNA was 
detected in 1/7 (14.3%) of Arab females. There were no Caucasian females 
in the sample.
4.7.4 Association with tobacco, alcohol and Paan
The association between HHV-8 and other major risk factors for 
OSCC (e.g. tobacco smoking, frequency of smoking, Paan use and alcohol
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intake) were examined. Human herpesvirus-8 DNA was detected in 6/29 
(20.7%) of non-smokers compared with 1/1 (100.0%) current smoker male 
smoking 10-15/day. There were no Paan users in the sample when the use 
of Paan was examined, HHV-8 DNA was found in 7/30 (23.3%) of non-Paan 
users. In addition, HHV-8 DNA was detected in 7/30 (23.3%) of non-alcohol 
drinkers only. Similarly, none of the sample reported that they drink alcohol.
4.7.5 Site of oral squamous cell carcinoma samples
Cross tabulation for HHV-8 DNA frequency and other characteristics 
are summarised in Table 4.18. Although, only small numbers were present in 
the samples, HHV-8 DNA was detected in the buccal mucosa and lateral 
border of the tongue. HHV-8 was detected in 3/5 (60.0%) of patients with no 
record of sample site. When stratified according to gender and biopsy site, 
HHV-8 was found in 1/2 (50.0%) of females and in 2/3 (66.7%) of males with 
no recorded data of biopsy site. HHV-8 was detected in 3/4 (75.0%) of the 
buccal mucosa in males.
4.7.6 Relevant medical history
Human herpesvirus-8 DNA was detected in 1/2 (50.0%) of patients 
with second primary OSCC compared with 6/25 (24.0%) of patients with no 
relevant medical history. When stratified according to gender and medical 
history, HHV-8 was detected in 1/5 (20.0%) of female patients with second 
primary OSCC compared with 5/20 (25.0%) of male within the same group. 
The results show that none of the individuals infected with HHV-8 DNA had 
received any corticosteroids, chemo/radiotherapy or had any immune 
diseases.
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4.7.7 HHV-8 infection in relation to KSA-OSCC
The results for HHV-8 infection in relation to OSCC are summarised in 
Table 4.19. In the sample of people, none of the normal controls was HHV- 
8+ve. However, some of the OSCC patients were HHV-8 +ve. Thus the 
OSCC patients were highly significantly more likely than normal controls to 
be HHV-8+ve in this sample (P<0.001, Fisher’s exact test). Since none of the 
controls were HHV-8+ve, it was not possible to calculate an odds ratio. 
Therefore, it was also not possible to control for the effects of any of the risk 
factors in this analysis.
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Table 4.20 Detection of human herpesvirus-8 versus demographics and risk factors for oral 
squamous cell carcinoma of KSA patients withoral lichen planus
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve
Female
No. (%)
-ve
Male
No.(%)
+ve 
Male 
No. (%)
Gender
Female 
Male 
Age (years)
11/19(57.9)
9/13(69.2)
8/19(42.1)
4/13(30.8)
20-30 2/3(66.7) 1/3(33.3) 1/1(100.0) 0/1(0.0) 1/2(50.0) 1/2(50.0)
30-40 5/7(71.4) 2/7(28.6) 4/6(66.7) 2/6(33.3) 1/1(100.0) 0/1(0.0)
40-50 5/9(55.6) 4/9(44.4) 3/7(42.9) 4/7(57.1) 2/2(100.0) 0/2(0.0)
50-60 4/8(50.0) 4/8(50.0) 1/2(50.0) 1/2(50.0) 3/6(50.0) 3/6(50.0)
60-70 4/5(80.0) 1/5(20.0) 2/3(66.7) 1/3(33.3) 2/2(100.0) 0/2(0.0)
Ethnicity
SEA* 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
FEA** 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
Arab
Tobacco
18/29(62.1) 11/29(37.9) 11/19(57.9) 8/19(42.1) 7/10(70.0) 3/10(30.0)
None
Smoking
20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(69.2) 4/13(30.8)
None
Paan
20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(69.2) 4/13(30.8)
None
Alcohol
20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(69.2) 4/13(30.8)
None 20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(69.2) 4/13(30.8)
Total 20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(692) 4/13(30.8)
*SEA=South East Asian
** FEA= Far East Asia
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Table 4.21 Cross tabulation for human herpesvirus-8 in KSA-oral lichen planus samples 
according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve
Male
No. (%)
Biopsy site ' :* ■ « '
Buccal mucosa 16/27(59.3) 11/27(40.7) 9/17(52.9) 8/17(47.1) 7/10(70.0) 3/10(30.0)
Lt. of tongue* 
Attached
1/1(100.0) 0/1(0.0)
1/1(100.0) 0/1 (0.0)
1/1(100.0) 0/1 (0.0)
gingiva 1/1(100.0) 0/1 (0.0) “
Ant. 2/3 of 
tongue** 0/1 (0.0) 1/1(100.0) - - 0/1 (0.0)
1/1(100.0)
Lip 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Other*** 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) - -
Relevant medical note
None 15/20(75.0) 5/20(25.0) 8/12(66.7) 4/12(33.3) 7/8(87.5) 1/8(12.5)
Asthma 0/1(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) - -
Cutaneous
disease
2/6(33.3) 4/6(66.7) 1/3(33.3) 2/3(66.7) 1/3(33.3) 2/3(66.7)
Diabetes
mellitus
Corticosteroids
3/5(60.0) 2/5(40.0) 2/3(66.7) 1/3(33.3) 1/2(50.0) 1/2(50.0)
None 
Immune status
20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(69.2) 4/13(30.8)
None
Therapies
20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(69.2) 4/13(30.8)
None 20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(69.2) 4/13(30.8)
Total 20/32(62.5) 12/32(37.5) 11/19(57.9) 8/19(42.1) 9/13(6942) 4/13(30.8)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** Other sites= Data not available
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Table 4.22 Human herpesvirus-8 infection in relation to KSA-oral lichen planus samples
KSA Gender Odds Ratio (95% Cl) P-value*
OLP
ALL OLP
+
HHV8 +
50 20 
0 12 N/C <0.001
F OLP
+
HHV8 +
29 11 
0 3 N/C <0.001
M OLP
+
HHV8 +
21 9 
0 4 N/C <0.001
N/C: could not be calculated because none of the normal controls were HHV-8 +ve 
* Calculated from Fisher’s exact test
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4.8 Human herpesvirus- 8 in oral lichen planus - KSA
The frequency of human herpsevirus-8 DNA among oral lesions is 
summarised in Table 4.1. An overall HHV-8 DNA positive proportion of 12/32 
(37.5%) was detected in OLP-KSA patients. Demographic characteristics and 
risk factors for OLP in the KSA pateints are summarised in Table 4.20
4.8.1 Gender
Human herpesvirus-8 DNA was detected in 8/19 (42.1%) of females 
compared with 4/13 (30.8%) in males.
4.8.2 Age groups
When HHV-8 DNA was examined in different age groups, the 
proportion was found in 1/3 (33.3%) of the 20-30 year age group, 2/7 (28.6%) 
of the 30-40 year age group, 4/9 (44.4%) of the 40-50 year age group and 
4/8 (50.0%) of the 50-60 year age group. In addition, HPV-DNA was found in 
1/5 (20.0%) in the 60-70 year age group. When stratified according to gender 
and age groups. Human herpesvirus-8 DNA was found in 1/2 (50.0%) of the 
female group aged 50-60 compared with 3/6 (50.0%) of males within the 
same age group.
4.8.3 Ethnic origins
Human herpesvirus-8 DNA was detected in 11/29 (37.9%) of Arabs 
compared with 1/2 (50.0%) of Far East Asians. When stratified according to 
gender and ethnicity, HHV-8 DNA was found in 8/19 (42.1%) of Arab females 
compared with 3/10 (30.0%) of males within the same ethnic group.
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4.8.4 Association with tobacco, alcohol and Paan
The association between HHV-8 and other major risk factors for OLP 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Human herpesvirus-8 DNA was found in 12/32 (37.5%) of 
non-smokers. When the use of Paan was examined, HHV-8 DNA was found 
in only 12/32 (37.5%) of non-Paan users. The rate of HHV-8 DNA was 
detected in 12/32 (37.5%) of non-alcohol drinkers. None of the sample 
reported having tobacco, alcohol or Paan habits.
4.8.5 Site of oral lichen planus samples
Cross tabulation for HHV-8 DNA frequency and other characteristics 
are summarised in Table 4.21. Human herpesvirus-8 DNA was detected in 
the buccal mucosa and in the anterior two thirds of the tongue. When further 
stratified according to gender and biopsy site, HHV-8 DNA was found in the 
buccal mucosa of 3/10 (30.0%) of males compared with 8/17 (47.1%) 
females within the same group.
4.8.6 Relevant medical history
Human herpesvirus-8 DNA was found in 5/20 (25.0%) of patients with 
no relevant medical history and 4/6 (66.7%) of patients with a cutaneous 
disease. In addition, HHV-8 was found in 1/2 (50.0%) of patients with asthma 
and in 2/5 (40.0%) of patients with diabetes. When further stratified according 
to gender and any relevant medical history, HHV-8 was detected in 4/12 
(33.3%) of female patients with no relevant medical history and in 1/8 
(12.5%) of male patients within the same group. HHV-8 was found in 2/3 
(66.7%) of patients with a cutaneous disease in both genders.
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The results show that HHV-8 DNA was found in 12/32 (37.5%) of 
patients who had received no corticosteroids or with any immune diseases. 
None of the patients who detected positive for HHV-8 DNA had received 
chemotherapy or radiotherapy.
4.8.7 HHV-8 infection in relation to KSA-OLP
The results for HHV-8 infection in relation to OLP are summarised in 
Table 4.22 In the sample of people, none of the normal controls was HHV- 
8+ve. However, some of the OLP patients were HHV-8 +ve. Thus the OLP 
patients were highly significantly more likely than normal controls to be HHV- 
8+ve in this sample (P<0.001, Fisher’s exact test). Since none of the controls 
were HHV-8+ve, it was not possible to calculate an odds ratio. Therefore, it 
was also not possible to control for the effects of any of the risk factors in this 
analysis.
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Table 4.23 Detection of human herpesvirus-8 versus demographicss and risk factors for oral 
squamous cell carcinoma of KSA patients with salivary gland lesions
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
-t-ve 
Female 
No. (%)
-ve
Male
No. (%)
+ve
Male
No. (%)
Gender
Female 
Male 
Age (years)
5/7(71.4)
10/13(76.9)
2/7(28.6)
3/13(23.1)
_ <" f
20-30 2/3(66.7) 1/3(33.3) 0/1(0.0) 1/1(100.0) 2/2(100.0) 0/2(0.0)
30-40 4/5(80.0) 1/5(20.0) 1/1(100.0) 0/1(0.0) 3/4(75.0) 1/4(25.0)
40-50 4/5(80.0) 1/5(20.0) 2/3(66.7) 1/3(33.3) 2/2(100.0) 0/2(0.0)
50-60 2/4(50.0) 2/4(50.0) 1/1(100.0) 0/1 (0.0) 1/3(33.3) 2/3(66.7)
60-70 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0) 2/2(100.0) 0/2(0.0)
Ethnicity <.  ^ «
SEA* 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
FEA** 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Arab 13/18(72.2) 5/18(27.8) 5/7(71.4) 2/7(28.6) 8/11(72.7) 3/11(27.3)
Tobacco
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Smokjng
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Paan
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Alcohol
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(2 8.6) 10/13(76.9) 3/13(23.1)
Total 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
*SEA=South East Asian
** FEA= Far East Asian
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Table 4.24 Cross tabulation for human herpesvirus-8 in KSA salivary gland samples 
according to biopsy site, relevant medical note, corticosteroids, immune status and therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal
mucosa 3/5(60.0) 2/5(40.0) 0/1(0.0) 1/1(100.0) 3/4(75.0) 1/4(25.0)
Floor of 
tongue 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Hard palate 8/9(88.9) 1/9(11.1) 3/3(100.0) 0/3(0.0) 5/6(83.3) 1/6(16.7)
Lip 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Retromolar 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1 (0.0) 0/1(0.0) 1/1(100.0)
Other * 1/2(50.0) 1/2(50.0) 0/1 (0.0) 1/1(100.0) 1/1(100.0) 0/1(0.0)
Relevant medical note
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Corticosteroids
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Immune status
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Therapies
None 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23.1)
Total 15/20(75.0) 5/20(25.0) 5/7(71.4) 2/7(28.6) 10/13(76.9) 3/13(23,1)
* Other sites= Data not available
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Table 4.25 Human herpesvirus-8 infection in relation to KSA salivary gland samples
KSA Gender Odds Ratio 
(95% Cl)
P-value*
Salivary
ALL Salivary
+
HHV8 +
50 15 
0 5 N/C <0.001
F Salivary
+
HHV8 +
29 5 
0 2 N/C <0.001
M Salivary
+
HHV8 +
21 10 
0 3 N/C <0.001
N/C: could not be calculated because none of the normal controls were HHV-8 +ve 
* Calculated from Fisher’s exact test
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4.9Human herpesvirus-8 in salivary gland lesions of patients from KSA
The frequency of human herpesvirus-8 DNA among oral lesions is 
summarised in Table 4.1. An overall HHV-8 DNA positive proportion of 5/25 
(25.0%) was detected in salivary gland lesions-KSA patients. Demographic 
characteristics and risk factors for salivary gland lesions in the KSA patients 
are summarised in Table 4.23
4.9.1 Gender
Human herpesvirus-8 DNA was detected in 2/7 (28.6%) of females 
compared with 3/13 (23.1%) in males.
4.9.2 Age groups
When HHV-8 DNA was examined in different age groups, the rate was 
1/1 (100.0%) in the 20-30 year age group and 1/3 (33.3%) in the 40-50 year 
age group of females and in 2/3 (66.7%) in the 50-60 year age group of 
males.
4.9.3 Ethnic origins
Human herpesvirus-8 DNA was detected in 5/18 (27.8%) of Arabs. 
When Stratified according to gender and ethnicity, HHV-8 DNA was found in 
2/7 (28.6%) of Arab females compared with 3/11 (27.3%) of male within the 
same ethnic group.
4.9.4 Association with tobacco, alcohol and Paan
The association between HHV-8 and other major risk factors for 
salivary samples (e.g. tobacco smoking, frequency of smoking, Paan use and 
alcohol intake) was examined. Human herpesvirus-8 DNA was found in 5/20
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(25.0%) of non-smokers. None of the sample reported having tobacco, 
alcohol and Paan habits.
4.9.5 Site of salivary gland samples
Cross tabulation for HHV-8 DNA frequency and other characteristics 
are summarised in Table 4.24. Human herpesvirus-8 DNA was found in the 
buccal mucosa, hard palate and retromolar area. No difference was readily 
apparent as regards the biopsy site and HHV-8 infection, similar proportions 
were found in both genders.
4.9.6 Relevant medical history
The results show that none of the individuals infected with HHV-8 DNA 
had received any corticosteroid therapy or had any systemic immune 
disease. In addition, HHV-8 DNA was detected in patients who received no 
therapy.
4.9.7 HHV-8 infection in relation to KSA-Salivary gland lesions
The results for HHV-8 infection in relation to salivary samples are 
summarised in Table 4.25. In the sample of people, none of the normal 
controls was HHV-8+ve. However, some of the salivary gland lesion patients 
were HHV-8 +ve. Thus the salivary gland lesion patients were highly 
significantly more likely than normal controls to be HHV-8+ve in this sample 
(P<0.001, Fishers exact test). Since none of the controls were HHV-8+ve, it 
was not possible to calculate an odds ratio. Therefore, it was also not 
possible to control for the effects of any other risk factors in this analysis.
Chapter 5 
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Table 5.1 Frequency of Epstein-Barr virus in examined oral pathologies
Country Lesion Gender -ve No. (%)
+ve 
No. (%)
UK
PVL All 6/12(50.0) 6/12(50.0)
F 3/6 (50.0) 3/6 (50.0)
M 3/6 (50.0) 3/6 (50.0)
OED All 44/45 (97.8) 1/45 (2.2)
F 22/22 (100.0) -
M 22/23 (95.70) 1/23 (4.3)
Normal control All 44/50(88.0) 6/50(12.0)
F 26/29(89.7) 3/29(10.3)
M 18/21(85.7) 3/21(14.3)
PVL = Proliferative verrucous leukoplakia 
OED *  Oral epithelial dysplasia
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Table 5.2 Detection of Epstein-Barr virus versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with proliferative verrucous leukoplakia
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female 
Male 
Age (years)
3/6(50.0)
3/6(50.0)
3/6(50.0)
3/6(50.0)
& ,ui m 1 1 -s' i *  ' -6*ib ,
40-50 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) - ■
50-60 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
60-70 2/3(66.7) 1/3(33.3) 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1 (0.0)
70-80 2/6(33.3) 4/6(66.7) 1/3(33.3) 2/3(66.7) 1/3(33.3) 2/3(66.7)
>80
Ethnicity
1/1(100.0) 0/1(0.0) “ 1/1(100.0) 0/1 (0.0)
Caucasian 1/5(20.0) 4/5(80.0) 1/4(25.0) 3/4(75.0) 0/1(0.0) 1/1(100.0)
N/A*
Tobacco
5/7(71.4) 2/7(28.6) 2/2(0.0) 0/2(0.0) 3/5(60.0) 2/5(40.0)
None 6/10(60.0) 4/10(40.0) 3/6(50.0) 3/6(50.0) 3/4(75.0) 1/4(25.0)
Current 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
Smoking
None 6/10(60.0) 4/10(40.0) 3/6(50.0) 3/6(50.0) 3/4(75.0) 1/4(25.0)
>20/day
Paan
0/2(0.0) 2/2(100.0) ■ " 0/2(0.0) 2/2(100.0)
None 6/11 (54.0) 5/11(45.5) 3/6(50.0) 3/6(50.0) 3/5(60.0) 2/5(40.0)
Current 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Alcohol
None 6/11 (54.0) 5/11(45.5) 3/6(50.0) 3/6(50.0) 3/5(60.0) 2/5(40.0)
>20 u/ w** 0/1(0.0) 1/1(100.0) - - 0/1(0.0) 1/1(100.0)
Total 6/12(50.0) 6/12(50.0) 3/6(50.0) 3/6(50.0) 3/6(50.6) 3/6(50.0)
*N/A= Data not available
** u/w= units per week
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Table 5.3 Cross tabulation for Epstein-Barr virus in UK-proliferative verrucous leukoplakia 
samples according to biopsy site, relevant medical note, corticosteroids, immune status and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve
Male
No. (%)
Biopsy site
Buccal mucosa 2/4(50.0) 2/4(50.0) 2/4(50.0) 2/4(50.0)
Lt. of tongue* 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
Floor of mouth 0/2(0.0) 2/2(100.0) - - 0/2(0.0) 2/2(100.0)
Hard palate 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) - -
Ant .2/3 of 
tongue** 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Lip 0/1(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) - -
Retromolar 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Relevant medical note
None 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0)
see*** 3/6(50.0) 3/6(50.0) 1/3(33.3) 2/3(66.7) 2/3(66.7) 1/3(33.3)
Candidal
infection 0/1 (0.0) 1/1(100.0) " " 0/1 (0.0) 1/1(100.0)
Penicillin allergy 0/2(0.0) 2/2(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0)
Corticosteroids
None 6/12(50.0) 6/12(50.0) 3/6(50.0) 3/6(50.0) 3/6(50.0) 3/6(50.0)
Immune status
None 6/12(50.0) 6/12(50.0) 3/6(50.0) 3/6(50.0) 3/6(50.0) 3/6(50.0)
Therapies
None 6/11 (54.5) 5/11 (45.5) 3/5(60.0) 2/5(40.0) 3/6(50.0) 3/6(50.0)
Chemotherapy 0/1 (0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) - -
Total 6/12(50.0) 6/12(50.0) 3/6(50.0) 3/6(50.0) 3/6(50.0) 3/6(50.0)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
*** SCC= Second primary Squamous Cell Carcinoma
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Table 5.4 Epstein-Barr virus infection in relation to UK proliferative verrucous leukoplakia
UK Gender
Crude Adjusted 
Odds Ratio Odds Ratio 
(95% Cl) (95% Cl)
PVL ,• .* » .. .. *•> .. -
All PVL
+
EBV + ^  ® 7.33(1.78,30.25) 173.34(2.64,11387.41)*
PVL
+
F EBV + 26 33 8.67(1.18,63.87) N/CH
PVL
+
M EBV + 13 3 6.00(0.08,44.95) N/CH
* Adjusted for age, ethnicity, smoking, Paan and alcohol
f  N/C= OR could not be calculated because some of the potential explanatory factors exhibit 
no variation.
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5.1 Epstein-Barr virus in proliferative verrucous leukoplakia - UK
The frequency of Epstein-Barr virus DNA among oral lesions is 
summarised in Table 5.1. An overall EBV-DNA positive proportion of 6/12 
(50.0%) was detected in PVL-UK patients. Demographic characteristics and 
risk factors for PVL in the UK pateints are summarised in Table 5.2.
5.1.1 Gender
Epstein-Barr virus DNA was detected in 3/6 (50.0%) of both genders.
5.1.2 Age groups
When EBV-DNA was examined in different age groups, EBV infection 
was 1/1 (100.0%) in the 50-60 year age group, 1/3 (33.3%) in the 60-70 year 
age groups and 4/6 (66.7%) in the 70-80 year age groups. When stratified 
according to gender and age, EBV-DNA was detected in 1/2 (50.0%) of the 
female aged 60-70 years and in 2/3 (66.7%) of the females aged 70-80 
years, while EBV-DNA was found in 1/1 (100.0%) of the males aged 50-60 
years and in 2/3 (66.7%) of males aged 70-80 years.
5.1.3 Ethnic origins
Epstein-Barr virus DNA was detected in 4/5 (80.0%) of Caucasians 
compared with 2/7 (28.5%) of cases with no recorded ethnicity. When 
stratified according to gender and ethnicity, 3/4 (75.0%) of the Caucasian 
females were EBV positive compared with 1/1 (100.0%) of Caucasians male 
were EBV positive, and 2/5 (40.0%) of male patients with no recorded 
ethnicity were EBV infected. Neither of the two females 0/2 (0.0%) of 
unknown ethnicities were EBV+ve.
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5.1.4 Association with tobacco, alcohol and Paan
The association between EBV and other major risk factors (e.g. 
tobacco smoking, frequency of smoking, Paan use and alcohol intake) was 
examined. Epstein-Barr virus DNA was detected in 2/2 (100.0%) of current 
smokers compared with 4/10 (40.0%) of non-smokers. Among the smokers 
group, EBV-DNA was detected in 2/2 (100.0%) of individuals smoking > 
20/day. When stratified according to gender and smoking, none of the 
females in this group were current smokers. Epstein-Barr virus DNA was 
detected in 1/4 (25.0%) of male non-smokers compared with 2/2 (100.0%) of 
males smoking >20/day.
When the use of Paan was examined, EBV-DNA was found in 5/11 
(45.5%) of non-Paan users compared with 1/1 (100.0%) of Paan users. 
When stratified according to gender and use of Paan, EBV-DNA was 
detected in 3/6 (50.0%) of female non-Paan user compared with 2/5(40.0%) 
of male non-Paan user. EBV-DNA was found in 1/1 (100.0%) male Paan 
user. There were no females Paan users in the sample.
Epstein-Barr virus DNA was detected in 5/11 (45.0%) of non-alcohol 
drinkers compared with 1/1 (100.0%) of individuals currently consuming >20 
units per week. When stratified according to gender and alcohol intake, the 
results show that EBV was detected in 3/6 (50.0%) of female non-alcohol 
drinkers compared with 2/5 (40.0%) of males within the same group. Among 
the male alcohol-drinking group, EBV-DNA was found in one of males 
consuming > 20 units per week. No females reported that they consumed 
alcohol.
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5.1.5 Site of proliferative verrucous leukoplakia samples
Cross tabulation for EBV-DNA frequency and other characteristics are 
summarised in Table 5.3. Epstein-Barr virus DNA was found in the buccal 
mucosa, lateral border of the tongue, floor of mouth and on the lip. No 
difference was readily apparent as regards the biopsy site and EBV infection.
5.1.6 Relevant medical history
Epstein-Barr virus DNA was detected in 3/6 (50.0%) of patients with 
second primary OSCC. EBV-DNA was found in 1/1 (100.0%) of males with 
candidal infection and in 2/2 (100.0%) of individuals allergic to penicillin. 
When stratified according to gender and medical history, EBV-DNA was 
found in 2/3 (66.7%) of females with second primary OSCC compared with 
1/3 (33.3%) of males within the same group. EBV-DNA was detected in 1/1 
(100.0%) of individuals with penicillin allergy in both genders.
The results show that none of the individuals infected with EBV-DNA 
had received any corticosteroid therapy nor did they have any immune 
diseases. Epstein-Barr virus DNA was found in 1/1 (100.0%) of female 
patients who had received chemotherapy compared to 5/11 (45.5%) in 
individuals who received no therapies.
5.1.7 EBV infection in relation to UK-PVL
The results for EBV infection in relation to PVL are summarised in 
Table 5.4. These crude results indicate that in this UK sample, people who 
have PVL are 7.33 times more likely to be infected with EBV than normal 
controls. Although the adjusted results (adjusted for age, ethnicity, smoking, 
Paan use and alcohol drinking), indicate that in this UK sample, people who
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are PVL are 173.34 times more likely to be infected with EBV than normal 
controls. However, it should be noted that the sample size is small and the 
very wide C.l indicated a high level of uncertainity from this result.
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Table 5.5 Detection of Epstein-Barr virus versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with oral epithelial dysplasia
Characteristic -veNo. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. ( % )
-ve 
Male 
No. {%)
+ve 
Male 
No. (%)
Gender
Female 
Male 
Age (years)
22/22(100.0)
22/23(95.7)
0/22(0.0)
1/23(4.3)
"  " \ f .  V , J v K  -* ' ■
20-30 0/1(0.0) 1/1(100.0) - * 0/1 (0.0) 1/1(100.0)
0-40 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0)
40-50 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
50-60 16/16(100.0) 0/16(0.0) 6/6(100.0) 0/6(0.0) 10/10(100.0) 0/10(0.0)
60-70 14/14(100.00 0/14(0.0) 7/7(100.0) 0/7(0.0) 7/7(100.0) 0/7(0.0)
70-80 9/9(100.0) 0/9(0.0) 7/7(100.0) 0/7(0.0) 7/7(100.00 0/7(0.0)
Ethnicity
Caucasian 30/30(100.0) 0/30(0.0) 14/14(100.0) 0/14(0.0) 16/16(100.0) 0/16(0.0)
SEA* 5/6(83.3) 1/6(16.7) 4/4(100.0) 0/4(0.0) 11/12(91.7) 1/12(8.3)
N/A** 9/9(100.0) 0/9(0.0) 9/9(100.0) 0/9(0.0) 5/5(100.0) 0/5(0.0)
Tobacco
None 23/24(95.8) 1/24(4.2) 15/15(100.0) 0/15(0.0) 8/9(88.9) 1/9(11.1)
Ex-smoker 3/3(100.0) 0/3(0.0) - - 3/3(100.0) 0/3(0.0)
Current 18/18(100.0) 0/18(0.0) 7/7(100.0) 0/7(0.0) 11/11(100.0) 0/11(0.0)
Smoking
None 23/24(95.8) 1/24(4.2) 15/15(100.0) 0/15(0.0) 8/9(88.9) 1/9(11.1)
10-15/day 12/12(100.0) 0/12(0.0) 4/4(100.0) 0/4(0.0) 8/8(100.0) 0/8(0.0)
>20/day 9/9(100.0) 0/9(0.0) 3/3(100.0) 0/3(0.0) 6/6(100.0) 0/6(0.0)
Paan
None 40/40(400.0) 0/40(0.0) 19/19(100.0) 0/19(0.0) 21/21(100.0) 0/21(0.0)
Current 4/5(80.0) 1/5(20.0) 3/3(100.0) 0/3(0.0) 1/2(50.0) 1/2(50.0)
Alcohol
None 22/23(95.7) 1/23(4.3) 11/11(100.0) 0/11(0.0) 11/12(91.7) 1/12(8.3)
< 5 u/w *** 4/4(100.0) 0/4(0.0) 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0)
5-20 u/ w 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
> 20 u/w 12/12(100.0) 0/12(0.0) 6/6(100.0) 0/6(0.0) 6/6(100.0) 0/6(0.0)
N/A** 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 012(0.0)
Total 44/45(97.8) 1/45(2.2) 22/22(100.0) 0/22(0.0) 22/23(95.7) 1/23(4.3)
*SEA=South East Asian 
**N/A= Data not available 
*** u/w = units per week
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Table 5.6 Cross tabulation for Epstien-Barr virus in UK oral epithelial dysplasia samples 
according to biopsy site, relevant medical note, corticosteroids, immune status and therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site 7 ‘
Buccal mucosa 7/8(87.5) 1/8(12.5) 3/3(100.0) 0/3(0.0) 4/5(80.0) 1/5(20.0)
Lt. of tongue* 12/12(100.0) 0/12(0.0) 6/6(100.0) 0/6(0.0) 6/6(100.0) 0/6(0.0)
Floor of mouth 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0)
Hard palate 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Soft palate 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Ant. 2/3 of 
tongue** 4/4(100.0) 0/4(0.0) 4/4(100.0) 0/4(0.0) - -
Lip 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0)
Commisure 9/9(100.0) 0/9(0.0) 3/3(100.0) 0/3(0.00 6/6(100.0) 0/6(0.0)
Retromolar 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
Salivary
Attanheri
1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
. 7------ 1/1(100.0)gingiva 
Relevant medical note
0/1(0.0) 1/1(100.0) 0/1(0.0)
None 20/20(100.0) 0/20(0.0) 11/11(100.0) 0/11(0.0) 9/9(100.0) 0/9(0.0)
s e e
Candidal
7/7(100.0) 0/7(0.0) 2/2(100.0) 0/2(0.0) 5/5(100.0) 0/5(0.0)
infection 5/5(100.0) 0/5(0.0) 2/2(100.0) 0/2(0.0) 3/3(100.0) 0/3(0.0)
Submucous
fibrosis 3/4(75.0) 1/4(25.0) 2/2(100.0)
0/2(0.0) 1/2(50.0) 1/2(50.00
HRT**** 5/5(100.0) 0/5(0.0) 5/5(100.0) 0/5(0.0) - -
Arthritis 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Asthma 2/2(100.0) 0/2 (0.0) - - 2/2(100.0) 0/2(0.0)
Diabetes
mellitus
Corticosteroids
1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
None 
Immune status
44/45(97.8) 1/45(2.2) 22/22(100.0) 0/22(0.0) 22/23(95.7) 1/23(4.3)
None 42/43(97.7) 1/43(2.3) 21/21(100.0) 0/21(0.0) 21/22(95.5) 1/22(4.5)
Systemic
Therapies
2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0)
None 40/41(97.6) 1/41(2.4) 18/18(100.0) 0/18(0.0) 22/23(95.7) 1/23(4.3)
Chemotherapy 4/4(100.0) 0/4(0.0) 4/4(100.0) 0/4(0.0) - -
Total 44/45(97.8) 1/45(2.2) 22/22(100.0) 0/22(0.0) 22/23(95.7) 1/23(4.3)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
***SCC=Second primary squamous cell carcinoma
****HRT=Hormone replacement therapy
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Table 5.7 Epstein-Barr virus infection in relation to UK-oral epithelial dysplasia samples
UK Gender
Crude 
Odds Ratio 
(95% Cl)
Adjusted 
Odds Ratio 
(95% Cl)
OED > , .
Ail OED
+
EBV +
44 44
6 1 0.17(0.02,1.44) N /C «
OED
+
F EBV +
26 22 
3 0 N/CH N/CH
OED
+
M EBV +
18 22 
3 1 0.27(0.03, 2.85) N/CUH
U N/C= OR could not be calculated because none of the OED was EBV infected
f l f  N/C= Adjusted OR could not be calculated because none of the OED was EBV infected in
at least 1 subgroup
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5.2 Epstein-Barr in oral epithelial dysplasia - UK
The frequency of Epstein-Barr DNA virus in OED was summarised in 
Table 5.1. An overall EBV-DNA positive proportion of 1/45 (2.2%) was 
detected in OED-UK samples. Demographic characteristics and risk factors 
for OED in the UK patients are summarised in Table 5.2.
5.2.1 Epstein-Barr virus demographic Characteristics
Epstein-Barr virus was only detected in one sample. This person was 
a South East Asian male aged 20-30 who was a non-smoker, non-drinker 
and a current user of Paan. He had a submucous fibrosis and the site of the 
lesion was the buccal mucosa. This patient had no history of any immune 
disease nor had received any therapy.
5.2.7 EBV infection in relation to UK-OED
The results based on the logistic regression analysis (the odds ratios 
(OR) and their corresponding 95% confidence intervals) for EBV in OED are 
summarised in Table 5.7. The crude results revealed an overall OR of 0.17; 
95% Cl= 0.02-1.44 (p=0.104). When stratified according gender and risk 
factors (age, ethnicity, smoking, alcohol and Paan), the crude results of OR 
in females could not be calculated because none of the OED was EBV 
infected. The OR of the males group of 0.27; 95% Cl= 0.03-2.85, (p=0.278), 
and the adjusted OR could not be calculated because none of the OED was 
EBV infected in at least 1 subgroup.
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Table 5.8 Demographics details of UK normal patients
-ve 
No. (%)
+ve 
No. (%)
-ve +ve -ve +ve
Characteristic Female 
No. (%)
Female 
No. (%)
Male 
No. (%)
Male 
No. (%)
Gender " ^  i ■?
Female 26/29(89.7) 3/29(10.3)
Male 18/21(85.7) 3/21(14.3)
Age (years)
<20 4/6(66.7) 2/6(33.3) 3/5(60.0) 2/5(40.0) 1/1(100.0) 0/1 (0.0)
20-30 10/11(90.9) 1/11(9.1) 6/6(100.0) 0/6(0.0) 4/5(80.0) 1/5(20.0)
30-40 7/8(87.5) 1/8(12.5) 4/4(100.0) 0/4(0.0) 3/4(75.0) 1/4(25.0)
40-50 6/6(100.0) 0/6(0.0) 4/4(100.0) 0/4(0.0) 2/2(100.0) 0/2(0.0)
50-60 7/8(87.5) 1/8(12.5) 3/3(100.0) 0/3(0.0) 4/5(80.0) 1/5(20.0)
60-70 3/4(75.0) 1/4(25.0) 3/4(75.0) 1/4(25.0) - -
70-80 4/4(100.0) 0/4(0.0) 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0)
>80 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
Ethnicity
Caucasian 33/37(89.2) 4/37(10.8) 22/23(95.7) 1/23(4.3) 11/14(78.6) 3/14(21.4)
SEA* 9/10(90.0) 1/10(10.0) 4/5(80.0) 1/5(20.0) 5/5(100.0) 0/5(0.0)
African 0/1 (0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) - -
Arab 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Tobacco
None 43/49(87.8) 6/49(12.2) 26/29(89.7) 3/29(10.3) 17/20(85.0) 3/20(15.0)
Ex-smoker 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Smoking * :
None 43/49(87.8) 6/49(12.2) 26/29(89.7) 3/29(10.3) 17/20(85.0) 3/20(15.0)
10-15/day 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Paan
None 42/48(87.5) 6/48(12.5) 26/29(89.7) 3/29(10.3) 16/19(84.2) 3/19(15.8)
Ex-user 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Alcohol
None 40/46(87.0) 6/46(13.0) 23/26(88.5) 3/26(11.5) 17/20(85.0) 3/20(15.0)
5-20 u/w 4/4(100.0) 0/4(0.0) 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0)
Total 44/50(88.0) 6/50(12.0) 26/29(89.7) 3/29(10.3) 18/21(85.7) 3/21(14.3)
*SEA= South East Asian
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Table 5.9 Cross tabulation for Epstein-Barr virus in normal oral samples according to biopsy 
site, relevant medical note, corticosteroids, immune status and therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve
Female
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal mucosa 10/11(90.9) 1/11(9.1) 7/7(100.0) 0/7(0.0) 3/4(75.0) 1/4(25.0)
Lt. of tongue* 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
Attarheri
gingiva 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Soft palate 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Ant.2/3 of 
tongue** 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Retromolar 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Floor of mouth 10/12(83.3) 2/12(16.7) 6/7(85.7) 1/7(14.3) 4/5(80.0) 1/5(20.0)
Hard palate 3/4(75.0) 1/4(25.0) 2/3(66.7) 1/3(33.3) 1/1(100.0) 0/1(0.0)
Lip 15/17(88.2) 2/17(11.8) 9/10(90.0) 1/10(10.0) 6/7(85.7) 1/7(14.3)
Relevant medical note
None 43/47(91.5) 4/47(8.5) 25/27(92.6) 2/27(7.4) 18/20(90.0) 2/20(10.0)
Asthma 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
HRT*** 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Penicillin allergy 0/1(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) - -
Corticosteroids
None 43/49(87.8) 6/49(12.2) 25/28(89.3) 3/28(10.7) 18/21(85.7) 3/21(14.3)
systematic 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) - -
Immune status
None 44/50(88.0) 6/50(12.0) 26/29(89.7) 3/29(10.3) 18/21(85.7) 3/21(14.3)
Therapies
None 44/50(88.0) 6/50(12.0) 26/29(89.7) 3/29(10.3) 18/21(85.7) 3/21(14.3)
Total 44/50(88.0) 6/50(12-0) 26/26(89.7) 3/29(10.3) 18/21(85.7) 3/21(14.3)
*Lt. of tongue* lateral border of the tongue
**Ant2/3 of tongue* anterior 2/3 of the tongue
***HRT= Hormone replacement therapy
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5.3 Epstein-Barr virus in normal oral mucosa-UK
The frequency of Epstein-Barr virus DNA among oral lesions is 
summarised in Table 5.1. An overall EBV-DNA positive rate of 6/50 (12.0%) 
was detected in normal control oral mucosa samples. Demographic 
characteristics and risk factors for normal oral mucosa in the UK patients are 
summarised in Table 5.
5.3.1 Gender
Epstein-Barr DNA was detected in 3/29 (10.3%) of females compared 
with 3/21 (14.3% ) in males.
5.3.2 Age groups
EBV-DNA was examined in different age groups. Epstein-Barr DNA 
was detected in 2/5 (40.0%) of females <20 year age group and in 1/4 
(25.0%) of females 60-70 year age group, EBV was found in male group in 
1/5 (20.0%) 20-30 year age group, 1/4 (25.0%) in 30-40 year age group and 
1/5 (20.0%) of 50-60 year age group.
5.3.3 Ethnic origins
Epstein-Barr DNA was found in 4/37(10.8%) of Caucasians, 
1/10(10.0%) and 1/1(100.0%) in South East Asians and Africans 
respectively.
5.3.4 Association with tobacco, alcohol and Paan
The association between EBV and other major risk factors for normal- 
control oral mucosa samples (e.g. tobacco smoking, frequency of smoking,
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Paan use and alcohol intake) was examined. None of the EBV positive 
patients were smokers, Paan-users or alcohol consumers.
5.3.5 Site of normal-control oral mucosa samples
Cross tabulation for EBV-DNA frequency and other characteristics are 
summarised in Table 5. With regard to EBV-DNA and biopsy site, EBV-DNA 
was detected in the buccal mucosa, floor of the mouth and lip of males and in 
the lateral border of the tongue, hard palate and lip of females.
5.3.6 Relevant medical history
Epstein-Barr virus DNA was positive in both genders with no relevant 
medical history and in one asthmatic male and one female who is allergic to 
penicillin. None of the patients had received any corticosteroid therapy or 
other treatments and had no immune problems.
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Table 6.1 Frequency of cytomegalovirus in examined oral mucosa
Lesion Gender -veNo.(%)
+ve 
No. (%)
PVL All 10/12 (83.3) 2/12(16.7)
F 5/6 (83.3) 1/6(16.7)
M 5/6 (83.3) 1/6(16.7)
OED All 38/45(84.4) 7/45(15.6)
F 19/22 (86.4) 3/22(13.6)
M 19/23 (82.6) 4/23(17.4)
Normal control All 49/50(98.0) 1/50(2.0)
F 28/29(96.9) 1/29(3.4)
PVL *  Proliferative verrucous leukoplakia 
OED» Oral epithelial dysplasia
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Table 6.2 Detection of cytomegalovirus versus demographics and risk factors for oral 
squamous cell carcinoma of UK pateints with proliferative verrucous leukoplakia
Characteristic -ve No. (%)
+ve
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
-i-ve 
Male 
No. (%)
Gender 4 ' * * *'<', t  < M »
Age (years)
Female
Male
5/6(83.3)
5/6(83.3)
1/6(16.7)
1/6(16.7)
40-50 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - ■
50-60 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
60-70 2/3(66.7) 1/3(33.3) 1/2(50.0) 1/2(50.0) 1/1(100.0) 0/1 (0.0)
70-80 5/6(83.3) 1/6(16.7) 3/3(100.0) 0/3(0.0) 2/3(66.7) 1/3(33.3)
>80 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Ethnicity
Caucasian 3/5(60.0) 2/5(40.0) 3/4(75.0) 1/4(25.0) 0/1 (0.0)
* *
1/1(100.0)
N/A* 7/7(100.0) 017( 0 .0) 2/2(100.0) 0/2(0.0) 5/5(100.0) 0/5(0.0)
Tobacco
None 9/10(90.0) 1/10(10.0) 5/6(83.3) 1/6(16.7) 4/4(100.0) 0/4(0.0)
Current 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
Smoking
None 9/10(90.0) 1/10(10.0) 5/6(83.3) 1/6(16.7) 4/4(100.0) 0/4(0.0)
>20/day 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
Paan
None 9/11(81.8) 2/11(18.2) 5/6(83.3) 1/6(16.7) 4/5(80.0) 1/5(20.0)
Current 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Alcohol
None 10/11(90.0) 1/11(9.1) 5/6(83.3) 1/6(16.7) 5/5(100.0) 0/5(0.0)
>20 u/w** 0/1(0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Total 10/12(83.3) 2/12(16,7) 5/6(83.3) 1/6(16.7) 5/6(83.3) 1/8(16.7)
*N/A= Data not available
** u/w = units per week
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Table 6.3 Cross tabulation for cytomegalovirus in UK proliferative verrucous leukoplakia 
samples according to biopsy site, relevant medical note, corticosteroids, immune status and 
therapies
Characteristic -ve No. (% )
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve
Male
No. (%)
+ve 
Male 
No. (%)
Biopsy site ■f
Buccal mucosa 3/4(75.0) 1/4(25.0) 3/4(75.0) 1/4(25.0) - -
Lt. of tongue* 2/2(100.0) 012(0.0) - - 2/2(100.0) 012(0.0)
Floor of mouth 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
Hard palate 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Ant. 2/3 of tongue** 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
Lip 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1(0.0) - -
Retromolar 1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1(0.0)
Relevant medical note
None 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0)
see*** 5/6(83.3) 1/6(16.7) 2/3(66.7) 1/3(33.3) 3/3(100.0) 0/3(0.0)
Candidal in fe c t io n 0/1 (0.0) 1/1(100.0) - - 0/1 (0.0) 1/1(100.0)
Penicillin allergy 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0)
Corticosteroids '* % >
None 10/12(83.3) 2/12(16.7) 5/6(83.3) 1/6(16.7) 5/6(83.3) 1/6(16.7)
immune status
None 10/12(83.3) 2/12(16.7) 5/6(83.3) 1/6(16.7) 5/6(83.3) 1/6(16.7)
Therapies
None 10/11(90.9) 1/11(9.1) 5/5(100.0) 0/5(0.0) 5/6(83.3) 1/6(16.7)
Chemotherapy 0/1(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) - -
Total 10/12(83.3) 2/12(16.7) 5/6(83.3) 1/6(16.7) 5/6(83.3) 1/6(16.7)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
***SCC= Second primary Squamous Cell Carcinoma
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Table 6.4 Cytomegalovirus infection in relation to UK-proliferative verrucous leukoplakia 
samples ______________________________________________________
UK Gender Odds Ratio (95% Cl)
PVL
All PVL
+
CMV +
49 10 
1 2 9.80(0.81,118.79)
PVL
+
F CMV +
28 5 
1 1 5.60(0.30,104.94)
PVL
+
M CMV +
21 5 
0 1 N/C
N/C= OR could not be calculated because none of the normal controls was CMV+ve in the 
males.
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6.1 Cytomegalovirus in proliferative verrucous leukoplakia - UK
The frequency of cytomegalovirus DNA among oral lesions is 
summarised in Table 6.1. An overall CMV-DNA positive proportion of 2/12 
(16.7%) was detected in PVL-UK patients. Demographic characteristics and 
risk factors for PVL in the UK patients are summarised in Table 6.2.
6.1.1 Gender
Cytomegalovirus-DNA was detected in 1/6 (16.7%) of each gender.
6.1.2 Age groups
When CMV-DNA was examined in different age groups, CMV-DNA 
was detected in 1/3 (33.3%) of 60-70 year age group and in 1/6 (16.7%) of 
the 70-80 year age group. When stratified according to gender and age, 
CMV-DNA was found in 1/2 (50.0%) of female aged 60-70 years and in 1/3 
(33.3%) of males aged 70-80 years.
6.1.3 Ethnic origins
Cytomegalovirus-DNA was detected in 2/5 (40.0%) of Caucasians. 
When stratified according to gender and ethnicity, CMV-DNA was found in 
1/4 (25.0%) of females and in 1/1 (100.0%) of males.
6.1.4 Association with tobacco, alcohol and Paan
The association between CMV and other major risk factors for PVL 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Cytomegalovirus-DNA was found in 1/10 (10.0%) of the non­
smoking group compared with 1/2 (50.0%) of individuals smoking > 20 /day. 
When stratified according to gender and smoking, none of the females in this
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group were current smokers. CMV-DNA was found in 1/2 (50.0%) of male 
current smokers.
When the use of Paan was examined, CMV-DNA was detected in 2/11 
(18.2%) of non-Paan users. When stratified according to gender and use of 
Paan, CMV-DNA was found in 1/6 (16.7%) of females compared with 1/5 
(20.0%) in males.
The proportion of CMV-DNA was detected in 1/11 (9.1%) of non­
alcohol drinkers compared with 1/1 (100.0%) in individuals currently 
consuming >20 units per week. When stratified according to gender and 
alcohol intake, the results show that none of the females in this group were 
current alcohol consumers compared with 1/1 (100.0%) of males consuming 
>20 units per week.
6.1.5 Site of proliferative verrucous leukoplakia samples
Cross tabulation for CMV-DNA frequency and other characteristics are 
summarised in Table 6.3. Cytomegalovirus-DNA was detected in 1/4 (25.0%) 
of the buccal mucosa samples of females and in 1/2 (50.0%) of the floor of 
mouth samples in males.
6.1.6 Relevant medical history
Cytomegalovirus-DNA was detected in 1/6 (16.7%) of patients with 
second primary OSCC and in 1/1 (100.0%) of patients with candidal infection. 
When stratified according to gender and medical history, CMV-DNA was 
found in 1/3 (33.3%) of females with second primary and in 1/1 (100.0%) of 
males with candidal infection.
236
Chapter 6 Cytomegalovirus -Results
The results show that none of the individuals were infected with CMV- 
DNA had received any corticosteroid therapy nor suffered from any known 
immune disease. Cytomegalovirus-DNA was found in 1/1 (100.0%) of 
patients who received chemotherapy compared with 1/11 (9.1%) of patients 
who had received no therapy.
6.1.7 CMV infection in relation to UK-PVL
The results based on the logistic regression analysis (the odds ratios 
(OR) and their corresponding 95% confidence intervals) for CMV in PVL are 
summarised in Table 6.4. The crude results indicate that in this UK sample, 
people who have PVL are 9.80 times more likely to be infected with CMV 
than normal controls. Adjusted OR could not be calculated because none of 
the PVL was CMV infected in at least one subgroup. It should be noted that 
the sample size is relatively small and the very wide C.l indicated a high level 
of uncertainly for this result.
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Table 6.5 Detection of cytomegalovirus versus demographics and risk factors for oral 
squamous cell carcinoma of UK patients with oral epithelial dysplasia
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female
Male
19/22(86.4)
19/23(82.6)
3/22(13.6)
4/23(17.4)
* : # ,  „
Age(years) ' ' ' ! 1 1 ~ # v ’ u
20-30 1/1(100.0) 0/1(0.0) - * 1/1(100.0) 0/1 (0.0)
30-40 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0)
40-50 2/3(66.7) 1/3(33.3) 0/1(0.0) 1/1(100.0) 2/2(100.0) 0/2(0.0)
50-60 15/16(93.8) 1/16(6.3) 6/6(100.0) 0/6(0.0) 9/10(90.0) 1/10(10.0)
60-70 11/14(78.6) 3/14(21.4) 6/7(85.7) 1/7(14.3) 5/7(71.4) 2/7(28.6)
Ethnicity
70-80 7/9(77.8) 2/9(22.2) 6/7(85.7) 1/7(14.3) 1/2(50.0) 1/2(50.0)
Caucasian 25/30(83.3) 5/30(16.7) 11/14(78.6) 3/14(21.4) 14/16(87.5) 2/16(12.5)
SEA* 5/6(83.3) 1/6(16.7) 4/4(100.0) 0/4(0.0) 1/2(50.0) 1/2(50.0)
Tobacco
N/A** 8/9(88.9) 1/9(11.1) 4/4(100.0) 0/4(0.0) 4/5(80.0) 1/5(20.0)
None 20/24(83.3) 4/24(16.7) 14/15(93.3) 1/15(6.7) 6/9(66.7) 3/9(33.3)
Ex-smoker 2/3(66.7) 1/3(33.3) - - 2/3(66.7) 1/3(33.3)
Smoking
Current 16/18(88.9) 2/18(11.1) 5/7(71.4) 2/7(28.6) 11/11(100.0) 0/11(0.0)
None 20/24(83.3) 4/24(16.7) 14/15(93.3) 1/15(6.7) 6/9(66.7) 3/9(33.3)
10-15/day 10/12(83.3) 2/12(16.7) 2/4(50.0) 2/4(50.0) 8/8(100.0) 0/8(0.0)
Paan
>20/day 8/9(88.9) 1/9(11.1) 3/3(100.0) 0/3(0.0) 5/6(83.3) 1/6(16.7)
None 34/40(85.0) 6/40(15.0) 16/19(84.2) 3/19(15.8) 18/21(85.7) 3/21(14.3)
Alcohol
Current 4/5(80.0) 1/5(20.0) 3/3(0.0) 0/3(0.0) 1/2(50.0) 1/2(50.0)
None 20/23(87.0) 3/23(13.0) 11/11(100.0) 0/11(0.0) 9/12(75.0) 3/12(25.0)
<5 u/w*** 4/4(100.0) 0/4(0.0) 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0)
5-20 u/w 2/3(66.7) 1/3(33.3) 0/1(0.0) 1/1(100.0) 2/2(100.0) 0/2(0.0)
> 20 u/w 9/12(75.0) 3/12(25.0) 4/6(66.7) 2/6(33.3) 5/6(83.3) 1/6(16.7)
N/A 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1(0.0) 2/2(100.0) 0/210.0)
Total 38/45(84.4) 7/45(15.6) 19/22(86.4) 3/22(13.6) 19/23(82.6) 4/23(17 A)
*SEA=South East Asian
**N/A= Data not available
*** u/w = units per week
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Table 6.6 Cross tabulation for cytomegalovirus in UK-oral epithelial dysplasia samples 
according to biopsy site, relevant medical note, corticosteroids, immune status, and 
therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Biopsy site
Buccal mucosa 6/8(75.0) 2/8(25.0) 3/3(100.0) 0/3(0.0) 3/5(60.0) 2/5(40.0)
Lt. of tongue* 9/12(75.0) 3/12(25.0) 4/6(66.7) 2/6(33.3) 5/6(83.3) 1/6(16.7)
Floor of mouth 3/3(100.0) 0/3(0.0) 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0)
Hard palate 1/2(50.0) 1/2(50.0) - - 1/2(50.0) 1/2(50.0)
Soft palate 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Ant. 2/3 of 
tongue** 3/4(75.0) 1/4(25.0) 3/4(75.0) 1/4(25.0) - -
Lip 2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0)
Commisure 9/9(100.0) 0/9(0.0) 3/3(100.0) 0/3(0.0) 6/6(100.0) 0/6(0.0)
Retromolar 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) - -
Salivary
Attarheri
1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) - -
. 7----- 1/1100.0gingiva 
Relevant medical note
0/1(0.0) 1/1(100.0) 0/1 (0.0)
None 18/20(90.0) 2/20(10.0) 9/11(81.8) 2/11(18.2) 9/9(100.0) 0/9(0.0)
see***
Candidal
5/7(71.4) 2/7(28.6) 2/2(100.0) 0/2(0.0) 3/5(60.0) 2/5(40.0)
in fe c t io n
4/5(80.0) 1/5(20.0) 2/2(100.0) 0/2(0.0) 2/3(66.7) 1/3(33.3)
Submucous
fibrosis 3/4(75.0) 1/4(25.0) 2/2(100.0) 0/2(0.0) 1/2(50.0) 1/2(50.0)
HRT**** 4/5(80.0) 1/5(20.0) 4/5(80.0) 1/5(20.0) - -
Arthritis 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1(0.0)
Asthma 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
Diabetic
Corticosteroids
1/1(100.0) 0/1(0.0) " 1/1(100.0) 0/1(0.0)
None 
Immune status
38/45(84.4) 7/45(15.6) 19/22(86.4) 3/22(13.6) 19/23(82.6) 4/23(17.4)
None 36/43(83.7) 7/43(16.3) 18/21(85.7) 3/21(14.3) 18/22(81.8) 4/22(18.2)
Systemic
Therapies
2/2(100.0) 0/2(0.0) 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0)
None 35/41(85.4) 6/41(14.6) 16/18(88.9) 2/18(11.1) 19/23(82.6) 4/23(17.4)
Chemotherapy 3/4(75.0) 1/4(25.0) 3/4(75.0) 1/4(25.0) - -
Total 38/45(84.4) 7/45(15.6) 19/22(86.4) 3/22(13.6) 19/23(82.6) 4/23(17.4)
* Lt. of tongue= lateral border of the tongue
** Ant. 2/3 of tongue= anterior 2/3 of tongue
***SCC= second primary Squamous Cell Carcinoma
****HRT=Hormone replacement therapy
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Table 6.7 Cytomegalovirus infection in relation to UK-oral epithelial dysplasia samples
UK Gender Odds Ratio (95% Cl)
OED ' •  %<
All OED
+
CMV +
49 38 
1 7 9.03(1.06, 76.54)
OED
+
F CMV +
28 19 
1 3 4.42(0.43, 45.76)
OED
+
M CMV +
21 19 
0 4 N/C
N/C= OR could not be calculated because none of the normal control were CMV+ve in the 
males.
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6.2 Cytomegalovirus in oral epithelial dysplasia of patients from UK
The frequency of cytomegalovirus DNA among oral lesions is 
summarised in Table 6.1. An overall CMV-DNA positive proportion of 7/45 
(15.6%) was detected in OED-UK patients. Demographic characteristics and 
risk factors for OED in the UK patients are summarised in Table 6.5.
6.2.1 Gender
Cytomegalovirus-DNA was detected in 3/22 (13.6%) of females 
compared with 4/23 (17.4%) in males.
6.2.2 Age groups
When CMV-DNA was examined in different age groups, CMV-DNA 
was found in 1/3 (33.3%) of the 40-50 year age group, in 1/16 (6.3%) of the 
50-60 year age group, in 3/14 (21.4%) of the 60-70 year age group and in 2/9 
(22.2%) of the 70-80 year age group. When stratified according to age and 
gender, CMV-DNA was found in 1/1 (100.0%) in the female 40-50 year age 
group and in 1/7 (14.3%) of both 60-70 and 70-80 year age female groups. 
Cytomegalovirus-DNA was detected in 2/7 (28.6%) of the 60-70 year age 
group compared with 1/2 (50.0%) of the 70-80 year age male group.
6.2.3 Ethnic origins
Cytomegalovirus-DNA was detected in 5/30 (16.7%) of Caucasians 
compared with 1/6 (16.7%) in South East Asians. When stratified according 
to gender and ethnicity, CMV-DNA was found in 3/14 (21.4%) of Caucasian 
females compared with 2/16 (12.5%) of Caucasian males. However, CMV- 
DNA was found in 1/2 (50.0%) of South East Asians. CMV-DNA was 
detected in 1/9 (11.1%) in individuals with no recorded ethnicity.
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6.2.4 Association with tobacco, alcohol and Paan
The association between CMV and other major risk factors for OED 
(e.g. tobacco smoking, frequency of smoking, Paan use and alcohol intake) 
was examined. Cytomegalovirus-DNA was found in 4/24 (16.7%) of non- 
smokers compared with 1/3 (33.3%) in the ex-smoking group and in 2/18 
(11.1%) of current smokers. Among the smoking group, CMV-DNA was 
detected in 2/12 (16.7%) of individuals smoking 10-15 /day, and in 1/9 
(11.1%) of individuals smoking >20/day. When stratified according to gender 
and smoking, CMV-DNA was detected in 2/4 (50.0%) of females smoking 10- 
15/day and in 1/15 (6.7%) of non-smokers females. CMV was found in 1/6 
(16.7%) of males smoking >20/day and in 3/9 (33.3%) of non-smoker males.
When the use of Paan was examined, CMV-DNA was found in 6/40 
(15.0%) of non-Paan users compared with 4/5 (80.0%) of current Paan 
users. When stratified according to gender and use of Paan, CMV-DNA was 
detected in 3/19 (15.8%) of females compared with 3/21 (14.3%) of males.
Cytomegalovirus-DNA was found in 3/23 (13.0%) of non-alcohol 
drinkers compared with 1/3 (33.3%) of individuals currently consuming 5-20 
units per week and in 3/12 (25.0%) of individuals currently consuming >20 
units per week. When stratified according to gender and alcohol intake, the 
results show that CMV-DNA was found in 1/1 (100.0%) of females 
consuming 5-20 units per week compared with 2/6 (33.3%) of females 
consuming > 20 units per week. Among the males group, CMV-DNA was 
detected in 3/12 (25.0%) of non-alcohol drinkers compared with 1/6 (16.7%) 
of males consuming > 20 units per week.
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6.2.5 Site of oral epithelial dysplasia samples
Cross tabulation for CMV-DNA frequency and other characteristics are 
summarised in Table 6.6. Cytomegalovirus-DNA was detcted in the buccal 
mucosa, lateral border of the tongue, hard palate and anterior two thirds of 
tongue. When stratified according to gender and biopsy site, no difference 
was readily apparent as regard the biopsy site and CMV infection.
6.2.6 Relevant medical history
Cytomegalovirus-DNA was detected in 2/20 (10.0%) of patients with 
no relevant medical history, in 2/7 (28.6%) of patients with second primary 
OSCC, in 1/5 (20.0%) of patients with candidal infection and in 1/4 (25.0%) of 
patients with submucous fibrosis. When stratified according to gender and 
relevant medical history, CMV was found in 1/5 (20.0%) of females received 
HRT compared with 2/11 (18.2%) of females with no relevant medical history. 
CMV-DNA was detected in 2/5 (40.0%) of male patients with second-primary 
OSCC, in 1/3 (33.3%) of male patients with candidal infection and in 1/2 
(50.0%) of male patients with submucous fibrosis.
The results show that none of the individuals infected with CMV-DNA 
had received any corticosteroids nor had any known immune disease. 
Cytomegalovirus-DNA was detected in 1/4 (25.0%) of individuals who had 
received chemotherapy compared with 6/41 (14.6%) of individuals who 
received no therapy. When stratified according to gender and treatment, 
CMV-DNA was found in 1/4 (25.0%) of female patients who had received 
chemotherapy. Cytomegalovirus-DNA was found in 2/18 (11.1%) of females 
who received no therapy compared with 4/23 (17.4%) of males within the 
same group.
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6.2.7 CMV infection in relation to UK-OED
The results based on the logistic regression analysis (the odds ratios 
(OR) and their corresponding 95% confidence intervals) for CMV in OED are 
summarised in Table 6.7. The crude results indicate that in this UK sample, 
people who have OED are 9.03 times more likely to be infected with CMV 
than normal controls. Adjusted OR could not be calculated because none of 
the OED was CMV infected in at least one subgroup. It should be noted that 
the sample size is relatively small and the very wide C.l indicated a high level 
of uncertainty for this result.
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Table 6.8 Demographics details of UK normal pateints
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve 
Male 
No. (%)
Gender
Female 
Male 
Age (years)
28/29(96.6)
21/21(100.0)
1/29(3.4)
0/21(0.0)
' 'H r ^
* ^  
. X  * -* ■
<20 5/6(83.3) 1/6(16.7) 4/5(80.0) 1/5(20.0) 1/1(100.0) 0/1 (0.0)
20-30 11/11(100.0) 0/11(0.0) 6/6(100.0) 0/6(0.0) 5/5(100.0) 0/5(0.0)
30-40 8/8(100.0) 0/8(0.0) 4/4(100.0) 0/4(0.0) 4/4(100.0) 0/4(0.0)
40-50 6/6(100.0) 0/6(0.0) 4/4(100.0) 0/4(0.0) 2/2(100.0) 0/2(0.0)
50-60 8/8(100.0) 0/8(0.0) 3/3(100.0) 0/3(0.0) 5/5(100.0) 0/5(0.0)
60-70 4/4(100.0) 0/4(0.0) 4/4(100.0) 0/4(0.0) - -
70-80 4/4(100.0) 0/4(0.0) 2/2(100.0) 0/2(0.0) 2/2(100.0) 0/2(0.0)
>80 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0) 2/2(100.0) 0/2(0.0)
Ethnicity
Caucasian 36/37(97.3) 1/37(2.7) 22/23(95.7) 1/23(4.3) 14/14(100.0) 0/14(0.0)
SEA* 10/10(100.0) 0/10(0.0) 5/5(100.0) 0/5(0.0) 5/5(100.0) 0/5(0.0)
Arab 2/2(100.0) 0/2(0.0) - - 2/2(100.0) 0/2(0.0)
African
Tobacco
1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) * *
None 48/49(98.0) 1/49(2.0) 28/29(96.6) 1/29(3.4) 20/20(100.0) 0/20(0.0)
Ex-smoker
Smoking
1/1(100.0) 0/1(0.0) * * 1/1(100.0) 0/1 (0.0)
None 48/49(98.0) 1/49(2.0) 28/29(96.6) 1/29(3.4) 20/20(100.0) 0/20(0.0)
10-15/day
Paan
1/1(100.0) 0/1 (0.0) " 1/1(100.0) 0/1(0.0)
None 47/48(97.9) 1/48(2.1) 28/29(96.6) 1/29(3.4) 20/20(100.0) 0/20(0.0)
Ex-user 
Alcohol
2/2(100.0) 0/2(0.0) " “ 1/1(100.0) 0/1 (0.0)
None 45/46(97.8) 1/46(2.2) 25/26(96.2) 1/26(3.8) 20/20(100.0) 0/20(0.0)
5-20 u/w*** 4/4(100.0) 0/4(0.0) 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0)
Total 49/50(98.0) 1/50(2.0) 28/29(96.6) 1/29(3.4) 21/21(100.0) 0/21(0.0)
*SEA=South East Asian
u/w= units per week
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Table 6.9 Cross tabulation for cytomegalovirus in UK-normal control samples according to 
biopsy site, relevant medical note, corticosteroids, immune status and therapies
Characteristic -ve No. (%)
+ve 
No. (%)
-ve 
Female 
No. (%)
+ve 
Female 
No. (%)
-ve 
Male 
No. (%)
+ve
Male
No.(%)
Biopsy site ■ - - * . .- , •
Buccal m ucosa 11/11(100.0) 0/11(0.0) 7/7(100.0) 0/7(0.0) 4/4(100.0) 0/4(0.0)
Lt. of tongue* 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) - -
Floor of m outh  
Attached
11/12(91.7) 1/12(8.3) 6/7(85.7) 1/7(14.3) 5/5(100.0) 0/5(0.0)
gingiva
1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Soft pala te 1/1(100.0) 0/1 (0.0) 1/1(100.0) 0/1 (0.0) - -
H ard pala te 4/4(100.0) 0/4(0.0) 3/3(100.0) 0/3(0.0) 1/1(100.0) 0/1 (0.0)
Ant. 2 /3  of 
tongue**
1/1(100.0) 0/1 (0.0) - - 1/1(100.0) 0/1 (0.0)
U p 17/17(100.0) 0/17(0.0) 10/10(100.0) 0/10(0.0) 7/7(100.0) 0/7(0.0)
R etrom olar 2/2(100.0) 
Relevant medical note
012( 0 .0 ) ■ * 2/2(100.0) 012(0.0)
none 46/47(97.9) 1/47(2.1) 26/27(96.3) 1/27(3.7) 20/20(100.0) 0/20(0.0)
H R T 1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) - -
Asthm a 1/1(100.0) 0/1(0.0) - - 1/1(100.0) 0/1 (0.0)
Penicillin a llergy  
Corticosteroids
1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1 (0.0) ■ "
N one 48/49(98.0) 1/49(2.0) 27/28(96.4) 1/28(3.6) 21/21(100.0) 0/21(0.0)
system atic  
Immune status
1/1(100.0) 0/1(0.0) 1/1(100.0) 0/1(0.0) ’ “
none
Therapies
49/50(98.0) 1/50(2.0) 28/29(96.6) 1/29(3.4) 21/21(100.0) 0/21(0.0)
none 49/50(98.0) 1/50(2.0) 28/29(96.6) 1/29(3.4) 21/21(100.0) 0/21(0.0)
49/50(98.0) 1/50(2.0) 28/29(96.6) 1/29(3.4) 21/21(100.0) 0/21(0.0)
* Lt. of tongue = lateral border of the tongue
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6.3 Cytomegalovirus in normal samples-UK
The frequency of CMV virus DNA among oral lesions is summarised in 
Table 6.1. An overall CMVV-DNA positive proportion of 1/50 (2.0%) was 
detected in normal control oral mucosa samples. Demographic 
characteristics and risk factors for CMV in normal oral mucosa samples are 
summarised in Table 6.
6.3.1 Cytomegalovirus in normal control demographic Characteristics
Cytomegalovirus was only detected in one sample. This person was a 
Caucasian female aged <20 who was a non-smoker, non-drinker and had no 
history of using Paan. She had no relevant medical history and had received 
no corticosteroid or any therapy. The site of the sample was the floor of the 
mouth.
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7.1 Human Papillomavirus
The present study has established that HPV was present in 79.4% 
and 56.7% of OSCC in persons sampled from the UK and KSA respectively. 
The proportions were high compared to the HPV-DNA in normal control 
mucosa (0.0%). Of note, the normal control samples in the present study 
were only obtained from UK individuals. The results of the pathological 
samples from both UK and KSA were compared to those of the UK normal 
control samples due to the lack of normal control samples from the KSA. It is 
accepted that it would have been better to compare the KSA samples with a 
group of controls drawn from the KSA, however, logistically this was difficult 
for the current study. Therefore, one recommendation for future research 
would be to recruit and analyse a group of KSA normal controls in order to 
either validate or refute the current results.
In a recent systematic review of published studies describing the 
prevalence of HPV in HNSCC biopsies world-wide (Kreimer et al., 2005), the 
overall prevalence of HPV in OSCC was 23.5%, this being much lower than 
the results of the current study. However, the results of the UK samples are 
correlate with those from Japan whereby 74% of the examined individuals 
with OSCC were HPV infected (Shima etal., 2000).
In the present study the high frequency of detection of HPV may 
reflect the use of more advanced molecular methods that can detect low viral 
copies within the cells (Ha and Califano, 2004).The detection of HPV in the 
paraffin-embedded material could have been difficult, however, the /3-globin 
gene was detected in all examined samples, hence it is likely that HPV 
detection rate presently observed is real (Gravitt et al., 1998; Sato et al.,
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2001; Kreimer et al., 2005). Although the methods of detection of HPV-DNA 
employed in the present study can detect a low number of copies 
(Remmerbach et al., 2004; Molijn et al., 2005), they do not permit the viral 
load within cells of the lesion, nor the expression of oncogenic E6 and E7 to 
be estimated (Ha et al., 2002; zur Hausen, 2002; Szentirmay et al., 2005). 
Thus, it cannot be said with definite certainty that HPV is of aetiological 
relevance in the present groups of HPV-infected lesions.
In the present study, HPV-16 was the only HPV type detcted in OSCC 
samples from both UK and KSA. Genotyping was undertaken by using a 
reverse line blotting technique (Jordens et al., 2000) which has the ability to 
accurately genotype more than 24 types and to detect multiple infections, 
however, this technique can omit novel types of HPV (van den Brule et al., 
1990; Molijn et al., 2005). The present results are in agreement with those of 
previous investigations of OSCC (Chang et al., 1989; zur Hausen, 1996; 
Smith et al., 2004; Kreimer et al., 2005), indicating that it is a high-risk type 
of HPV that is associated with OSCC. It is known that E6 and E7 mRNA are 
expressed in OSCC (Hafkamp et al., 2004) and thus the present results 
suggest that there is a viral oncogenic potential in OSCC patients both in the 
UK and KSA. The high detection rate of HPV-16 (known to be associated 
with malignancy at other mucosal surfaces) would seem to suggest that the 
presence of HPV-16 in the mouth might predispose to malignant 
transformation (Kreimer et al., 2005). However, such data do not truly 
establish that HPV is the major cause of OSCC, as although, the OR of HPV 
carriage for the development of OSCC is *  3.7-5.4 (independent of tobacco
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and alcohol) (Syrjanen, 2005), and it is much less than the OR of HPV for 
cervical malignancy reaching *  74 (Munoz, 2000; Garland, 2002).
Oral squamous cell carcinoma is not completely analogous to cervical 
cancer as HPV infection appears to be neither necessary nor sufficient for 
malignant progression in OSCC. The physical status of the HPV-DNA (i.e. 
episomal or integrated) may be of relevance in the pathogenesis of OSCC 
(Koskinen et al., 2003). A recent study by Syrjanen in 2005, suggested that 
integration is an early event in HPV-induced carcinogenesis, however, in 
cervical malignancy integration is not essential for oncogenesis (Syrjanen, 
2005). This aspect was not examined in the present study.
7.1.1 Human papillomavirus and demographic characteristics of the patients
The results of the present study indicate that the frequency of 
detection of HPV-DNA in OSCC in samples from the UK and KSA was 79.4% 
and 56.7% respectively. This difference may reflect differences in lifestyle or 
genetic predispositions. A study of Japanese patients found variation in the 
oral carriage of HPV in patients from two different geographical (and 
ethnically different) regions. HPV was found to be more prevalent in the 
Okinawa area (known to have migrants from Taiwan and Fuzuho in PR 
China-both reported as high HPV infection areas), than in Sapporo region 
(that does not have a high migrant population) (Tsuhako et al., 2000). There 
are some geographic areas known to have a higher incidence of HNSCC 
than other parts, this probably reflecting local relevant habits such as 
chewing betel quid in Southern Asia and consumption of hot mat§ in South 
America (Castelletto et al., 1994; Sewram et al., 2003; Brennan and 
Boffetta, 2004). Such social habits are likely to underly any geographic
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variations in the occurrence of OSCC rather than variations in HPV carriage 
rates.
Recently published studies have suggested that the prevalence of 
HPV in OSCC may be higher in patients from North America compared with 
those from Europe and Asia (Herrero et al., 2003; Ha and Califano, 2004; 
Kreimer et al., 2005). However, a review of the incidence of HPV in HNSCC 
in different countries (including India, France, Israel, Scotland, and North 
America) did not indicate that the association between HPV and HNSCC was 
significantly influenced by geographic locale or ethnicity (Gillison and Shah,
2001). In accordance with other studies of Europeans, the present study 
showed similar prevalence rates for HPV in OSCC-UK when compared with 
studies from Greece (94.7%) and Italy (61.5%), that both used the same 
methods as employed in this study (Bouda et al., 2000; Giovannelli et al.,
2002). Such high proportions would thus be in agreement with the conclusion 
of the recent meta-analysis; namely that geographic locale is not a major 
influence of HPV carriage in OSCC (Gillison, 2004). The raised frequency of 
HPV infection in the UK as compared to the KSA-OSCC samples may reflect 
some undetectable differences in some social habits e.g. alcohol usage.
In the present study, there was no evidence of any differences in the 
proportion of HPV infection among Caucasian and South East Asian patients 
resident in the UK with OSCC. Furthermore, the current results substantiate 
that the use of Paan among South East Asians did not affect the proportion 
of HPV in the mouth, this would thus be in agreement with the frequency of 
HPV infections detected in a previous study of individuals with submucous 
fibrosis (D'Costa etal., 1998).
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Genders have been included in the statistical analysis of the present 
study in view of the fact that this research is studying HPV known to infect 
mostly the genital tract in females (Palefsky, 2003), and oral cancer is known 
to affect more males than females world-wide (Kreimer et al., 2005). The 
results of the present study showed no evidence of differences in the 
prevalence of HPV infection in OSCC as regards gender which is in 
agreement with the findings of some (Herrero et al., 2003), but not all studies, 
in which HPV was found to be more prevalent in males (Ringstrom et al., 
2002; Ritchie et al., 2003). The absence of gender differences in HPV may 
indicate that HPV is not of aetiological significance for OSCC, as this tumour 
is more prevalent in males than females in the UK.
The current study found that HPV was present in patients over 40 
years of age rather than in other age groups less than 40 years of age. 
These results were in agreement with those of other studies (Cruz et al., 
1996; Schwartz et al., 2001), where individuals older than 60 years of age 
showed a high detection rate of HPV. In contrast, Hafkamp et al., 2004 and 
Smith et al., 2004 observed HPV to be more common in younger aged 
patients less than 40 years of age. Furthermore, a recent study by Sisk et al. 
(2000) observed that the incidence of HPV in younger patients is not 
significantly different from older patients, suggesting a similar role for HPV in 
all age groups. In the present study, the higher frequency of HPV in patients 
over 40 years of age could reflect the development of OSCC after a long 
period of persistence of HPV, or perhaps an age-linked accumulation of risk 
of acquiring HPV (unrelated to any OSCC risk).
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Recent data by Koutsky et al. 2002, suggests that in 
immunocompromised patients a defective immune response may be an 
additional important factor that leads to progression from potentially 
malignant to OSCC. The present results indicate that HPV was detected in 
78.1% and 56.7%  of OSCC patients from the UK and KSA respectively with 
no indication of immunodeficiency. In addition, HPV was detected among 
patients who had received no chemo/radiotherapy, hence, it would seem that 
immunosuppression is not a major influence upon the oral acquisition of HPV 
in the present samples.
In the present study, the prevalence of HPV in KSA-OSCC samples 
was found to be 56.7%. A number of features within the KSA group suggest 
that HPV is not of importance in the development of these tumours. HPV was 
detected in (71.4%) of females and in (52.2%) of males, yet OSCC is more 
common in males than females in KSA (Akhtar etal., 2003). In addition, HPV 
was detected in patients aged over 60 years, yet the mean age of OSCC in 
KSA residents is 47.7 (Akhtar etal., 2003). Taking into consideration age and 
gender, the present evidence do not suggest that HPV may be playing a 
significant role in the development of OSCC in KSA, although the data from 
the present study does not permit a formal statistical testing of this 
hypothesis since there was no available KSA normal control samples to 
compare with. It seems to be that tobacco habits are probably a more likely 
cause of OSCC than HPV among patients from the KSA. Oral squamous cell 
carcinoma is the third most common cause of malignancy in KSA after 
lymphoma and leukaemia (Al-Balawi and Nwoku, 2002), and it has been 
suggested that smokeless tobacco and a Shamma habit are strongly related
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to the type of cancer in KSA. In the South Western region (Gazan) of Saudi 
Arabia, where the use of White Shamma is very common, oral cancer 
accounts for up to 20% of all cancers diagnosed in local people (Ibrahim et 
al., 1986). While the exact geographic origin of the present group of patients 
is not clear, it is likely that many of the present group of KSA patients were 
residents of the South West of this country, as the Saudi samples were 
obtained from referral centers in the capital (Riyadh) known to manage oral 
cancer cases referred from the South West region of the KSA (Al-Balawi and 
Nwoku, 2002; Akhtar et al., 2003).
HPV was commonly associated with OSCC of the buccal mucosa and 
lateral border of tongue in patients from both KSA and the UK. However, 
there were no specific trends in the location of HPV-associated tumours. The 
present observation of the tongue being a site of HPV-associated OSCC is in 
agreement with previous studies (Ha and Califano, 2004), but there is a need 
to explore this in more detail. It is known that the oropharynx is a more likely 
site of detection of HPV in persons without OSCC (Chen et al., 2005b), thus 
explaining the possible association of HPV with tonsillar SCC (Syrjanen, 
2004), but there are no studies of the intra-oral site specificity of HPV in 
individuals without OSCC.
7.1.2 HPV and potentially malignant oral diseases
In the present study, HPV was detected in 42.2% of the examined 
specimens of OED from the UK. The frequency of HPV was high when 
compared with that of normal control samples (0.0%). The results of the 
current study are in agreement with those of studies from India (33.8%) 
(D'Costa et al., 1998) and the UK (33.3%) (Elamin et al., 1998) that utilized
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similar PCR methods targeting L1-ORF. The presently observed frequency is 
however less than that of a study of Japanese patients in which 60% of 
lesions contained HPV-DNA (Sugiyama etal., 2003).
Oral squamous cell carcinoma has been recognized to follow a 
genetic multistep progression from normal to malignant disease (Chen et al., 
2005a). The most likely clinically and histopathologically detectable lesions to 
progress to OSCC remains oral epithelial dysplasia (OED), the progression 
to OSCC usually being predictable based upon the degree of dysplasia (Ha 
and Califano, 2004; Syrjanen, 2005). Hence, if HPV was to play an 
aetiological role in the pathogenesis of HNSCC, it should be present in such 
potentially malignant lesions. Certainly, HPV is present in about 40% of the 
present group of OED lesions; however, there was no correlation between 
the frequency of HPV and the degree of dysplasia. This would thus suggest 
that HPV does not cause dysplasia of oral mucosa, but that HPV carriage 
may be a secondary event, perhaps to alcohol and tobacco usage. The 
present study did not attempt to determine if the presence of HPV within 
OED was associated with later changes to a more severe form of OED, nor 
transformation to OSCC. Thus, it remains unclear whether HPV causes OED 
or drives it to malignancy. Previous studies of potentially malignant disease 
have often failed to indicate whether the lesions were truly dysplastic. 
However, the results of the present study of known dysplasia suggest that 
HPV is not of primary aetiological importance in the development of cellular 
atypia of the oral mucosa.
The results of the detection of HPV in PVL do not elucidate the link 
between HPV and potentially malignant and malignant oral mucosal
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diseases. Previous studies have reported that HPV may be present in 10- 
100% of the examined lesions (Hansen et al., 1985; Palefsky et al., 1995; 
Gopalakrishnan et al., 1997; Silverman S Jr and Gorsky, 1997; Batsakis et 
al., 1999; Fettig et al., 2000; Femiano etal., 2001; Campisi et al., 2004). In 
the present study, 58.3% of PVL lesions from the UK contained HPV-DNA. 
While the outcomes of the present group of patients with PVL are not known, 
the close similarity in rates of HPV detection in PVL and OED would suggest 
that HPV is not an important factor in causing or perhaps influencing the 
behaviour of PVL.
An association between HPV and oral lichen planus (OLP) has been 
previously reported. In the present study 30% of examined OLP lesions 
contained HPV-DNA which is in agreement with most (Sand et al., 2000; 
Giovannelli eta l., 2002; Ostwald etal., 2003), but not all, reports (Campisi et 
al., 2004). The presence of HPV-16 in OLP is unlikely to be the reason that 
OLP has some malignant potential. Since only <1- 5.3% of OLP lesions are 
reported to be associated with present or later OSCC (Lo et al., 1998; 
Mattsson etal., 2002), the high frequency of HPV in OLP (in comparison with 
its unclear low malignant potential), and the absence of any correlation 
between HPV presence and degree of dysplasia, all suggest that HPV 
infection does not account for any malignant transformation of OLP.
7.1.3 HPV in normal control oral mucosa
In the present study, HPV was not detected in any of the normal 
control samples and is thus, in agreement with some studies (Bouda et al., 
2000; Sand et al., 2000; Yang etal., 2004; Kurose etal., 2004; Lin etal., 
2005; Hansson et al., 2005), but contradicts other studies whereby HPV has
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been detected in the normal control samples (Terai etal., 1999; Sugiyama et 
al., 2003; Zhang et al., 2004; Shimizu etal., 2004). The general prevalence 
of HPV in normal oral mucosa has not, as of yet, been clear since the 
sampling of normal healthy mucosa for relevant findings has not been 
standardized. In some studies the investigators have examined normal oral 
mucosa samples adjacent to oral cancer lesions, thus it was not possible to 
determine whether HPV-DNA was located in the normal tissues or in the 
adjacent “clinically appeared as lesion-free” epithelium (Maitland etal., 1987; 
Shindoh et al., 1995; Koppikar et al., 2005). The detection of HPV in normal 
mucosa may be due to a long latency of HPV infection before 
clinical/histological change manifested. However, the presence of HPV-DNA  
in the normal samples might also suggest that most HPV infection does not 
lead to malignancy.
7.T.4 HPV in HIV-infected individuals
In the present study, the incidence of oral HPV in HIV individuals from 
UK was relatively high (36.0%) compared with 11.2% in a study of Canadian 
patients (Coutlee et al., 1997), but higher than (1-4%) in some European 
studies including Italy, UK, Greece and the Netherlands (Patton et al., 2002). 
Recently published studies demonstrated that HIV infection increases the 
frequencies of HPV infection among women (Palefsky and Holly, 2003; 
Palefsky, 2003). Longitudinal studies have found an increasing incidence of 
new HPV infections, persistence of HPV-DNA and infection with multiple 
types of HPV in HIV infected women and men (King et al., 2002; Kreimer et 
al., 2004). Although there are no reports indicating any strong increase in 
HNSCC in HIV individuals, if HPV-16 was to be of aetiologically importance
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in the development of OSCC, it might be expected that such disease would 
have been observed in HIV infected individuals, especially as HIV disease is 
so common worldwide. HjV-infected individuals may also have sexual 
behaviours which are likely to increase the risk of acquisition of HPV in the 
mouth (Scully, 2005). However, the potential for OSCC in patients receiving 
long term HAART does exist as a consequence of their increased longevity 
of life as patients may maintain social habits likely to give rise to OSCC (e.g. 
tobacco and alcohol).
7.1.5 HPV in salivary gland neoplasms
The current study found HPV in 5/25 (25.0%) of the examined salivary 
gland tumours from KSA. This is a high proportion compared with other 
similar studies (Rommel et al., 1991; Atula etal., 1998; Henley etal., 2004). 
The failure of the previous studies to detect HPV-DNA may be explained by 
the nature of HPV in requiring the availability of proliferating mucosal 
epithelial cells, which is not the case in salivary tissues. As previously 
mentioned, HPV has no viraemic phase in humans so the infection is not 
widely disseminated in the body. Thus it would be expected that HPV- 
associated malignancies would occur site-specifically where the virus enters 
the body. The detection of HPV in the present group of salivary gland 
pathologies could reflect the presence of HPV in the overlying oral mucosal 
tissues near the gland orifices, or perhaps the epithelial lining of the duct and 
clearly, this needs to be explored more thoroughly.
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7.1.6 Relative risk of HPV in OED compared to OSCC
Previous studies have demonstrated that the prevalence of HPV is 
higher in OED than in OSCC (Sugiyama et al., 2003), possibly suggesting 
that HPV may be involved in the early stages of carcinogenesis. In contrast 
to the results of the present study (Table 3.29), the comparison between HPV 
infection in OED and in OSCC demonstrated that patients with OSCC are 
approximately 5.3 times more likely to be infected with HPV than patients 
with OED. In accordance with the observed trend of the meta-analysis 
described by Miller and Johnstone, the overall results showed that HPV was 
2 to 3 times more likely to be detected in potentially malignant lesions and
4.7 times more likely to be detected in OSCC than in normal mucosa (Miller 
and Johnstone, 2001). This may suggest that HPV does not initiate the 
malignancy, but the accumulation in the OSCC lesions might act as requisite 
for.the maintainance and progression of proliferation of the malignant state.
7.2 Conclusion of HPV
The present results indicate that there may be an association between 
HPV and OSCC. HPV is present in oral epithelial dysplasia (OED) and 
proliferative verrucous leukoplakia (PVL), but there is no evidence of HPV- 
DNA in the normal oral mucosa. Although the expression of HPV oncogenes 
was not investigated, the present results suggest that HPV may be present in 
OSCC and OED and may drive future oncogenesis.
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7.3 Herpes viruses in oral mucosal lesions
Human herpes viruses, particularly EBV and HHV-8, are known 
causes of some malignancies in the head and neck area. EBV is considered 
as the causative agent of Burkitt’s lymphoma, nasopharyngeal carcinoma 
and opportunistic B cell lymphoma in immunocompromised patients, while 
HHV-8 gives rise to Kaposi’s sarcoma. Few data have been published 
investigating the role of these herpesviruses and their association with OSCC 
(Yang etal., 2004).
7. 3.1 Cytomegalovirus
Cytomegalovirus can be present in the oral epithelium and oral fluids 
of healthy persons (Beyari et al., 2005), indeed the mouth may be a site of 
residency of this virus. In immunocompromised individuals (e.g. iatrogenic 
immunosuppression and in particular HIV disease), CMV may gives rise to 
both oral mucosal and gingival ulceration (Kanas et al., 1987; Schubert et 
al., 1993; Flaitz etal., 1996; Syrjanen etal., 1999). Cytomegalovirus has the 
ability to transform a variety of cell lines in vitro and thus, may have the ability 
to be oncogenic, and certainly oral cancer cell lines do contain CMV 
promoter (Shillitoe and Noonan, 2000). However, there is no evidence that 
CMV gives rise to oral malignancy in severely immunocompromised 
individuals such as those with HIV disease (Frezzini et al., 2005), thus, it 
would seem unlikely that CMV is associated with OSCC or OED.
The present observations of a lack of association of CMV with OSCC 
are in agreement with previous similar studies. For example, CMV-DNA was 
not detected in any of 37 examined OSCC samples from Taiwan (Yang etal., 
2004). Similarly, the lack of association between CMV and HIV disease
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observed in the present study is in agreement with a recent report of HIV- 
infected individuals from Italy (Ammatuna et al., 2001). While the mouth can 
be a site of residency of the virus, oral fluids may act as a mean of non- 
sexual transmission of CMV (Beyari et al., 2005), this virus is unlikely to play 
any aetiological role in the development of potentially malignant or malignant 
disease of the mouth.
In the present study, CMV was not found to be associated with 
salivary gland tumours. This is in agreement with previous such studies of 
such tumours from Scandinavia (Karja et al., 1997; Atula et al., 1998), and 
the USA (Laane et al., 2002), and thus, it can be concluded that CMV plays 
no role in the salivary gland tumourogenesis.
7.3.2 Epstein-Barr virus
The role of Epstein-Barr virus (EBV) in oral carcinogenesis is highly 
controversial. Studies have reported that the frequency of detection of EBV- 
DNA or RNA within OSCC to range from 0 to 72% (Horiuchi et al., 1995; 
Kobayashi et al., 1999; Tsuhako etal., 2000; Cruz etal., 2000; Sand etal., 
2002; Tsang et al., 2003; Higa et al., 2003; lamaroon et al., 2004). The 
highest frequency of detection of EBV-DNA in OSCC has been observed in 
Japan (particularly in the south) (Tsuhako et a!., 2000), and in contrast, the 
lowest frequency has been in Scandinavia and the USA (Sand et al., 2002; 
Goldenberg etal., 2004).
The detection of EBV-DNA in OSCC has been found sometimes to 
reflect the presence of either EBV-infected saliva or invading lymphocytes 
(Cruz et al., 1997; Tsuhako et al., 2000), however, the detection of 
transcripts of EBV oncogenes within tumour cells (e.g. Baw, Hiw, EBER)
262
Chapter 7 Discussion and Conclusions
(Mao and Smith, 1993; Shimakage et al., 2002; lamaroon et al., 2004) has 
suggested that the EBV in OSCC is oncogenically active. Nevertheless, more 
recent extensive studies of EBV-DNA positive OSCC using a range of 
molecular biological methods have not detected transcripts of EBV 
oncogenes EBNER and EBNA-1, nor oncogenic proteins such as a ZEBRA 
or LMP-1 (Cruz et al., 2000). A recent extensive retrospective investigation of 
300 head and neck cancers (exclusive of nasopharyngeal carcinoma) that 
included 113 OSCC did not detect EBV using quantitative PCR (Goldenberg 
etal., 2004).
It would thus seem that, while an association between EBV and OSCC 
may exist in persons from Japan, there is no evidence for such an 
association in Europeans. There are no data concerning KSA, however, the 
present results of the individuals with OSCC suggest that EBV is unlikely to 
play any aetiological role in oral carcinogenesis. The present low prevalence 
of EBV in OED samples may provide a further evidence for the lack of any 
carcinogenic role of EBV in OSCC. As in the present study, Epstein-Barr 
virus has been detected in OED-like lesions (e.g. oral leukoplakia 
(Shimakage et al., 2002)), but the lack of any statistical association in the 
present study correlates with the findings of a lack of oncogenic potential for 
EBV in the oncogenesis of OSCC in Europeans and those from KSA.
Epstein-Barr virus DNA has previously been detected in 26.1% of OLP 
lesions from patients in Sweden (Sand et al., 2002). In the present study, 
EBV was not detected in OLP lesions from both UK and KSA. However, in 
previous studies, EBV in OLP does seem to be predominantly present within 
the lymphoid element of OLP (Shimakage et al., 2002), it seems unlikely,
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particularly when the relevant data concerning OSCC is considered, that EBV 
plays a role in any malignant potential of OLP.
The detection of EBV-DNA in 50% of PVL lesions is the only reliable 
finding with respect to this virus and the examined lesions. The link between 
EBV and PVL is however unclear. PVL is known to contain histological 
evidence of dysplasia (Hansen et al., 1985), and to be potentially malignant 
(Silverman S Jr and Gorsky, 1997) and often recurrent. The only oral 
mucosal lesion with a similar clinical appearance known to be caused by 
EBV is oral hairy leukoplakia. Oral hairy leukoplakia (OHL) probably reflects 
an EBV-induced epithelial hyperplasia (Greenspan et al., 1985) and has no 
known malignant potential (Frezzini et al., 2005) and is almost always 
associated with immunosuppression (typically HIV disease) (Triantos et al., 
1998). The present group of PVL lesions were not distinct to the tongue (a 
site of EBV binding) (Triantos et al., 1998) and together with the lack of 
detection of EBV in the present group of patients with HIV disease, and the 
knowledge that PVL and OHL do not show similar aetiological, 
histopathological and clinical features, these observations suggest that EBV 
is not causative of PVL. It may be that EBV is accounting for some of the 
hyperplasia of PVL, however, as PVL is not distinct to the tongue, this also 
seems unlikely. Thus, the explanation of the detection of EBV in 50% of the 
present samples of PVL remains unknown. However, in view of the absence 
of EBV in OED and OSCC, and the knowledge that immunosuppression- 
related OHL does not lead to malignant changes. Further exploration of the 
role of EBV in oral mucosal oncogenesis does not seem warranted.
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Epstein-Barr virus may be of an aetiological importance in salivary 
gland malignancies, the virus being detected in up to 95% of some series of 
salivary adenolymphoma (Warthin’s tumour) (Takezawa et al., 1998), 
although no association has been observed in other similar studies (Karja et 
al., 1997; Wolvius et al., 1997; van Heerden eta l., 1999; Laane etal.,
2002). The association between EBV and pleomorphic adenoma also seems 
unlikely (Atula et al., 1998; Laane et al., 2002). Epstein-Barr virus may be 
present in lymphoepithelioma-like carcinoma of the salivary glands, but as 
this tumour is histopathologically indistinguishable from undifferentiated 
nasopharyngeal carcinoma (which is associated with EBV), this finding is 
perhaps not unexpected (Tsai et al., 1996). In the present study, EBV was 
not found to be associated with salivary gland tumours. Hence, it would seem 
that EBV plays no role in the pathogenesis of salivary gland tumours, indeed 
such a link would seem unlikely as there is no increased frequency of 
salivary gland malignancy (other than non-Hodgkin’s lymphoma and Kaposi’s 
sarcoma) in severely immunocompromised patients (Frezzini etal., 2005).
7.3.3 Human herpes virus-8
In the present study, human herpesvirus 8 (HHV-8) was found in 
(48.0%) of HIV-infected individuals. This was to be expected as HHV-8 can 
be detected with epithelial cells (Chang et al., 1994; Hengge et al., 2002a) 
and mucosal ulcers (Di Alberti L. etal., 1997) in HIV-infected individuals. Oral 
prevalence of HHV-8 has predominantly been associated with HIV disease, 
however, it is known that this virus can be carried within the mouths of 
individuals who have neither HIV disease nor Kaposi’s sarcoma (acquisition
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occurring via non-sexual routes (presumably via saliva)) (Cook et al., 
2002b).
Human herpesvirus-8 is the cause of Kaposi’s sarcoma, pulmonary 
effusion lymphoma (PEL) and multicentric Castleman’s disease (Hengge et 
al., 2002b). It has never been found to be associated with an epithelial 
tumour and the present evidence of a lack of association with any examined 
potentially malignant or malignant lesions is in agreement with this.
The present data do not suggest that HHV-8 plays a role in the 
aetiology of non-KS salivary gland tumours. A study of 58 different salivary 
gland tumours (that included 11 pleomorphic adenomas), HHV-8 was 
detecccted in one sample of mucosa-associated lymphoid tumour (MALT) in 
a patient who had Sjogren's syndrome (Klussmann et al., 2000). In addition, 
HHV-8 was detected in an intra-salivary gland Kaposi’s sarcoma in HIV 
individuals (Castle and Thompson, 2000). Furthermore, in a study of 19 
pleomorphic adenomas and 19 malignant salivary gland tumours of persons 
in Finland, HHV-8 was not detected in any examined lesion (Atula et al., 
1998).
The present and previous, lack of an association between HHV-8 and 
salivary gland malignancy is expected - otherwise it would be likely that 
salivary gland tumours would be a common feature of HIV disease - which is 
not the case (Frezzini etal., 2005).
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7.4 Human herpes viruses (CMV, EBV and HHV-8) in normal oral 
mucosa
The present study results detected no HHV-8 among the normal 
control samples while EBV and CMV were detected in 12.0% and 2.0% of 
normal samples respectively. The detection of such viruses found to be 
common within normal mucosa. Hence, the variations of the detection 
methods, sample size and the nature of the sample would affect the viral 
proportion within the samples. The complete absence or the low proportion of 
such viruses of the present study is in accordance with other many studies 
(Boldogh et al., 1996; Lucht et al., 1998; Ammatuna et al., 2001; Laane et 
al., 2002; Hao et al., 2003; Yang et al., 2004), which indicate that CMV, 
EBV and HHV-8 are not commonsal viruses in most of the healthy individuals 
but the occasional presence of such viruses may indicate a future pathogenic 
role.
7.5 Conclusion of human herpesviruses
The results of the current study conclude that herpesviruses, Epstein- 
Barr virus (EBV), cytomegalovirus (CMV) and human herpesvirus-8 (HHV8) 
play no role in the pathogenesis of potentially malignant and malignant oral 
diseases, although HHV-8 may be present in HIV-infected individuals and be 
a cause of later KS.
7.6 Single and double infection of viruses in OSCC
A previous study of oral ulceration unrelated to malignancy indicated 
that the frequency of carriage of only one virus was far greater than that of 
the frequencies of carriage of two or more viruses (Lin et al., 2005), thus
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perhaps suggesting that, infection with only one virus may suffice to elicit 
pathology. In the present study, both HPV and HHV-8 were found as single 
infections in the OSCC samples in 54.7% and 1.6% respectively. In addition, 
these two viruses were also found as a double infection in 14.0% of the 
samples, thus suggesting that interactions between HPV and HHV-8 are 
unlikely to be a common cause of OSCC and OED.
It has been suggested that co-infection of HSV-2 and HPV might 
enhance HPV-driven oncogenesis. While HSV-2 does not itself cause 
cervical malignancy. Co-infection of HSV-2 and HPV is common in cervical 
malignancy (Di Luca et al., 1987; Di Luca etal., 1989), and epidemiological 
studies indicated that women infected with HSV-2 and HPV are at great risk 
of developing cervical carcinoma compared to women infected with only one 
virus (Hildesheim et al., 1991). In vitro, studies have demonstrated that HSV- 
2 transforming fragments (mtr II and mtr III) can act with HPV to transform 
human cell lines (e.g. fibroblasts and keratinocytes) (Jones, 1995), inducing 
DNA damage or chromosomal abnormalities in epithelial cells that are 
latently infected with HPV. In the current study there was no evidence of any 
interaction between different viruses in the OSCC cases, therefore, 
suggesting that only one virus was able to cause the malignancy or the 
sample size was too small to validate the results.
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7.7 Conclusions
The results of the present work indicate that an association may exist 
between HPV and OSCC in persons from the UK. While this may suggest an 
aetiopathological link between HPV and a malignant potential of the oral 
mucosa, the lack of association of HPV with the examined potentially 
malignant oral mucosal disease and OSCC in persons from KSA points away 
from such an aetiological link. Herpes viruses probably play no role in the 
development or maintenance of potentially malignant or malignant disease of 
the oral epithelium. Finally, HPV, CMV, EBV and HHV-8 are unlikely to be of 
importance in the pathogenesis of tumours derived from salivary gland 
tissue.
Nevertheless, the continued observations of OSCC arising in persons 
who neither smoke tobacco nor drink alcohol, the detection of high risk types 
of HPV that express oncogenes within OSCC and the suggestion that HPV 
may be particularly associated with OSCC of the posterior tongue, all cannot 
be ignored, particularly as HPV may be transmitted sexually. It would thus 
seem important to focus future research upon the frequency of carriage and 
molecular characteristics of HPV in the posterior tongue and pharynx in 
sexually active persons to determine if HPV infection truly is an early event in 
malignant change at this site. Such work will determine whether there is a 
need to consider vaccine-based prevention of head and neck disease likely 
to lead to malignant change. Research focused upon possible aetiological 
associations between known HPV types or herpes viruses with tumours 
derived from salivary gland tissues should not be pursued.
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Appendix 2.1 Genovar DNA extraction protocol
GenoVar
diagnostics ltd
ro
•v jo
NUCLEIC ACID 
EXTRACTION KIT 
FOR PARAFFIN 
EMBEDDED TISSUE
www.genovar.co.uk
GenoVar diagnostics ltd 
1030 Heetey Close 
Sittingbourne Research Centre 
Sittmghoume 
KENT 
ME98HL 
United Kingdom
Tel +44 (0) 1795 436688
Fax +44 (0) 1795 436699 
Email help@genovar.co.uk
Intended Use:
This kit is designed to extract total nucleic 
acid from formalin-fixed, paraffin 
embedded tissue. The kit is optimised for 
extraction from one section up to 20pm in 
thickness in less than an hour.
Kit Contents:
• 4 bags of 25 reaction tubes containing 
Extraction Buffer
• 4 tubes containing Powder B.
• 1 bottle containing 20ml of Buffer A. 
This buffer is sterile so aseptic 
technique should be used.
• 1 instruction leaflet.
Preparation. Storage and Handling:
• Before use, 4ml of Buffer A should be 
added to each glass bottle. The resulting 
solution, Buffer C, should be stored at - 
20°C. Each 4ml bottle contains enough 
of Buffer C for 25 extractions.
• Unused glass bottles containing Powder 
B should be stored at -20°C.
EXTRACTION PROTOCOL:
1. Place the tissue section into a reaction 
tube on top of the wax layer.
2. Add 150jil of Buffer C to the tube.
3. Centrifuge the tube briefly at low speed 
to ensure the tissue section is 
submerged.
4. Heat the tube to 60°C in a heating 
block, water bath or thermal cycler.
5. Once the wax has melted (usually 
around 2 minutes at 60°C) mix gently 
by vortexing.
6. Incubate the sample at 60°C for 30 
minutes.
7. Heat the tube to 99°C in a heating 
block, water bath or thermal cycler and 
incubate for 5 minutes.
8. Mix the sample vigorously by vortexing 
and quickly transfer the tube to a non­
refrigerated centrifuge (i.e. Benchtop) 
and spin at M l speed for 5 minutes..
9. Place the samples on ice for 5 minutes 
to ensure the wax layer is Mly 
solidified. This will make the next step 
easier.
10. Carefully excise or pierce the wax layer 
using a sterile pipette tip.
11. Remove the liquid phase to a clean 
fresh tube, taking care not to transfer 
any resin or cellular debris.
12. Before analysis, centrifuge the nucleic 
acid to pellet any residual debris, 
contaminants or resin.
13. Use 0.5 to 5.0pl in PCR (1 or 2pl is 
usually optimal), or 5 to 10(il for first 
strand synthesis.
Final buffer (after all additions to the tube)
25mM Tris pH8.3
50mM KCI
2mM MgCI2
0.45% v/v Tween 20
0.45% v/v Nonidet P40
Proteinase K (200 micrograms per ml)
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